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ABSTRACT	  
RNA	  recently	  remained	  unexploited	  and	  is	  now	  drawing	  interest	  as	  a	  potential	  drug	  
target.	   The	  methodology	   and	   available	   drug	   libraries	   for	  RNA	   targeting/screening	  
are	   in	   rudimentary	   stages.	   The	   interactions	   made	   by	   ligands	   with	   RNA	   can	   be	  
explored	   for	   RNA	   based	   drug	   development.	   The	   dissertation	   is	   composed	   of	   4	  
chapters.	   The	   first	   chapter	   focuses	   on	   the	   structural	   features	   of	   RNA	   and	   the	  
attempts	   made	   to	   target	   RNA	   previously.	   The	   second	   chapter	   focuses	   on	   the	  
development	  of	  a	  small	  molecule	  library	  enriched	  with	  substructures	  derived	  from	  
RNA	  binding	   ligands.	   	   For	   this	   study	   a	   fragment-­‐based	   approach	   (fragment	   based	  
approach	   is	   detailed	   in	   chapter	   2)	   is	   used	   in	   order	   to	   accommodate	   the	  
conformational	   flexibility	   of	   RNA.	   The	   library	   molecules	   are	   used	   for	   screening	  
against	  suitable	  RNA	  targets	  using	  NMR.	  We	  identified	  at	  least	  5	  ligands	  out	  of	  which	  
2	  are	  novel	  ligands	  binding	  to	  the	  ribosomal	  16s	  rRNA.	  	  
	  
	  The	   third	   chapter	   is	   focused	   on	   the	   role	   of	   small	   molecules	   in	   inducing	  
conformational	  changes	  in	  an	  RNA	  genetic	  regulatory	  element	  called	  the	  S-­‐Adenosyl	  
methionine	   (SAM)	   SAM-­‐I	   riboswitch.	   The	   mechanistic	   features	   of	   the	   SAM-­‐I	  
riboswitch	   to	   understand	   the	   basis	   for	   specificity	   and	   discrimination	   and	   its	   gene	  
regulation	   mechanism	   are	   reported.	   To	   address	   the	   conformational	   dynamics	  
Bacillus	   subtilis	   and	   Thermoanearobacter	   tencongensis	   SAM-­‐I	   riboswitches	   in	  
response	   to	  SAM	  binding	  several	  conformer	  mimics	  are	  designed,	  synthesized	  and	  
characterized	  using	  NMR,	  equilibrium	  dialysis,	  and	  inline	  probing.	  The	  study	  shows	  
that	  apart	  from	  the	  conserved	  residues	  of	  the	  binding	  pocket,	  residues	  downstream	  
	   x	  
of	  the	  binding	  pocket	  are	  involved	  in	  detecting	  SAM	  and	  assist	  the	  binding	  of	  SAM	  to	  
the	  riboswitch	  with	  weak	  affinity.	  	  
Our	   data	   highlights	   the	   capacity	   of	   a	   so-­‐called	   antiterminator	   helix	   from	   the	  
expression	   platform	   to	   assist	   the	   formation	   of	   a	   partial	   P1	   helix	   of	   the	   aptamer	  
domain.	  A	  stable	  P1	  is	  involved	  in	  recognition	  and	  tight	  binding	  of	  SAM.	  Our	  in	  vitro	  
experiments	   suggest	   that	   the	   riboswitch	   could	   switch	   from	   an	   unbound	  
conformation	  to	  tightly	  SAM	  bound	  structure	  through	  weakly	  binding	  intermediate	  
structures	   in	   the	   presence	   of	   the	   small	   molecule	   SAM.	   The	   future	   directions	   are	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CHAPTER	  1:	  INTRODUCTION	  
	  
1.1.	  RNA	  as	  a	  Potential	  Small	  Molecule	  Drug	  Target	  
	  
Until	  recent	  times,	  RNA	  was	  mostly	  considered	  as	  a	  passive	  messenger	  in	  cellular	  protein	  
synthesis.	  New	  RNA	  structures	  with	  hitherto	  unknown	  functions	  are	  projecting	  RNA	  as	  an	  
active	   element	   with	   significant	   roles	   in	   enzyme-­‐like	   catalysis	   [1],	   gene	   regulation	   [2]	  
transcriptional	   control,	   and	   translational	   control	   [3-­‐5].	   Recently	   non-­‐coding	   RNAs	  
(ncRNA)	   in	   prokaryotes	   and	   eukaryotes	   have	   been	   shown	   to	   be	   involved	   in	   gene	  
regulatory	   function.	   In	   eukaryotes,	   evidence	   is	   established	   for	   roles	   of	   ncRNA	   in	  
epigenetic	  memory,	  physiology	  and	  development	  and	  also	  in	  chromatin	  architecture	  [6].	  
These	   recent	   discoveries	   conspicuously	   indicate	   RNA	   as	   a	   potential	   drug	   target	   for	  
various	   diseases.	   In	   some	   pathogenic	   viruses,	   RNA	   is	   the	   genetic	   material	   and	   plays	   a	  
crucial	   role	   in	   replication.	  Various	  RNA	  structures	  within	   the	  human	   immunodeficiency	  
virus	  (HIV-­‐I)	  genome	  interact	  with	  host	  proteins	  [7].	  Such	  RNA	  structures	  also	  prove	  RNA	  
as	  a	  potential	  drug	  target.	   It	  could	  be	  more	  effective	  to	  attack	  such	  viruses	  at	  RNA	  level	  
and	  protein	  level	  since	  the	  virus	  utilizes	  host	  protein	  machinery	  to	  synthesize	  its	  proteins	  
(strategies	  involving	  combination	  therapies).	  	  
Proteins	  and	  DNA	  are	  extensively	  explored	  drug	  targets.	  Out	  of	  the	  numerous	  thousands	  
of	   cellular	  proteins,	  nearly	  1620	  have	  been	   identified	   to	  be	   involved	   in	  genetic	  diseases	  
and	  out	  of	  these,	  only	  about	  207	  proteins	  have	  been	  targeted	  within	  humans	  [8].	  It	  is	  also	  
shown	  by	  other	  analysis	  that	  only	  about	  15%	  of	  the	  total	  proteome	  is	  accessible	  for	  drug	  
targeting	  [9].	  Success	  with	  protein	  targeting	  has	  been	  largely	  with	  specific	  protein	  classes	  
such	  as	  kinases,	  neuraminidases,	  GPCRs	  (G	  protein-­‐coupled	  receptor),	  nuclear	  receptors,	  
cytochrome	  proteins	  and	  ligand	  gated	  ion	  channels	  [8].	  The	  common	  protein	  targets	  used	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for	  drug	  discovery	  are	  enzymes	  with	  compact	  active	  sites.	  One	  of	  the	  difficult	  challenges	  
in	   targeting	   some	   large	   proteins	   is	   to	   deal	  with	   a	   large	   interfacial	   area	   involved	   in	   the	  
interaction	   (particularly	   in	   protein-­‐protein,	   protein-­‐DNA	   interactions)	   required	   for	  
specific	   recognition.	   The	   interfacial	   area	   is	   recognizable	   through	   surface	   polarity	   and	  
distribution	   of	   charge	   [10].	   Principles	   for	   drug	   discovery	   targeting	   DNA	   have	   been	  
established	  based	  on	  the	  understanding	  of	  the	  interactions	  with	  natural	  ligands	  [11,	  12].	  
Such	  ligands	  have	  less	  druggable	  properties	  because	  of	  issues	  with	  solubility	  and	  nuclear	  
membrane	  permeability	  and	  toxicity	  [13].	  However,	  the	  drug-­‐DNA	  interactions	  are	  less	  in	  
number	  as	  compared	  to	  the	  Drug-­‐protein	  interactions	  but	  have	  more	  successful	  stories	  in	  
drug	   discovery.	   Since	   RNA	   is	   similar	   structurally	   to	   DNA	   and	   functionally	   (folding)	   to	  
protein,	  the	  aforementioned	  considerations	  while	  targeting	  RNA	  should	  be	  considered.	  
In	   most	   cases,	   the	   function	   of	   the	   RNA	   is	   dependent	   upon	   binding	   of	   either	   a	   small	  
molecule	   or	   a	   protein	   or	   a	   small	   RNA	   to	   the	   functional	   RNA.	   Such	   binding	   events	   are	  
potential	   points	   of	   intervention	   for	   drug	   targeting.	   	   Though	   RNA	   is	  much	   simpler	   than	  
proteins	  in	  basic	  constitution,	  its	  structural	  properties	  allow	  it	  to	  create	  pockets	  for	  ligand	  
binding.	  Small	  molecules	  can	  counteract	   the	   long	  range	   tertiary	   interactions	  constituted	  
by	  hydrogen	  bonds	  and	  Van	  der	  Waals	  and	  weak	  electrostatic	   forces	  between	  helices	   in	  
the	   secondary	   structure	   of	   the	   RNA[14].	   Other	   structural	   features	   of	   RNA	   like	   non	  
Watson-­‐Crick	  base	  pairing,	  coaxial	  stacking	  and,	  bulges	  etc.,	  are	  significant	   in	  binding	  to	  
small	   molecules	   [15,	   16].	   However,	   RNA	   based	   small	   molecule	   drug	   targeting	   did	   not	  
reach	   to	   the	   point	   of	   having	   established	   principles	   and	   methodology	   as	   compared	   to	  
proteins	   and	   DNA	   based	   drug	   discovery.	   The	   folding	   of	   RNA	   and	   small	   molecule	  
interactions	  have	  only	  recently	  been	  the	  subject	  of	  focused	  study.	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1.2. RNA	  Structural	  Features	  and	  Their	  Contribution	  towards	  Small	  	  
Molecule	  Binding	  
	  
1.2.1. RNA	  Structural	  Hierarchy	  
	  
Commonly,	  four	  repeating	  nucleotide	  residues	  comprise	  the	  basic	  sequence	  of	  RNA	  unlike	  
proteins,	   which	   are	   comprised	   of	   20-­‐plus	   amino	   acids.	   Albeit	   like	   proteins,	   RNA	   has	  
structural	   hierarchy	   with	   primary,	   secondary	   and	   tertiary	   structures.	   The	   primary	  
structure	   is	   comprised	   of	   the	   nucleotide	   sequence.	   Helices,	   bulges	   and	   internal	   loops	  
formed	  by	  unpaired	  nucleotide	  residues,	  hairpin	  loops,	  junctions	  and	  branch	  points	  form	  
the	   secondary	   structure	   of	   RNA.	   The	   tertiary	   structure	   of	   RNA	   is	   formed	   by	   weak	  
interactions	  such	  as	  Van	  der	  Waals	  interactions,	  weak	  hydrogen	  bonds,	  and	  electrostatic	  
interactions	  between	  residues	  of	  different	  secondary	  structure	  elements.	  Distant	  tertiary	  
contacts	   are	   mediated	   through	   metal	   ions,	   anions,	   or	   small	   molecules	   [17-­‐19].	   The	  
amount	  of	  energy	  required	  to	  stabilize	  the	  tertiary	  structure	  is	  less	  than	  that	  required	  for	  
secondary	  structure	  stabilization	  contributed	  from	  Watson-­‐Crick	  base	  pairing	  [20].	  Table	  
1.1	  summarizes	  the	  energies	  required	  for	  the	  stabilization	  of	  RNA	  secondary	  structures.	  	  
	  	  	  	  
1.2.2. RNA	  Secondary	  Structure	  in	  Detail	  
The	  dominant	  representatives	  of	  the	  RNA	  secondary	  structures	  are	  helices.	  The	  Watson-­‐
Crick	  base	  pairs	  are	  the	  dominant	  base	  pairs	  present	  in	  the	  RNA	  double	  helix	  structures.	  
The	  double	  helix	  adopted	  by	  RNA	  is	  usually	  an	  A-­‐form	  helix	  with	  11	  base	  pairs	  per	  turn.	  
The	  A-­‐form	  helix	  is	  shorter	  and	  wider	  than	  the	  B-­‐form	  helix,	  which	  predominates	  in	  DNA.	  
The	  major	  groove	  is	  deep	  and	  narrow	  and	  the	  minor	  groove	  is	  shallow	  to	  allow	  the	  close	  
packing	  of	  the	  double	  helical	  and	  single	  stranded	  RNA	  for	  function	  [22-­‐24]	  (Figure	  1.1	  a).	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Table	  1.1:	  	  The	  thermodynamics	  of	  the	  RNA	  secondary	  structures.	  “n”	  is	  the	  number	  





The	   sugar	   ring	   in	   nucleic	   acids	   is	   inherently	   nonplanar.	   This	   nonplanarity	   is	   termed	  
puckering.	   The	   configuration	   of	   the	   non-­‐planar	   sugar	   ring	   in	   the	   nucleotides	   is	  
determined	  by	  the	  sugar-­‐pucker	  phase	  angle	  and	  the	  sugar	  pucker	  amplitude.	  The	  sugar	  
ring	  can	  be	  specified	  by	  the	  five-­‐endocyclic	  torsion	  angles	  (Figure	  1.1c).	  The	  sugar-­‐pucker	  
phase	   angle	   and	   amplitude	   are	   defined	   in	   terms	   of	   the	   five	   torsion	   angles.	   The	   most	  
common	  configurations	  of	  the	  sugar	  pucker	  are	  C2’endo	  and	  C3’	  endo	  (Figure	  1.1b).	  The	  
C2’	   and	   C3’	   are	   carbon	   positions	   in	   the	   sugar	   ring.	   The	   endo	   or	   exo	   describes	   the	  
orientation	  of	  the	  carbon	  towards	  the	  plane	  (facing	  the	  5’OH	  of	  the	  sugar)	  or	  outside	  the	  
plane	   respectively.	   The	   2’	   OH	   of	   the	   ribose	   sugar	   in	   RNA	   contributes	   to	   the	   C3’	   endo	  
conformation,	   inhibiting	  the	  formation	  of	  C2’	  endo	  conformation	  in-­‐turn	  resulting	  in	  the	  
A-­‐form	  geometry	  [22].	  The	  deep	  and	  narrow	  major	  groove	  does	  not	  allow	  the	  formation	  
of	  binding	  pockets	  in	  classic	  A-­‐form	  helices.	  The	  major	  groove	  is	  information	  rich	  because	  
the	   functional	   groups	   of	   the	   nucleotide	   bases	   are	   projected	   into	   the	   major	   groove,	  
resulting	  in	  a	  varied	  electrostatic	  landscape	  [23].	  The	  major	  groove	  widens	  upon	  binding	  
by	   protein,	   peptide,	   or	   small	  molecules	   like	   deoxystreptamine	   [15,	   25,	   26].	   This	  major	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groove	  widening	  is	  favored	  near	  non	  paired	  bulges	  and	  hairpins	  [22].	  For	  these	  reasons,	  
interacting	  proteins	  or	  peptides	  can	  achieve	  specific	  recognition	  by	  contacting	  the	  major	  
groove	   near	   non-­‐paired	   regions.	   Figure	   1.2	   demonstrates	   the	   secondary	   structure	  
schematics	   of	   some	   of	   these	   unpaired	   secondary	   structure	   motifs	   a)	   Duplex,	   b)	   Bulge	  
loops	  that	  cannot	  base	  pair	  on	  one	  side	  of	  the	  structure,	  c)	  Interior	  loops	  that	  cannot	  form	  
base	  pairs	  on	  both	  the	  sides	  of	  the	  RNA,	  d)	  hairpin	  loop	  e)	  mismatch	  f)	  symmetric	  internal	  
loop	  g)	  asymmetric	   internal	   loop	  h)	  Junctions	   in	  which	  two	  or	  more	  helices	   integrate	  to	  




Figure	  1.1:	  A	  form	  and	  B	  form	  helices	  (left),	  sugar	  pucker	  configurations	  (right)	  in	  
nucleic	   acids	   [[27],Sugar	   pucker	   (bottom).	   	   (Figure	   Adapted	   from	   [[27-­‐29].	   The	  
cartoons	   for	   the	   A-­‐form	   (nucleotide	   database	   ID:	   2KUW)	   and	   B-­‐form	   (nucleotide	  
database	   ID:	   BDL018)	   helix	   are	   generated	   using	   RCSB	   Jmol	   viewer	   and	   the	  
biological	  assembly	  generated	  using	  PISA	  software).	  A	  cartoon	  representation	  of	  a	  
RNA	   double	   helix	   showing	   the	   minor	   groove	   with	   the	   sugar	   moieties	   and	   the	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1.2.3.	  RNA	  Secondary	  Structure	  Is	  a	  Rational	  Target	  for	  Small	  Molecules	  
	  
As	  mentioned	  earlier,	  the	  RNA	  major	  groove	  has	  varying	  electronegative	  potential.	  This	  
arises	  because	  of	  the	  phosphate	  groups	  of	  the	  nucleotide	  residues	  but	  also	  from	  oxygen	  
and	  nitrogen	  moieties	  on	  the	  bases.	  
	  
Figure	   1.2:	   Schematics	   of	   the	   secondary	   structure	   elements	   that	   are	   frequently	  
found	  in	  RNA.	  A)	  duplex	  b)	  bulge	  c)	  single	  stranded	  RNA	  between	  two	  hairpins	  d)	  
hairpin	   	   e)	   mismatch	   f)	   symmetric	   internal	   loop	   g)	   asymmetric	   internal	   loop	  
h)Three	  stem	  i)	  four	  stem	  (	  The	  three	  and	  the	  four	  stem	  show	  the	  junction)	  J)	  Single	  
nucleotide	  bulge.	  	  
	  
	  
The	   functional	   groups	   of	   the	   nucleo-­‐bases	   face	   the	   major	   groove	   resulting	   in	   the	  
projection	   of	   the	   2’OH	   groups	   of	   the	   residues	   into	   the	   minor	   groove.	   	   Various	   RNA	  
structures	   like	   the	  ribozymes	   [30,	  31],	  HIV-­‐1	  RRE	  [32],	  and	  A-­‐site	   rRNA	  bind	   to	   ligands	  
near	   bulge	   regions	   or	   stem	   loops.	   Some	   small	  molecules	   are	   involved	   in	  minor	   groove	  
interactions	  with	  specific	  2’OH	  hydrogen	  bonding	  [33].	  
The	  energy	  required	  for	  the	  formation	  of	  the	  tertiary	  structure	  in	  RNA	  is	  lower	  than	  that	  
required	  for	  the	  formation	  of	  the	  secondary	  structure.	  The	  latter	  is	  strongly	  stabilized	  by	  
base	  pairing	  and	  by	  stacking	  interactions	  between	  each	  base	  pair.	  Hence	  perturbation	  of	  
the	   tertiary	   structure	   to	   prevent	   the	   interactions	   between	   independent	   secondary	  
structures	   is	   the	   key	   to	  manipulating	   RNA	   structure	   and	   function	   with	   small	   molecule	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ligands.	   The	   riboswitches	   (detailed	   in	   later	   sections)	   present	   a	   new	   class	   of	   novel	   RNA	  
targets	  in	  which	  small	  molecule	  ligand	  binding	  perturbs	  the	  RNA	  secondary	  structure.	  	  
	  
1.3. Molecular	  RNA	  Targets	  	  
	  
Several	  molecular	  RNA	  targets	  with	  crucial	  biological	  functions	  have	  been	  identified	  and	  
shown	   to	   bind	   to	   various	   small	   molecule	   ligands	   to	   date.	   Some	   of	   the	   targets	   include	  
bacterial	  ribosomal	  RNA,	  bacterial	  T-­‐box	  RNA,	  bacterial	  tRNA,	  Hepatitis	  C	  Virus	  Internal	  
ribosome	   entry	   site	   (IRES)	  RNA,	  Human	   immunodeficiency	   viral	   (HIV)	  Trans	   activating	  
response	  element	  (TAR)	  RNA,	  Rev	  Response	  element	  (RRE)	  RNA,	  mRNA	  structures	   that	  
include	   riboswitches,	   and	   3’	   untranslated	   regions	   [34-­‐37].	   In	   all	   these	   examples,	   the	  
efficacy	  of	  the	  small	  molecule	  depends	  on	  its	  ability	  to	  prevent	  the	  RNA-­‐protein,	  RNA-­‐RNA,	  
RNA-­‐DNA	  interactions.	  The	   intervening	  small	  molecule	  binding	  may	  block	  the	  biological	  
function	  of	  the	  RNA.	  
	  
1.4. Small	  Molecule	  RNA	  Interactions:	  Insights	  from	  Aminoglycosides	  
	  
Amongst	  the	  various	  small	  molecule	  species	  the	  Aminoglycosides	  represent	  the	  species	  of	  
small	  molecules	   that	  have	  been	  studied	   in	  complex	  with	  RNA	  the	  most	  extensively.	  The	  
following	   sections	   will	   briefly	   summarize	   lessons	   learnt	   from	   the	   RNA-­‐Aminoglycoside	  
interactions.	  
	  
1.4.1. Amine	  groups	  of	  the	  Aminoglycosides	  Are	  Responsible	  for	  the	  	  
	  	  Electrostatic	  Interactions	  between	  Small	  Molecules	  and	  RNA	  
	  
The	  amine	  groups	  of	  the	  Aminoglycosides	  recognize	  the	  phosphate	  backbone	  of	  the	  RNA	  
[31,	  32].	   	  The	  binding	  affinity	  of	  the	  small	  molecule	  is	  also	  dependent	  on	  the	  number	  of	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amines	  present	  on	  the	  small	  molecule.	  The	  electronegative	  charge	  spectrum	  created	  by	  
the	  phosphate	  backbone,	  and	  oxygen	  and	  nitrogen	  moieties	  of	  the	  bases	  of	  the	  RNA	  in	  the	  
major	  groove	  creates	  a	  charge	  contour	  for	  small	  molecule	  recognition	  and	  binding	  similar	  
to	  that	  of	  protein	  surface	  charge	  spectrum.	   	  Altering	  the	  pH	  in	  vitro	  altered	  the	  binding	  
affinity	   of	   certain	   Aminoglycosides	   [38,	   39].	   By	   introducing	   more	   electro	   positively	  
charged	   groups	   (Guanidinium	   groups)	   in	   the	   place	   of	   amine	   groups	   in	   the	  
Aminoglycosides,	   increased	  affinity	   is	  observed	   to	  RNA	   [40-­‐42].	  The	   significance	  of	   the	  
electrostatic	   interactions	   are	   also	   demonstrated	   using	   varying	   salt	   concentrations	   in	  
binding	   assays	   [41].	   By	   varying	   the	   NaCl	   concentration,	   the	   binding	   affinity	   could	   be	  
increased	  or	  decreased.	  Further	  thermodynamic	  studies	  of	  aminoglycoside	  binding	  with	  
ribosomal	  RNA	   in	  humans	  and	  E.coli	   show	  that	  more	   than	  half	  of	   the	  binding	  energy	   is	  
constituted	  from	  electrostatic	  interactions	  [40,	  43].	  	  
The	  electrostatic	  interactions	  between	  RNA	  and	  small	  molecule	  contribute	  to	  high	  affinity	  
binding.	   However	   one	   disadvantage	   with	   electrostatic	   interaction	   is	   that	   a	   number	   of	  
non-­‐specific	  interactions	  with	  many	  RNA	  targets	  leading	  to	  promiscuous	  RNA	  binding	  are	  
observed	  with	  many	   Aminoglycosides.	   However	   the	   specificity	   of	   the	   Aminoglycosides	  
could	  be	  increased	  by	  increasing	  the	  salt	  concentrations	  in	  the	  binding	  assay	  to	  eliminate	  
weak	  electrostatic	  interactions	  [44].	  	  	  
	  
1.4.2.	  	  Nonionic	  Interactions	  
	  
Though	   the	  Aminoglycosides	   are	  positively	   charged	   and	   the	  RNA	   is	   negatively	   charged,	  
various	  nonionic	  interactions	  such	  as	  stacking	  and	  packing	  interactions	  stabilize	  the	  RNA-­‐
Aminoglycoside	  complex.	  Several	  Aminoglycosides	  make	  nonionic	  interactions	  that	  bury	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the	  non-­‐polar	  moieties	  of	  the	  small	  molecule	  into	  the	  hydrophobic	  groove	  of	  the	  RNA.	  It	  is	  
observed	   from	   16s	   rRNA	   A-­‐site	   construct,	   that	   ring	   I	   of	   the	   Gentamycin	   is	   involved	   in	  
stacking	  interaction	  with	  the	  G1491	  and	  A1492	  residues	  of	  the	  RNA	  [45].	  
	  
1.4.2. Pseudo	  Base	  Pairs	  Facilitate	  Small	  Molecule	  Recognition	  
	  
RNA	   is	   highly	   structured	   as	   mentioned	   in	   the	   previous	   sections.	   It	   consists	   of	   A-­‐form	  
double	  helices	  with	   intervening	  bulges,	  and	   loops	  resulting	   from	  the	  non-­‐canonical/non	  
Watson-­‐Crick	  base	  pairs.	  	  A	  close	  look	  at	  the	  aminoglycoside	  bound-­‐RNA	  complexes,	  show	  
that	  the	  rings	  of	  the	  Aminoglycosides	  stabilize	  such	  unpaired/non-­‐canonical	  residues.	  The	  
stabilizing	  interactions	  could	  be	  the	  mode	  of	  recognition	  in	  the	  binding	  sites	  of	  the	  RNA.	  
This	  recognition	  mode	  is	  well	  studied	  through	  NMR	  and	  Circular	  Dichroism	  for	  an	  A-­‐site	  
RNA	  construct	  (a	  specific	  construct	  designed	  and	  synthesized	  for	  in	  vitro	  studies)	  with	  the	  
Deoxystreptamine	  Aminoglycosides	  such	  as	  Apramycin	  [47].	  
Westhof	   and	   colleagues	   have	   shown	   high-­‐resolution	   structures	   for	   the	   A-­‐site	   RNA	   in	  
complex	  with	   the	   Aminoglycosides	   Gentamycin	   and	   Paromomycin	   [46,	   48].	   They	   have	  
done	   extensive	   work	   on	   the	   role	   of	   the	   base	   pairs	   and	   pseudobasepairs	   in	   ligand	  
recognition.	  
	  
1.4.4.	  Water	  Mediated	  Contacts	  
	  
The	   2’OH	   group	   of	   the	   ribose	   sugar	   in	   RNA	   is	   a	   strong	   hydrogen	   bond	   donor.	   It	  
contributes	   to	   the	   excessive	  hydration	  of	  RNA	   in	   the	  minor	   groove	  by	   forming	  a	  highly	  
ordered	  water	   network	   [49].	   The	   excess	   water	  molecules	   in	   various	   ligand	   interacting	  
regions	  of	  the	  RNA	  mediate	  ligand	  binding.	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Figure	   1.3:	   A	   cartoon	   representation	   of	   the	   Gentamicin	   C1A	   and	   the	   A-­‐site	   RNA	  
fragment.	  Orientation	  of	  Gentamicin	  C1A	  (ball	  and	  stick	  representation)	  molecule	  
inside	  the	  A	  site	  RNA	  duplex	  (pink	  cartoon).	  Ring	  numbers	  of	  Gentamycin	  C1a	  are	  
designated	   I–III.	   (Figure	   using	   adapted	   from	   [46]	   and	   generated	   with	   crystal	  
structure	  of	  NDB	  ID:	  DR0015	  	  with	  RCSB	  Jmol	  viewer).	  	  
	  
	  
The	  water	  molecules	   rearrange	   themselves	   and	   optimize	   the	   hydrogen	   bond	   distances	  
between	  the	  small	  molecules	  and	  the	  RNA.	  The	  Aminoglycosides	  are	  well	  explored	  in	  the	  
context	  of	  water	  mediated	  hydrogen	  bond	  formation	  in	  the	  16s	  A-­‐Site	  ribosomal	  RNA	  [40,	  
44].	  Such	  studies	  establish	  that	  the	  water	  molecules	  also	  have	  a	  role	  in	  compensating	  the	  
energy	  penalty	  of	  dehydration	  within	   the	  RNA	  binding	  pocket	  upon	  tight	  binding	  of	   the	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1.4.3. Conformational	  Flexibility	  of	  RNA	  Accounts	  for	  Small	  Molecule	  Binding	  and	  	  
Attaining	  Shape	  Complementarity	  
	  
A	  small	  subset	  of	  ligand	  bound	  RNA	  structures	  show	  that	  RNA	  allows	  the	  recognition	  of	  
the	   small	   molecule	   ligand	   and	   by	   conformational	   adaptation,	   the	   RNA	   attains	   high	  
binding	  affinity	  with	  the	  ligand.	  The	  conformational	  flexibility	  of	  RNA	  is	  a	  bane	  for	  RNA	  
based	  drug	  discovery,	  as	  it	  is	  problematic	  for	  structure	  based	  drug	  design	  [51].	  From	  the	  
lessons	   learned	   from	   the	   hammerhead	   ribozyme-­‐aminoglycoside	   binding	   and	   A-­‐Site-­‐
aminoglycoside	   binding,	   it	   is	   hypothesized	   that	   the	   RNA	   conformationally	   adapts	   to	   a	  
structure	  that	  attains	  high	  affinity	  with	  the	  ligand	  [52-­‐54].	  	  
	  
1.5. Riboswitches	  Are	  Classic	  RNA	  Systems	  to	  Understand	  Diverse	  
Small	  Molecule-­‐RNA	  Interactions	  
	  
From	  the	  above	  literature	  review	  focused	  on	  identifying	  small	  molecule	  ligands	  binding	  to	  
RNA,	   the	   two	   reviews	   by	   Aboul-­‐Ela	   [55]	   and	   Hergenrother	   [56]	   that	   comprehensively	  
summarize	  the	  various	  small	  molecules	  developed	  to	  target	  RNA,	  it	  is	  evident	  that	  most	  of	  
the	   RNA	   binders	   (or	   at	   least	   the	   most	   frequently	   studied)	   are	   Aminoglycosides,	  
Chloramphenicols,	   Tetracyclines,	   and	   DNA	   binding	   intercalators.	   As	   discussed	   above,	  
Aminoglycosides	  and	  their	  derivatives	  are	  nonspecific	  as	  observed	  by	  their	  ability	  to	  bind	  
to	   many	   RNA	   targets.	   Even	   derivatization	   of	   the	   Aminoglycosides	   has	   not	   resulted	   in	  
achieving	  high	   specificity	  and	  affinity	   in	  most	   cases	   [57,	  58].	  Other	  major	  drawbacks	   in	  
using	   Aminoglycosides	   as	   drug	   molecules	   are	   their	   cytotoxicity	   at	   high	   dosages	   (for	  
attaining	  high	  affinity	  with	  the	  target	  RNA)	  and	  problems	  with	  drug	  delivery.	  	  
The	  recent	  discovery	  of	  regulatory	  mRNA	  elements	   in	  the	  non-­‐coding	  regions	  called	  the	  
‘Riboswitches’	   has	   opened	   venues	   for	   understanding	   RNA-­‐small	   molecule	   interactions	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and	   RNA	   based	   drug	   discovery.	   New	   riboswitches	   have	   been	   discovered	   continuously	  
during	   the	   last	   decade.	   Each	   of	   these	   riboswitches	   recognize	   their	   cognate	   ligand	  with	  
high	   specificity	   and	   bind	   with	   high	   affinity	   [59].	   The	   ligands	   that	   interact	   with	   the	  
riboswitches	  are	  structurally	  diverse.	  The	  mechanisms	  by	  which	  the	  riboswitches	  interact	  
with	  their	  ligands	  vary	  from	  one	  riboswitch	  to	  another	  [59,	  60].	  	  
Riboswitches	  are	  functionally	  significant	  for	  their	  gene	  regulatory	  mechanisms.	  They	  are	  
gene	  regulatory	  elements	   that	   function	  at	   the	   translational	  or	   transcriptional	   levels	  and	  
that	  work	  with	  minimal	  gene	  regulatory	  machinery[61].	  The	  riboswitches	  operate	  within	  
two	   domains.	   The	   aptamer	   domain	   binds	   to	   the	   ligand	   and	   the	   expression	   platform	  
undergoes	  structural	  changes	  upon	  ligand	  binding	  to	  modulate	  gene	  expression[61,	  62].	  
High	  sequence	  specificity	  is	  found	  in	  the	  ligand-­‐binding	  domain	  in	  classes	  of	  riboswitches	  
that	   bind	   to	   the	   same	   ligand.	   For	   example	   there	   is	   sequence	   conservation	   between	   the	  
SAM-­‐I,II,IV	   riboswitch	   classes.	  All	   the	   three	   classes	  bind	   to	   the	   small	  molecule	   ligand	  S-­‐
Adenosyl	   Methionine	   (SAM).	   The	   non-­‐conserved	   expression	   platform	   signifies	   that	  
though	   some	   riboswitches	   recognize	   similar	   ligands,	   they	   can	   operate	   by	   different	  
mechanisms.	   The	   sequence	   conservation	   in	   the	   ligand-­‐binding	   domain	   is	   shown	   to	   be	  
responsible	  for	  the	  specific	  recognition	  of	  the	  cognate	  ligands.	  An	  in-­‐depth	  understanding	  
of	  small	  molecule	  interactions	  with	  riboswitches,	  increases	  the	  scope	  for	  developing	  more	  
novel	   and	   structurally	   diverse	   RNA	   targeting	   drugs[63].	   The	   structural	   and	  mechanical	  
studies	  that	  decipher	  the	  reasons	  for	  the	  riboswitch	  specificity	  to	   its	  cognate	   ligand	  and	  
the	   ability	   of	   the	   small	   molecule	   to	   alter	   the	   riboswitch	   structure	   upon	   binding	   will	  
contribute	  significantly	  towards	  RNA	  based	  drug	  development.	  The	  following	  few	  sections	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will	  describe	  aspects	  of	   the	  riboswitches	   including	  structures	  of	   ligand	  binding	  domains	  
and	  their	  gene	  expression	  controlling	  mechanisms.	  
	  
1.5.1. Riboswitches	  in	  Gene	  Expression	  Regulation	  
	  
The	  process	  of	   gene	  expression	   includes	   the	   transcription	  of	  DNA	   into	  messenger	  RNA	  
(mRNA).	   The	   information	   on	   the	   mRNA	   is	   then	   translated	   into	   protein.	   Various	   gene	  
expression	  control	  mechanisms	  have	  been	  discovered	  at	  transcriptional	  and	  translational	  
levels.	   These	   mechanisms	   involve	   DNA-­‐protein,	   DNA-­‐DNA,	   DNA-­‐RNA,	   RNA-­‐Protein	  
interactions.	   The	   role	   of	   RNA	   in	   gene	   regulation	   as	   attenuators	   in	   E.coli	   trp	   operon	  
located	  near	  the	  5’	  untranslated	  region	  is	  shown	  previously	  [64].	  The	  non-­‐coding	  RNAs	  
(ncRNA)	  operate	  by	  either	  interacting	  with	  coding	  mRNA	  through	  complementarity	  or	  by	  
interacting	  with	   gene	   regulatory	   proteins	   [65,	   66].	   The	   riboswitch	   ability	   to	  modulate	  
gene	   expression	   gained	   attention	   since	   the	   last	   decade	   since	   Henkin	   and	   coworkers	  
identified	   gene	   regulatory	   elements	   in	   the	   5’	   untranslated	   regions	   of	   gram-­‐positive	  
bacteria.	   These	   regulatory	   mRNA	   elements	   called	   the	   riboswitches	   operate	   at	  
transcriptional	   and	   translational	   levels	   by	   interacting	   with	   small	   molecules	   without	  
accessory	   proteins	   or	   DNA	   [61,	   67].	   The	   riboswitches	   have	   high	   selectivity	   for	   their	  
cognate	   ligands	  [68,	  69].	  They	  undergo	  structural	  and	   functional	  switching	  upon	   ligand	  
binding.	  	  
In	   transcriptional	   riboswitches	   the	   expression	   platform	   undergoes	   structural	  
rearrangement	  upon	  ligand	  binding.	  The	  conformational	  changes	  lead	  to	  the	  stabilization	  
or	  destabilization	  of	  a	  transcription	  terminator	  hairpin	  downstream	  of	  the	  ligand	  binding	  
site	   [70].	   In	   the	   presence	   of	   the	   ligand	   the	   terminator	   helix	   is	   stabilized.	   This	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configuration	   is	   referred	   to	  as	   the	   ‘OFF’	   state.	   In	   the	   ligand	   free	  state,	   the	  RNA	   folds	   to	  
form	  an	  alternative	  helix	   called	   the	  antiterminator	   (AT)	   that	  prevents	   the	   formation	  of	  
the	   intrinsic	   terminator.	   The	   RNA	   with	   AT	   is	   referred	   to	   as	   the	   ‘On’	   state.	   	   Some	  
riboswitches	  work	   by	   positive	   feedback	   regulation.	   The	   binding	   of	   the	   ligand	   in	   these	  
riboswitches	   will	   stabilize	   the	   On	   state.	   The	   interplay	   of	   these	   mutually	   exclusive	  
terminator	  and	  antiterminator	  helices	  in	  the	  presence	  or	  absence	  of	  the	  ligand	  results	  in	  
gene	  expression	  control.	  	  
During	   translation	   of	   the	   mRNA,	   the	   Shine-­‐Dalgarno	   (SD)	   sequence	   on	   the	   mRNA	   is	  
necessary	   for	   translation	   initiation	   by	   ribosomal	   recruitment	   onto	   the	   mRNA.	   In	  
translational	  riboswitches,	  the	  ligand	  binding	  to	  the	  aptamer	  leads	  to	  sequestration	  of	  the	  
SD	  sequence	  via	  the	  formation	  of	  anti-­‐SD	  helix	  (ASD).	  In	  the	  “On”	  state,	  the	  formation	  of	  
the	  ASD	  is	  prevented	  by	  an	  alternative	  helix	  anti-­‐anti-­‐SD	  (AASD)	  [71,	  72].	  	  
A	   third	   category	   of	   riboswitch	   mechanism	   is	   through	   splicing.	   Ligands	   binding	   to	   the	  
ribozyme	  based	  riboswitches	  undergo	  structural	  changes	   to	  stabilize	  a	   ribozyme	   in	   the	  
catalytic	   state.	   The	   ribozyme	   cleaves	   the	   mRNA	   preventing	   further	  
transcription/translation	  [73,	  74].	   	  Schematic	  depiction	  of	   the	   transcription,	   translation	  
and	  ribozyme	  based	  riboswitch	  mechanisms	  are	  shown	  in	  Figure	  1.4.	  
	  
1.5.2.	  Classification	  and	  Distribution	  of	  Riboswitches	  
	  
The	  Riboswitches	  respond	  to	  a	  variety	  of	  biological	  and	  physical	  stimuli	  that	  range	  from	  
temperature	   to	   metabolite	   and	   metal	   ion	   concentrations	   in	   the	   cellular	   environment.	  
Most	   effector	   molecules	   are	   metabolites	   such	   as	   amino	   acids,	   nucleic	   acids,	   vitamins,	  
enzyme	  cofactors	  and	  metal	  ions.	  The	  metabolite	  effectors	  of	  riboswitches	  in	  most	  cases	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are	  the	  end	  products	  of	  cellular	  metabolic	  pathways.	  Hence	  the	  riboswitches	  are	  involved	  
in	  gene	  regulation	  based	  on	  a	  feedback	  mechanism	  that	  can	  result	  in	  down-­‐regulation	  or	  
up-­‐regulation	   of	   genes	   involved	   in	   the	   metabolite	   synthesis.	   Sequence	   conservation	   is	  
limited	   to	   the	   aptamer	   domain	   in	   riboswitches	   belonging	   to	   the	   same	   class.	   However	  
more	   than	   sequence	   conservation,	   the	   secondary	   structural	   elements	   are	   conserved	   in	  
the	  aptamer	  domains	  responsible	  for	  ligand	  recognition	  [75].	  Riboswitches	  are	  classified	  
as	   families	   and	   classes.	   The	   classification	   is	   based	  mainly	   on	   the	   secondary	   structural	  
elements	  and	  the	  effector	  ligands	  or	  the	  signal	  to	  which	  the	  riboswitch	  responds.	  
For	  example	  the	  SAM	  riboswitch	  family	  (All	  the	  riboswitches	  that	  detect	  SAM	  fall	  into	  this	  
family)	  has	  5	   classes	   (SAM	  riboswitches	  with	   conserved	  secondary	   structural	   elements	  
fall	   into	  a	  designated	  class).	   	   	  To	  date	  24	  classes	  of	   the	  riboswitches	  are	   identified	  with	  
autonomous	  gene	  control	  mechanisms	  in	  various	  forms	  of	  life	  [76].	  
The	  riboswitches	  based	  on	  mechanism	  of	  gene	  regulation	  and	  location	  of	  the	  expression	  
platform	   and	   aptamer	   are	   categorized	   into	   five	   categories.	   The	   five	   categories	   include	  
antisense	   regulation,	   transcription	   regulation,	   translation	   regulation,	   dual	   transcription	  
and	  translation	  regulation	  and	  direct	  translation	  regulation	  [59].	  
In	  the	  case	  of	  SAM	  riboswitches,	  there	  are	  five	  classes.	  The	  secondary	  structural	  elements	  
required	   for	   SAM	   recognition	   are	   conserved	   more	   than	   the	   sequence	   of	   the	   aptamer	  
domains	  in	  each	  class.	  Less	  sequence	  but	  more	  secondary	  structure	  conservation	  is	  seen	  
in	   the	   expression	   platforms	   because	   the	   riboswitches	   that	   bind	   to	   the	   same	  metabolite	  
(SAM	   riboswitches)	   have	   different	   modes	   of	   gene	   regulation	   at	   transcriptional	   or	  
translational	  levels.	  Such	  diverse	  mode	  of	  operation	  of	  the	  riboswitches	  in	  response	  to	  the	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same	   metabolite	   indicates	   shared	   origin	   but	   independent	   evolution	   of	   individual	  




Figure1.4:	   Schematic	   representation	   of	   riboswitch	   mechanisms.	   The	   red	   circle	  
indicates	   the	   metabolite	   molecule.	   RBS	   is	   the	   ribosome-­‐binding	   site.	   The	   single	  
arrow	  indicates	  the	  cleavage	  point	  in	  ribozyme	  control.	  
	  
Several	  methods	  have	  been	  implemented	  in	  identifying	  the	  prevalence	  of	  riboswitches	  in	  
various	  organisms.	  The	  search	  for	  known	  riboswitches	  and	  new	  riboswitches	   in	  various	  
organisms	   is	   complicated	  when	  using	  simple	  genomic	  database	  searches	  because	  of	   the	  
sequence	   variability	   in	   the	   expression	   platform	   and	   aptamers	   as	   mentioned	   earlier.	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Identification	   of	   riboswitches	   in	   the	   5’	   untranslated	   region	   of	   mRNA	   has	   been	  
implemented	   using	   comparative	   genomics,	   specific	   sequence	   elements,	   consensus	  
secondary	   structure	   elements	   and	   covariance	   models	   [59,	   78].	   Most	   riboswitches	  
discovered	  to	  date	  are	  found	  in	  bacteria.	  Some	  riboswitches	  are	  found	  in	  all	  three	  forms	  of	  
life	   [79,	  80].	  The	  riboswitch	  studies	   from	  metagenomics	   indicate	   that	   the	  THI	  box,	  B12,	  
and	  glycine	  riboswitches	  are	  the	  most	  abundant	  riboswitches	  followed	  by	  SAM	  and	  FMN	  
riboswitches	  while	  glmS,	  lysine,	  and	  purine	  riboswitches	  representing	  the	  least	  abundant.	  	  
Very	  few	  riboswitches	  have	  so	  far	  been	  identified	  in	  the	  eukaryotes.	  	  
	  
1.5.3.	  	  	  Non	  Cognate	  Riboswitch	  Small	  Molecule	  Ligands	  for	  Antibacterial	  Drugs	  
	  
As	  mentioned	   in	   the	   earlier	   sections,	   nearly	   24	   classes	   of	   riboswitch	   are	   discovered	   to	  
date	  and	  most	  of	  them	  are	  found	  in	  bacteria.	  Riboswitches	  are	  novel	  chemical	  scaffolds	  for	  
antibacterial	   drug	   targets	   with	   their	   distribution	   in	   such	   vast	   a	   spectrum	   of	  
microorganisms	   and	   their	   involvement	   in	   potential	   gene	   regulation	   of	   essential	  
metabolites.	  The	  Figure	  1.5	  [63]	  summarizes	  the	  gene	  control	  by	  riboswitches	  in	  various	  
pathogenic	  bacteria.	  	  
The	  presence	  of	  different	  riboswitch	  classes	  in	  such	  a	  variety	  of	  bacteria	  opens	  venues	  for	  
developing	  novel	  RNA	  binding	  antibacterial	  drugs.	  The	  antibacterial	  activity	  by	  targeting	  
riboswitches	   can	   be	   achieved	   largely	   by	   1)	   Developing	   ligands	   that	   compete	   with	   the	  
cognate	  ligand	  and	  prevent	  the	  binding	  of	  the	  latter	  to	  fix	  the	  riboswitch	  either	  in	  the	  ‘On’	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Figure	   1.5:	   	   The	   distribution	   of	   riboswitches	   in	   pathogenic	   bacterial	   species.	   The	  
numbers	   indicate	   the	   representatives	   of	   each	   class,	   the	   number	   in	   parenthesis	  
indicates	   the	   number	   of	   genes	   regulated,	   red	   color	   signifies	   that	   the	   genes	  
regulated	   by	   those	   riboswitches	   are	   responsible	   for	   virulence	   of	   the	   bacteria	  	  
(Adapted	  from	  [63]).	  	  
	  
or	   	   ‘Off’	   configuration	   (based	   on	   the	   mechanism	   of	   the	   riboswitch),	   2)	   by	   developing	  
ligands	   that	   bind	   sites	   other	   than	   the	   aptamer	   site	   and	   preventing	   the	   cognate	   ligand	  
binding	   in	   a	   non	   competitive	   manner	   or	   sequestering	   the	   elements	   in	   the	   expression	  
platform	   required	   for	   the	   formation	   of	   decision	  making	   helices	   (AT,AAT,SD,	  ASD,	  AASD	  
etc).	  	  
From	  Figure	  1.5	   it	   is	  evident	   that	   the	  Thiamine	  pyrophosphate	  (TPP)	  riboswitch,	  Flavin	  
mononucleotide	   riboswitch	   (FMN),	   Purine	   riboswitch,	   Adocobalamine	   (AdoCbl)	  
riboswitch	  and	  the	  SAM-­‐I	  riboswitch	  are	  prevalent	  in	  most	  pathogenic	  bacteria.	  It	  is	  also	  
noteworthy	  that	  the	  some	  of	  the	  genes	  that	  are	  regulated	  by	  these	  riboswitches	  in	  these	  
bacteria	   are	   responsible	   for	   the	   virulence	   of	   these	   bacteria.	   Several	  methods	   that	   have	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Numerous other RNA motifs also have been explored as potential drug 
targets20. In most of these examples, association of the ligand with the 
RNA target is a fortuitous interaction, rather than the natural function 
of the RNA. As a consequence, the design of new ligands directed at these 
targets can be problematic due to a lack of selectivity21.
Riboswitches are fundamentally different RNA drug targets, in that 
they have evolved as structured receptors for the purpose of binding low-
molecular weight ligands. As a consequence, riboswitches form ligand-
receptor interfaces with a level of structural complexity and selectivity 
that approaches that of proteins. For example, the receptor of a guanine-
binding riboswitch from Bacillus subtilis forms a three-dimensional (3D) 
structure in which the ligand is almost completely enveloped (Fig. 3a)22–24.
Guanine intercalates between two aromatic base triads, and four addi-
tional riboswitch nucleotides form hydrogen-bonding interactions that 
recognize each polar functional group of guanine. The intimacy of this 
interaction enables the riboswitch to discriminate against even closely 
related purine analogs22, and the sequence conservation of the nucleo-
tides that form the binding pocket implies that all guanine riboswitches 
form the same core receptor structure (Fig. 3a)22.
Members of other riboswitch classes form similarly intricate ligand-
receptor interfaces and show equally high levels of ligand selectivity. 
For instance, TPP riboswitches form a recep-
tor comprised of one subdomain that rec-
ognizes every polar functional group of the 
4-amino-5-hydroxymethyl-2-methylpyrimi-
dine (HMP) moiety (Fig. 3b, left panel) and a 
second subdomain that coordinates two metal 
ions and several water molecules to bind the 
negatively charged pyrophosphate (PP) moiety
(Fig. 3b, right panel)25,26. These two subdo-
mains are positioned so that the riboswitch 
can sense the length of its ligand. The recep-
tor is probably not selective for the structure 
of the thiazole ring, since its only contact with 
the receptor is a long-range electrostatic inter-
action. In a similar example, the 3D structure 
and biochemical data for class 1 SAM-binding 
riboswitches reveal a receptor in which nearly every functional group of 
SAM is important for binding (Fig. 3c)27,28.
Collectively, these data provide compelling evidence that riboswitches 
form structured receptors that are among the most selective of any RNA 
drug target. Thus, it is likely that riboswitch-targeting compounds could 
be designed that are highly selective and do not bind to other cellular 
targets. It is also anticipated that the 3D structure models for riboswitch 
receptors will enable the rational design of such compounds.
Several known antibacterial compounds function by targeting ribo-
switches. Historical validation exists that riboswitches can be antibac-
terial drug targets. Pyrithiamine is an analog of thiamine that inhibits 
the growth of several bacterial and fungal species29,30. Until recently, 
the toxicity mechanism of pyrithiamine was not well understood. 
Like thiamine, pyrithiamine is readily phosphorylated inside cells to
pyrithiamine pyrophosphate31 (PTPP, Fig. 4a), which differs from TPP 
only in that the central thiazole ring is replaced by a pyridinium ring. 
Remarkably, PTPP binds to several TPP riboswitches in vitro with com-
parable affinity to TPP and represses the expression of a reporter gene 
fused to a TPP riboswitch inside bacteria9. This suggests the possibility 




























































































































































































































































































































































































































Figure 2  The distribution of known riboswitch 
classes in selected bacterial pathogens.
(a) The secondary structure models of the 
receptor domains of 12 riboswitch classes and 
the chemical structures of the metabolites 
they bind. The expected protonation states at 
physiological conditions are shown for each 
functional group. Three different structural 
classes of riboswitches have been reported that 
recognize SAM. A star denotes a riboswitch 
class for which a representative 3D structure 
has been reported. Approximately a half-dozen 
additional classes of conserved RNA motifs 
that may be riboswitches have been identified 
in bacteria61,62. (b) Selected human bacterial 
pathogens that carry riboswitches. The number 
of representatives of each riboswitch class 
that is found in each species is given, followed 
in parentheses by the total number of genes 
regulated by those riboswitches. The red numbers 
indicate that at least one of the genes regulated 
by that riboswitch is predicted to be essential 
for survival or virulence. Some bacteria have two 
glycine aptamers (asterisks) in the same 5!-UTR 
that cooperatively bind two molecules of glycine 
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been	  adapted	  from	  general	  drug	  discovery	  have	  been	  used	  to	  identify	  novel	  ligands	  that	  
bind	  to	  these	  riboswitches.	  	  
	  
1.5.3.1.	  	  	  FMN	  Riboswitch	  Ligands	  
	  
The	   FMN	   riboswitch	   is	   found	   in	   the	   5’UTRs	   of	   gram-­‐positive	   bacteria.	   It	   regulates	   the	  
expression	   of	   genes	   involved	   in	   riboflavin	   metabolism.	   FMN	   is	   a	   phosphorylated	  
derivative	   of	   riboflavin.	   Inline	   probing	   studies	   have	   revealed	   that	   the	   FMN	   riboswitch,	  
also	   called	   the	   RFN	   element,	   controls	   gene	   expression	   by	   transcription/translation	  
termination	  [81,	  82].	  
A	   naturally	   occurring	   pigment,	   roseoflavin	   binds	   to	   the	   FMN	   riboswitch.	   [81].	   Inline	  
probing	   analysis	   (Method	  described	   in	   chapter	  3)	   of	   the	   ribD	  FMN	  riboswitch	   indicates	  
that	  roseoflavin	  binds	  with	  an	  “apparent	  Kd”	  of	  ~100nM	  as	  compared	  to	  its	  cognate	  ligand	  
FMN	   of	   3nM	   and	   riboflavin	   of	   5nM.	   (The	   affinity	   is	  mentioned	   as	   apparent	   Kd	  in	   some	  
references	  because	  the	  measured	  value	  is	  not	  the	  actual	  Kd,	  it	  is	  the	  Kd	  observed	  using	  a	  
particular	   method,	   in	   this	   case	   inline	   probing.	   Different	   Kd	  values	   are	   reported	   for	   the	  
same	   SAM	   riboswitch	   construct	   using	   different	   techniques	   (table	   3.3	   in	   chapter	   3).	  
However	   some	   authors	   report	   apparent	   Kd	   as	   Kd).	   The	   phosphate	   groups	   of	   the	   FMN	  
render	   tighter	   binding	   with	   the	   aptamer.	   	   The	   ribityl	   groups	   of	   the	   riboflavin	   and	  
roseoflavin	  bind	  differently	  than	  the	  FMN	  ribityl	  group.	  Mutational	  analysis	  and	  structural	  
probing	  data	  suggest	   that	   the	  aptamer	  adapts	   to	   the	  ribityl	  groups	  of	   the	  riboflavin	  and	  
roseoflavin	   during	   binding.	   Such	   binding	  with	   riboflavin	   and	   roseoflavin	   is	   observed	   in	  
FMN	  riboswitches	  of	  more	  than	  one	  bacterial	  species	  [83].	  The	  role	  of	  the	  FMN	  riboswitch	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is	   in	  agreement	  with	  the	  antibacterial	  activity	  of	  roseoflavin	  from	  the	  experimental	  data	  
mentioned	  above.	  	  
	  
1.5.3.2.	  Lysine	  Analogs	  Targeting	  Lysine	  Riboswitch	  
	  
The	   lysine	   riboswitch	   is	   found	   in	   many	   gram	   positive	   and	   gram-­‐negative	   bacteria	  
including	  pathogenic	  E.coli	   and	  B.subitilis.	  The	  riboswitch	  controls	   the	  expression	  of	   the	  
lysC	  gene	  that	  codes	  for	  aspartasekinase	  II	  enzyme	  responsible	  for	  lysine	  synthesis	  [84].	  It	  
also	  controls	   the	  expression	  of	  other	  genes	  such	  as	  yvsH	  involved	   in	   the	   transport	  of	  L-­‐
lysine.	  The	  lysine	  riboswitch	  aptamer	  senses	  the	  L-­‐lysine	  and	  modulates	  gene	  expression	  
by	   transcription	   termination.	   The	   lysine	   riboswitch	   secondary	   structure	   elements	  
consists	   of	   the	   helices	   P1-­‐P6,	   junction	   regions	   and	   loop	   E	   involved	   in	   interhelical	  
interactions	  and	  Kink-­‐turn	  (Loop	  E	  is	  an	  internal	  symmetric	  loop	  with	  non-­‐canonical	  base	  
pairs,	   kink	   turn	   is	   a	   sharp	   bend	   or	   kink	   between	   two	   double-­‐stranded	   elements	   and	   it	  
bends	   toward	   the	   minor/shallow	   groove	   [85-­‐87])	   formation	   [88].	   The	   secondary	  
structure	  undergoes	  reorganization	  upon	  ligand	  binding	  [89,	  90].	  The	  ligand-­‐binding	  site	  
is	  within	  the	  P1-­‐P5	  helices.	  The	  P1,	  P2	  and	  P4,	  P5	  helices	  are	  stacked	  with	  the	  inter-­‐helical	  
tertiary	  interactions	  between	  loop	  regions	  mediated	  by	  a	  kink-­‐turn	  motif	  in	  the	  P2	  helix	  
[91].	   The	   crystal	   structure	   of	   the	   lysine	   riboswitch	   aptamer	   in	   complex	   with	   lysine	  
revealed	   the	  structural	  elements	  required	   for	   the	   lysine	  recognition.	  Charges	  associated	  
with	  the	  two	  amino	  groups	  and	  a	  carboxyl	  group	  at	  the	  two	  ends	  of	  Lysine	  are	  recognized	  
by	   the	  aptamer.	  The	  high	  structural	  organization	  of	   the	  binding	  pocket	   for	   lysine	   in	   the	  
aptamer	  domain	  ensures	  high	  discrimination	  of	  lysine	  against	  its	  metabolite	  analogs	  [91].	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The	  Figure	  1.13	   illustrates	   the	  binding	  pocket	   interactions	  of	   the	   lysine	  riboswitch	  with	  
lysine	  from	  the	  crystal	  structure.	  
	  
	  
	  Figure1.6:	   	  Lysine	  analogs	  that	  were	  designed	  to	  target	  the	  lysine	  riboswitch	  (The	  
shaded	  regions	  are	  the	  modified	  functional	  groups)	  (Figure	  adapted	  from	  [88,	  91]).	  	  
	  
In	   spite	   of	   the	   lysine	   riboswitch’s	   high	   selectivity	   for	   lysine,	   several	   antibacterial	   lysine	  
analogs	  such	  as	  L-­‐4-­‐Oxalysine,	  L-­‐Homoarginine,	  N-­‐6-­‐Acetyl-­‐L-­‐lysine,	  N	  2-­‐Methyl-­‐L-­‐lysine,	  
N	  6-­‐Trimethyl-­‐L-­‐lysine,	   3-­‐Amino-­‐L-­‐tyrosine	   are	   shown	   to	   bind	   to	   the	   lysine	   riboswitch.	  
These	  analogs	  not	  only	  bind	  to	  the	  riboswitch	  but	  also	  decrease	  the	  growth	  of	  the	  bacteria	  
invivo	   [88].	   Further	   examination	   of	   the	   binding	   pocket	   revealed	   that	   a	   cavity	   in	   the	  
binding	   pocket	   allows	   the	   binding	   of	   the	   lysine	   analogs.	   Of	   all	   the	   analogs,	   the	   S-­‐(2-­‐
aminoethyl)-­‐	   L-­‐cysteine	   (AEC)	  binds	  with	  30	   fold	   less	   affinity	   as	   compared	   to	   L-­‐Lysine.	  
The	  AEC	  modulates	  the	  structure	  of	  the	  riboswitch	  at	  high	  concentration.	  It	  is	  also	  shown	  
that	   the	   antibacterial	   resistance	  against	   these	   analogs	   is	   obtained	  by	  altering	   structural	  
elements	   involved	   in	   aptamer	   tertiary	   interactions[92].	   In	   a	   research	   conducted	   by	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Breaker	   et	   al,	   they	   observed	   that	   the	   growth	   of	  B.anthracis	   and	  B.subtilis	   in	   lysine	   rich	  
media,	  in	  the	  presence	  of	  the	  above	  ligands,	  is	  not	  inhibited[88].	  This	  indicates	  that	  some	  
ion	  transporters	  assist	  the	  bacteria	  in	  using	  the	  lysine	  from	  the	  media[93].	  In	  such	  a	  case,	  
though	  the	  genes	  responsible	  for	  lysine	  biosynthesis	  are	  repressed,	  through	  targeting	  the	  
lysine	  riboswitch,	  potential	  bacterial	  growth	  inhibition	  cannot	  be	  attained	  if	  the	  bacteria	  
can	  depend	  on	  host	  lysine	  alternatively.	  	  
	  
1.5.3.3.	  Small	  Molecules	  That	  Target	  TPP	  Riboswitches	  
The	  Thiamine	  pyrophostphate	  (TPP)	  class	  of	  riboswitches	  are	  involved	  in	  the	  regulation	  
of	  genes	  involved	  in	  thiamine	  metabolism	  and	  transport.	  Thiamine	  is	  a	  crucial	  cofactor	  of	  
enzymes	   involved	   in	   catalysis	   of	   glycolytic,	   citric	   acid	   cycle,	   and	   pentose	   pathway	  
reactions.	   Intracellular	   thiamine	   is	   phosphorylated	   to	   TPP.	   TPP	   participates	   in	   the	  
aforementioned	   reactions	   to	   cleave	   carbon-­‐carbon	   bonds	   adjacent	   to	   carbonyl	   groups.	  
The	  TPP	  riboswitch	  is	  found	  in	  the	  5’UTRs	  in	  bacteria,	  plants	  and	  fungi.	  It	  binds	  to	  the	  TPP	  
specifically	   and	   alters	   the	   gene	   expression	   of	   the	   downstream	   genes	   thiM	   and	   thiC	  
involved	  in	  Thiamine	  metabolism[94].	  The	  modes	  of	  operation	  for	  TPP	  riboswitches	  vary	  
in	   different	   organisms.	   In	   certain	   bacteria,	   it	   operates	   at	   the	   translational	   level	   by	  
sequestering	   the	   SD	   sequence.	   In	   fungi,	   a	   ribozyme	  mediated	   gene	   control	   by	   the	   TPP	  
riboswitch	   that	   controls	   the	  mRNA	   splicing	   is	   seen[74].	   Inline	  probing	   studies	  with	   the	  
thiC	  and	  thiM	  TPP	  riboswitches	  have	  indicated	  that	  the	  phosphate	  groups	  and	  the	  amino	  
group	  make	  specific	  contacts	  with	  the	  TPP	  riboswitch	  aptamer	  (Figure	  1.15).	  
Equilibrium	  dialysis	  studies	  and	  inline	  probing	  studies	  with	  the	  TPP	  riboswitch	  show	  that	  
various	   analogs	   of	   TPP	   such	   as	   Benfotiamine,	   Amprolium,	   Oxythiamine	   and	   Thiamine	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disulfide	  make	  weak	  contacts	  with	  the	  thiM	  and	  thiC	  riboswitch.	  However	  these	  analogs	  
though	  similar	  to	  TPP,	  fail	  to	  modulate	  the	  overall	  riboswitch	  structure	  upon	  binding[94].	  
In	   the	   same	   research,	   the	   authors	   also	   observed	   that	   the	   TPP	   derivatives,	   Thiamine	  
phosphate	   and	   Thiamine	   bind	   to	   the	   thiC	   and	   thiM	   riboswitch	   and	   modulate	   the	  
riboswitch	  structure	  as	  observed	  by	  the	  inline	  probing	  studies.	   	  In	  several	  instances,	  the	  
isosteric	   Thiamine	   analog	   Pyrithiamine	   (PT)	   is	   shown	   to	   inhibit	   the	   growth	   of	   many	  
bacteria	   and	   fungi	   and	   in	   eukaryotes,	   PT	   is	   phosphorylated	   to	   PTPP	   like	   Thiamine	   and	  
PTPP	  inhibits	  the	  role	  of	  TPP	  in	  enzyme	  catalysis[95,	  96].	  In	  other	  microbial	  studies,	  it	  is	  
seen	  that	  the	  expression	  of	  genes	  involved	  in	  the	  thiamine	  metabolism	  like	  the	  thiA,	  tenA	  
are	   altered	   when	   certain	   fungi	   and	   bacteria	   are	   grown	   in	   media	   containing	   PT.	   The	  
binding	  of	  PT,	  PTPP	  and	  thiamine	  to	  the	  TPP	  riboswitches	  was	  studied	  recently	  to	  probe	  
the	   involvement	   of	   the	   TPP	   riboswitches	   in	   the	   antibacterial	   and	   antifungal	   activity	   as	  
mentioned	  above[97].	  	  
The	  Inline	  probing	  analysis	  with	  the	  tenA	  bacterial	  TPP	  riboswitch	  shows	  that	  the	  PT	  and	  
Thiamine	  and	  PTPP	  significantly	  bind	  to	  the	  riboswitch	  with	  an	  affinity	  of	  ~6µM,	  50µM,	  
160nM	  respectively	  as	  compared	  to	  50nM	  with	  TPP.	  These	  compounds	  are	  shown	  to	  have	  
antibacterial	   activity	   and	   PT	   resistant	   bacteria	   are	   shown	   to	   undergo	  mutations	   in	   the	  
TPP	  riboswitch	  aptamer[97].	  	  The	  thiA	  TPP	  riboswitch	  in	  the	  Aspergillus	  oryzae	  fungi	  also	  
is	  shown	  to	  bind	  to	  the	  PTPP	  with	  an	  affinity	  of	  56nM	  as	  compared	  to	  50nM	  with	  TPP.	  It	  
induces	  structural	  changes	  to	  alter	  gene	  expression	  control	  in	  fungi	  [97].	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1.5.3.4.	  Purine	  Analogs	  That	  Bind	  the	  Guanine	  Responsive	  Riboswitch	  
The	  Guanine	   responsive	   riboswitch	   controls	   the	  expression	  of	   genes	   involved	   in	  purine	  
metabolism	  and	  transport.	  The	  secondary	  structure	  of	  the	  aptamer	  domain	  of	  the	  Guanine	  
riboswitch	   consists	   of	   helices	   P1,P2,P3	   and	   loops	   L2	   and	   L3.	   The	   tertiary	   interactions	  
between	  the	  helices	  are	  mediated	  through	  a	  pseudoknot	  motif.	  The	  L2	  and	  L3	  loops	  are	  
pre-­‐structured	  and	  assist	  the	  aptamer	  in	  ligand	  recognition.	  Upon	  ligand	  recognition,	  the	  
three	  helices	   bind	   tightly	   by	   completely	   enveloping	   the	   ligand	   [98,	   99].	   	   A	   downstream	  
terminator	  helix	  is	  formed	  upon	  ligand	  binding.	  In	  the	  absence	  of	  the	  ligand	  an	  AT	  helix	  is	  
formed	  and	  prevents	  formation	  of	  the	  terminator.	  Sequence	  comparison	  of	  four	  common	  
Guanine	  riboswitches	  suggested	  that	  common	  Guanine	  analogs	  could	  be	  used	  to	  target	  all	  
the	   Guanine	   riboswitches	   [100].	   	   The	   crystal	   structure	   of	   the	   Guanine	   bound	   Guanine	  
riboswitch	   shows	   that	   a	  Watson-­‐Crick	   base	   pair	   in	   the	   aptamer	   is	   crucial	   for	   Guanine	  
binding	  and	  also	  the	  examination	  of	  two	  regions	  in	  the	  aptamer	  revealed	  that	  additional	  
groups	  could	  be	  added	  in	  the	  C2	  and	  the	  C6	  region	  of	  the	  aptamer	  without	  loosing	  binding	  
affinity.	   Sixteen	  purine	   analogues	  have	  been	  designed	   rationally	   to	  bind	   to	   the	  Guanine	  
riboswitch.	   Inline	  probing	   analysis,	  mutational	   analysis	   and	   invivo	   studies	   indicate	   that	  
the	   G7,	   G6	   and	   G15	   compounds	   bind	  with	   significant	   affinity	   to	   two	   different	   bacterial	  
guanine	   riboswitches.	   The	   G7	   compound	   shows	   antibacterial	   activity	   [100,	   101].	   Four	  
novel	   purine	   riboswitch	   ligands	   are	   obtained	   by	   Brenk	   and	   group	   using	   RNA-­‐ligand	  
docking	  [101].	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Figure	   1.7:	   The	   ligands	   designed	   for	   targeting	   the	   Guanine	   riboswitch	   with	  
apparent	  KD	  values	  with	  the	  guanine	  riboswitch.	  (Figure	  adapted	  from	  [102]).	  
	  
1.5.3.5.	  T-­‐Box	  RNA	  and	  Its	  Ligands	  
The	  T	  Box	  RNA	  is	  one	  such	  regulatory	  RNA	  in	  the	  gram-­‐positive	  bacteria.	  The	  T	  Box	  RNA	  
is	   found	   in	   the	   5’	   untranslated	   region	   of	   the	   mRNA	   in	   B.SUBTILIS	   tyrS	   gene,	   encoding	  
tyrosyl-­‐tRNA	   synthetase.	   It	   is	   involved	   in	   regulating	   the	   amino	   acyl	   tRNA	   synthetases	  
[103].	   	  The	  regulatory	  effect	   is	  a	  result	  of	   the	  conformational	  alteration	  of	   the	  mRNA	  to	  
form	  either	  a	  terminator	  or	  an	  antiterminator	  helix	  in	  the	  presence	  or	  absence	  of	  charged	  
tRNA	  respectively.	  The	  anticodon	  loop	  of	  the	  tRNA	  interacts	  with	  the	  5’	  region	  stem	  loop	  
of	  the	  T	  Box	  RNA.	  The	  5’	  portion	  of	  the	  T	  Box	  detects	  the	  presence	  of	  the	  amino	  acid	  in	  the	  
charged	   tRNA.	   In	   the	   absence	   of	   the	   charged	   tRNA,	   the	   3’	   end	   of	   the	   uncharged	   tRNA	  
interacts	  with	  the	  3’	  region	  of	   the	  T	  Box	  to	   form	  a	  stable	  antiterminator	   that	  allows	  the	  
synthesis	  of	  proteins	  necessary	  for	  charging	  of	  the	  tRNAs.	  The	  bulge	  of	  the	  antiterminator	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is	   conformationally	   free	   as	   calculated	   from	   NMR	   studies[104].	   This	   region	   is	   logically	  
amenable	  for	  targeting	  with	  small	  molecules	  and	  the	  3’	  end	  recognizing	  bases	  of	  the	  T	  Box	  
also	   indicate	   sites	   for	   small	   molecule	   binding.	   Neomycin,	   streptomycin,	   oxazolidinones	  
are	  a	  few	  examples	  of	  T	  Box	  antiterminator	  binding	  molecules	  [105].	  	  
	  
1.5.3.5	  Ligands	  Binding	  to	  S-­‐Adenosyl	  Methionine	  (SAM)	  Riboswitch	  
The	  X-­‐ray	  crystal	  structures	  of	  the	  SAM	  riboswitches,	  in	  recent	  years	  revealed	  the	  binding	  
pocket	  at	  very	  high	  resolution.	  Five	  classes	  of	  SAM-­‐I	  riboswitches	  (SAM-­‐I	  to	  SAM-­‐V)	  are	  
identified	   to	  date	   and	   each	   class	  has	   its	   own	   conserved	  mechanism	  of	   SAM	   recognition	  
and	  binding.	  Previously	  the	  SAM	  analogs	  S-­‐Adenosyl	  Homocysteine	  (SAH)	  and	  S-­‐Adenosyl	  
Cysteine	   (SAC)	   have	   been	   shown	   to	   bind	   to	   the	   SAM-­‐I	   riboswitch	   by	   isothermal	  
calorimetry	  and	  equilibrium	  dialysis	  [106,	  107].	  From	  these	  experiments,	  it	  is	  shown	  that	  
the	   SAM	   analogs	   can	   only	   bind	   to	   the	   SAM-­‐I	   riboswitch	  with	  weak	   affinity,	   but	   cannot	  
replace	   the	   SAM	   even	   at	   very	   high	   concentrations.	   Very	   recently	   a	   set	   of	   SAM	   analogs	  
were	   shown	   to	   bind	   the	   SAM-­‐II	   riboswitch.	   The	   authors	   chose	   SAM-­‐II	   riboswitch	   after	  
comparing	   the	  SAM	   interactions	  with	   the	  SAM-­‐I	  and	  SAM-­‐II	   riboswitches	   in	   the	  binding	  
pocket.	  The	  SAM	  is	  tightly	  packed	  in	  a	  U	  conformation	  in	  the	  SAM-­‐I	  aptamer	  with	  almost	  
all	   the	  moieties	  of	  SAM	  making	  contacts	  with	   the	  aptamer	  residues	  [108].	   In	   the	  SAM-­‐II	  
riboswitch,	  SAM	  is	  in	  linear	  configuration	  rendering	  the	  amino	  terminal	  and	  the	  carboxy	  
terminal	   of	   the	   SAM	   some	   degree	   of	   freedom	   in	   the	  major	   groove	   of	   the	   aptamer.	   The	  
authors	  speculated	  that	  analogs	  of	  SAM	  modified	  in	  the	  amino	  and	  carboxy	  terminals	  can	  
potentially	  bind	  to	  the	  SAM-­‐II	  riboswitch	  without	   loosing	  any	  affinity.	  Five	  SAM	  analogs	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(Figure	  1.17)	  have	  been	   tested	  and	   interestingly,	   analog	  5	  binds	   to	   the	   SAM-­‐II	   aptamer	  




Figure	  1.8:	  S-­‐Adenosyl	  Methionine	  and	  its	  analogs	  (Figure	  adapted	  from	  [109]).	  	  
	  
	  It	   is	  discussed	   in	   the	  earlier	   sections	  on	  RNA	  based	  drug	  discovery	   that	  promiscuity	  of	  
RNA	   binding	   small	   molecule	   ligands	   is	   a	   concern	   to	   attain	   specificity	   and	   affinity.	   The	  
riboswitches	  are	  novel	  RNA	  small	  molecule	  targets,	  since	  they	  are	  highly	  selective	  to	  their	  
cognate	  ligands.	  The	  riboswitches	  are	  proved	  to	  be	  good	  antibacterial	  RNA	  drug	  targets	  as	  
mentioned	  in	  the	  above	  sections.	  The	  approach	  to	  target	  the	  riboswitches	  mainly	  involves	  
the	  characterization	  of	   the	  specific	  elements	  required	   for	   the	  recognition	  of	   the	  cognate	  
ligand	   by	   the	   riboswitch.	   An	   in-­‐depth	   understanding	   of	   the	   mechanism	   of	   the	   ligand	  
recognition	   by	   the	   riboswitches	   and	   the	   discrimination	   by	   the	   ligand	   between	   the	   two	  
states	  of	  the	  riboswitch	  (ON	  and	  Off	  states)	  may	  facilitate	  the	  design	  of	  ligands	  targeting	  
riboswitches.	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Our	  goal	   is	   to	  understand	   the	  RNA-­‐small	  molecule	   interactions	  and	  develop	  methods	   to	  
identify	  novel	  small	  molecules	  directed	  to	  RNA	  binding	  for	  RNA	  based	  drug	  development.	  
The	  specific	  aims	  of	  my	  research	  are	  1)	  To	  develop	  a	  RNA	  directed	  small	  molecule	  library	  
(chapter	   2)	   from	   the	   lessons	   learnt	   from	   aminoglycoside-­‐RNA	   interactions	   and	   from	  
Fragment	   based	   drug	   development	   strategies	   (since	   the	   RNA	   conformational	   flexibility	  
and	  plasticity	  pose	   issues	  against	  the	  use	  of	  Structure	  based	  drug	  development	  (SBDD))	  
and	  screen	  against	  RNA	  targets,	  and	  2)	  To	  probe	  the	  mechanism	  of	  the	  SAM-­‐I	  riboswitch	  
(chapter	  3)	  with	  the	  goal	  of	  understanding	  the	  structural	  features	  of	  the	  riboswitch	  that	  
contribute	   to	   the	   ligand	   specificity	   and	   to	   discrimination	   by	   SAM	   between	   SAM-­‐I	  
riboswitch	  gene	  expression-­‐controlling	  conformers.	  	  
	  
1.6. Concepts	  of	  Prokaryotic	  Transcription	  
Our	  work	  with	  the	  SAM-­‐I	  riboswitch	  mentioned	  in	  chapter	  three	  is	  related	  to	  prokaryotic	  
mRNA	   transcription.	   A	   brief	   review	   of	   prokaryotic	   transcription	   is	   introduced	   in	   this	  
section.	  The	  bacterium	  E.coli	  is	  the	  organism	  in	  which	  mRNA,	  RNA	  polymerase	  have	  been	  
first	   discovered	   [110].	   The	   ground	   work	   for	   delineating	   the	   principles	   of	   the	   RNA	  
transcription	  in	  Eukaryotes	  and	  prokaryotes	  started	  with	  E.coli	  transcription.	  	  
	  
	  
	  Figure	  1.9:	  RNA	  polymerase	  schematic	  in	  the	  closed-­‐promoter-­‐complex.	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The	  prokaryotic	  RNA	  polymerase	  is	  a	  polypeptide	  with	  four	  subunits	  α,	  β,	  β′,	  and	  σ.	  The	  
subunit	  σ	  is	  involved	  in	  the	  recognition	  of	  the	  transcription	  initiation	  sites.	  The	  core	  of	  the	  
RNA	  polymerase	  consists	  of	  the	  subunits	  α(2),	  β(1)	  and	  β′(1)	  subunits.	  They	  catalyze	  the	  
polymerization	  of	  the	  NTPs	  to	  RNA	  based	  on	  the	  information	  on	  the	  DNA	  strand.	  	  
Sequence	  comparisons	  of	  the	  genes	  in	  E.coli	   led	  to	  the	  identification	  of	  the	  transcription	  
initiation	  sites	  called	  the	  promoters	  [111]	  The	  RNA	  polymerase	  σ	  subunit	  recognizes	  the	  
promoter	   on	   the	   DNA	   and	   initiates	   polymerization.	   The	   nucleotide	   where	   the	  
transcription	  is	  initiated	  on	  the	  DNA,	  called	  the	  start	  site,	  is	  designated	  +1.	  The	  promoter	  
elements	   include	   two	   conserved	   six	   nucleotide	   sequences	   upstream	   of	   the	   start	   site	   at	  
positions	   -­‐10	   and	   -­‐35	   [112].	   Footprinting	   and	  mutation	   analysis	   at	   these	   two	   positions	  
indicate	  that	  the	  σ	  subunit	  of	  the	  polymerase	  specifically	  binds	  to	  these	  sequences	  during	  
transcription	  initiation.	  Lack	  of	  the	  σ	  subunit	  in	  the	  RNA	  polymerase	  leads	  to	  nonspecific	  
binding	  by	  the	  enzyme	  [113,	  114].	  	  
The	  RNA	  polymerase	  when	  first	  bound	  to	  the	  DNA	  is	  called	  the	  closed-­‐promoter-­‐complex.	  
In	  a	  subsequent	  step,	  the	  RNA	  polymerase	  unwinds	  the	  DNA	  to	  form	  the	  Open-­‐Promoter-­‐
Complex.	  The	  open-­‐promoter-­‐complex	  consists	  of	   the	  DNA	  with	  15	  unwound	  bases	  and	  
the	  RNA	  polymerase.	  The	  DNA	  strand	  on	  which	  the	  RNA	  polymerase	  synthesizes	  RNA	  is	  
called	  the	  template	  strand	  (Figure	  1.1.9).	   	  The	  σ	  subunit	  is	  released	  from	  the	  core	  of	  the	  
RNA	  polymerase	  after	  the	  first	  10	  NTPs	  are	  incorporated	  into	  the	  nascent	  RNA.	  After	  the	  
release	  of	  the	  σ	  subunit,	   the	  polymerase	  moves	  from	  the	  initiation	  site	  to	  “elongate”	  the	  
RNA	  with	  the	  elongation	  complex	  comprised	  of	  the	  RNA	  polymerase	  and	  DNA	  unwound	  
to	   17	   base	   pairs.	   The	   elongation	   of	   the	   RNA	   occurs	   by	   the	   movement	   of	   the	   RNA	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Polymerase	  along	  the	  template	  DNA	  strand,	  adding	  appropriate	  NTPs	  to	  the	  growing	  RNA	  
strand	  in	  5’-­‐3’	  direction.	  	  
The	  RNA	  transcription	  is	  terminated	  when	  the	  RNA	  polymerase	  reaches	  the	  transcription	  
termination	   signal	   on	   the	   DNA.	   There	   are	   two	   common	   modes	   of	   prokaryotic	  
transcription	  termination	  1)	  Rho-­‐dependent	  (Rho	  proteins	  are	  found	  in	  lower	  eukaryotes	  
with	   function	  other	   than	   transcription	   termination	   [115])	  and	  2)	  Rho	   independent.	  The	  
Rho-­‐independent	   transcription	   termination	   depends	   on	   the	   formation	   of	   an	   intrinsic	  
terminator	  loop	  [116].	  The	  termination	  signal,	  when	  transcribed	  leads	  to	  the	  formation	  of	  
RNA	  segment	  that	   forms	  a	  GC	  rich	  hairpin	  structure	  (terminator	  helix)	   followed	  by	  a	  U-­‐
rich	   segment.	   The	   stable	  GC	   rich	   terminator	   destabilizes	   the	  DNA-­‐DNA	  dependent	  RNA	  
polymerase	   interaction.	   The	   mechanical	   stress	   due	   to	   the	   stable	   terminator	   hairpin	  
breaks	   the	   U-­‐A	   bonds	   and	   releases	   the	   RNA	   strand	   and	   the	   RNA	   polymerase	   from	   the	  
elongation	   complex.	   A	   proposed	   model	   for	   the	   release	   of	   the	   RNA	   strand	   form	   the	  
polymerase	   is	   that	   the	   polymerase	   translocates	   forward	   without	   RNA	   synthesis	   [117],	  
however,	   Nudler	   et	   al,	   have	   shown	   that	   the	   hairpin	   formation	   is	   the	   starting	   or	   the	  
nucleation	   step	   for	   termination	   [118].	   The	   hairpin	   then	   invades	   the	   RNA	   polymerase,	  
causing	  RNA:DNA	  hybrid	  melting,	  structural	  changes	  of	  the	  catalytic	  site,	  and	  DNA-­‐clamp	  
(DNA	   clamp	   is	   a	   protein	   fold	   that	   assists	   the	   DNA	   dependent	   polymerase	   in	   	   catalytic	  
activity	  by	  preventing	  the	  enzyme	  dissociation	  from	  the	  template	  strand)	  followed	  by	  the	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CHAPTER	  2:	  	  DESIGN	  AND	  IMPLEMENTATION	  OF	  AN	  RIBONUCLEIC	  ACID	  
(RNA)	  DIRECTED	  FRAGMENT	  LIBRARY	  
	  
2.1.	  Introduction	  
Drug	   development	   strategies	   targeting	   proteins	   rely	   on	   Structure	   Based	   Drug	   Design	  
(SBDD)	   and	   High	   throughput	   Screening	   (HTS)	   in	   which	   millions	   of	   compounds	   are	  
screened	  against	  a	  target	  to	  identify	  relatively	  strong	  binding	  molecules	  (medium	  and	  low	  
throughput	  screening	  is	  done	  with	  small	  number	  of	  ligands).	  The	  SBDD	  is	  a	  strategy	  that	  
is	   based	   on	   the	   use	   of	   a	   three	   dimensional	   target	   structure	   obtained	   by	   X-­‐ray	  
crystallography	  or	  NMR	  for	  drug	  development.	   In	  SBDD,	  a	  stable	  target	  structure	  with	  a	  
defined	   binding	   pocket	   can	   be	   used	   to	   design	   small	   molecules	   specific	   to	   the	   binding	  
pocket.	   In	  the	  case	  of	  RNA	  targeting,	   the	  flexible	  nature	  of	  RNA	  poses	  a	  challenge	  to	  the	  
SBDD.	  	  
In	   recent	   years,	   Fragment	   Based	   Drug	   design	   along	  with	   structural	   biology	   resulted	   in	  
viable	  clinical	  drugs	  targeting	  proteins	  [119,	  120].	  In	  fragment	  based	  approach	  	  “leadlike”	  
molecules	  are	  obtained	  instead	  of	  “drug-­‐like”	  molecules.	  Lipinski’s	  “rule	  of	  5”	  (not	  more	  
than	   5	   hydrogen	   bond	   donors	   (OH	   and	   NH	   groups),	   no	   more	   than	   10	   hydrogen	   bond	  
acceptors	   (notably	  N	   and	  O),	   a	  molecular	  weight	   under	   500	   and	   CLogP	   (solubility	   of	   a	  
molecule	   in	   a	   polar	   and	   non	   polar	   solvent)	   under	   5	   [121])	   is	   traditionally	   accepted	   by	  
researches	  in	  drug	  discovery	  as	  a	  criterion	  for	  drug	  like	  molecules.	  The	  leadlike	  molecules	  
are	  smaller	  with	  a	  molecular	  weight	  of	  less	  than	  300,	  and	  they	  contain	  smaller	  polar	  and	  
hydrophobic	  surface	  areas	  than	  the	  drug-­‐like	  molecules.	  A	  significant	  difference	  between	  
leadlike	  and	  drug	  like	  molecules	   is,	   the	   lead	  like	  molecules	  are	  defined	  by	  the	  minimum	  
limit	  of	  polar	  groups	  (Polar	  functionalities	  are	  necessary	  for	  chemically	  growing)	  the	  drug	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like	   molecules	   are	   defined	   by	   the	   maximum	   limit	   of	   the	   polar	   groups.	   The	   “leadlike”	  
molecules	  are	  more	  amenable	  for	  “derivatization”	  to	  pick	  up	  additional	  interactions	  with	  
the	   binding	   site	   and	   thus	   increase	   the	   affinity	   to	   the	   target	   and	   still	   be	   drug	   like	   after	  
derivatization.	  	  
Though	   3d	   X-­‐ray	   and	   NMR	   structures	   of	   many	   RNA	   elements	   are	   available,	   specific	  
binders	   other	   than	   promiscuous	   Aminoglycosides	   have	   not	   been	   readily	   obtained,	  
perhaps	  because	  of	  the	  flexibility	  of	  RNA	  and	  its	  plasticity.	  Few	  studies	  discovered	  novel	  
RNA	   binding	   ligands	   through	   generic	   screens	   [122,	   123].	   In	   this	   context,	   the	   fragment-­‐
based	  strategy	  may	  be	  more	  useful	  in	  targeting	  RNA	  over	  SBDD	  and	  HTS.	  We	  adapted	  the	  
principles	  from	  Fragment	  Based	  Drug	  Design	  and	  used	  cheminformatics	  tools	  to	  develop	  
an	  RNA	  directed	  small	  molecule	  library	  to	  enhance	  the	  probability	  of	  binding	  to	  RNA.	  We	  
developed	   the	  RNA	  directed	   library	  by	   identifying	  120	  RNA	  binding	   ligands	  reported	   in	  
literature.	   A	   total	   of	   114	   fragments	   similar	   to	   the	   substructures	   of	   the	   RNA	   binding	  
ligands	   from	   similarity	   search	   are	   incorporated	   into	   the	   library.	   The	   substructures	   are	  
with	  molecular	   weight	   less	   than	   300,	   with	   less	   than	   three	   hydrogen	   bond	   donors	   and	  
acceptors	  and	  ClogP	  value	  3.	  The	   fragments	  are	   then	  screened	  using	  NMR	  spectroscopy	  
against	   a	   27	   nucleotide	   ribosomal	   A-­‐site	   RNA	   that	   is	   shown	   to	   bind	   to	   aminoglycoside	  
antibiotics.	  We	  obtained	  a	  set	  of	  hits	  out	  of	  which	  at	  least	  two	  of	  them	  are	  not	  reported	  as	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2.2.	  	  	  	  	  Methods	  and	  Materials	  
2.2.1	  RNA-­‐Binding	  Ligand	  Database	  
The	  RNA	  binding	  ligands	  are	  identified	  from	  literature	  and	  included	  into	  the	  RNA-­‐binding	  
ligand	  database	  on	  the	  following	  criteria.	  	  We	  chose	  ligands	  that	  interact	  with	  RNA	  under	  
a	  Kd	  value	  of	  50μM.	  In	  the	  case	  where	  a	  series	  of	  similar	  compounds	  as	  in	  Figure	  1.8,	  the	  
compounds	   with	   highest	   affinity	   are	   chosen	   along	   with	   the	   compounds	   that	   have	  
distinctive	  functional	  groups	  (if	  they	  are	  within	  the	  50μM	  Kd	  range.	  	  
	  
2.2.2.	  Fragmenting	  the	  Ligands	  from	  the	  Ligand	  Database	  In	  silico	  
The	  RNA	  binding	  ligands	  are	  fragmented	  using	  the	  software	  “chemdraw”	  Insilco	  to	  obtain	  
substructures	  of	   the	   ligands.	  The	   fragmenting	   is	  done	  considering	   the	   rule	  2	  and	  rule	  3	  
proposed	  by	  Schuffenhauer	  et	  al.	  The	  rule	  two	  states	  that	  for	  a	  given	  chemical	  structure,	  	  
“Do	  Not	  Remove	  Rings	  with	  more	   than	   or	   equal	   to	   12	  Atoms	   if	   There	  Are	   Still	   Smaller	  
Rings	  To	  Remove”	  and	  rule	  3	  states	  that	  	  “Choose	  the	  Parent	  Scaffold	  Having	  the	  Smallest	  
Number	   of	  Acyclic	   Linker	  Bonds”	   [125].	   The	   linker	   regions	   in	   the	   ligand	   structures	   are	  
chosen	  as	  the	  point	  of	  fragmentation.	  We	  tried	  to	  retain	  the	  RNA	  binding	  moieties	  of	  the	  
ligands	  in	  the	  substructures	  hence	  the	  remaining	  rules	  mentioned	  in	  the	  above	  reference	  
are	  not	  considered.	  The	  fragmentation	  is	  also	  done	  to	  obtain	  substructures	  that	  fall	  within	  
the	  “rule	  of	  3”	  with	  molecular	  weight	   less	   than	  250.	   In	  some	  cases	  where	  the	  polycyclic	  
rings	  (e.g.,	  tetracycline)	  did	  not	  have	  fragmentation	  points,	  the	  polycyclic	  ring	  was	  broken	  
into	  components	  containing	  two	  to	  three	  rings	  each,	  but	  the	  original	  compound	  was	  also	  
included	   as	   a	   fragment.	   Very	   large	   macrocycles,	   such	   as	   those	   occurring	   in	   some	  
macrolides,	  were	  retained	  intact	  for	  the	  clustering	  analysis	  (section	  2.2.3).	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2.2.3.	  Clustering	  of	  the	  Fragment	  Database	  
The	   fragments	  obtained	   from	   the	   fragmenting	  of	   the	  RNA	  binding	   ligands	  are	   clustered	  
into	  descriptive	  and	  fingerprint	  clusters	  in	  Molecular	  Operating	  Environment	  (MOE).	  The	  
descriptive	  clustering	  is	  based	  on	  the	  descriptive	  properties	  of	  a	  small	  molecule	  such	  as	  
a_acid	   (Number	   of	   acidic	   atoms),	   a_base	   (Number	   of	   basic	   atoms),	   A_hyd	   (Number	   of	  
hydrophobic	   atoms),	   B_rotN	   (Number	   of	   Rotatable	   bonds),	   B_ar	   (Number	   of	   aromatic	  
bonds),	  B_single	  (Number	  of	  single	  bonds),	  B_double	  (Number	  of	  double	  bonds),	  B_triple	  
(Number	   of	   triple	   bonds),	   Lip_don	   (The	   number	   of	   OH	   and	   NH	   atoms),	   Lip_acc	   (The	  
number	   of	   O	   and	   N	   atoms),	   Rings	   (The	   number	   of	   aromatic/	   heterocyclic	   rings).	   The	  
descriptive	   clustering	   is	   done	   using	   Principle	   component	   analysis.	   (The	   Principle	  
component	  analysis	  is	  a	  mathematical	  procedure	  used	  to	  convert	  the	  values	  of	  correlating	  
variables	  into	  a	  set	  of	  values	  of	  uncorrelated	  variables	  called	  principal	  components).	  We	  
used	   the	   Molecular	   Operating	   Environment	   from	   the	   Chemical	   computing	   group	   to	  
perform	  the	  cheminformatics	  analysis.	  
The	  fingerprint	  clustering	  is	  based	  on	  the	  FP:MACCS	  keys.	  The	  FP:MACCS	  keys	  describe	  a	  
chemical	  structure	  in	  binary	  terms.	  The	  fingerprint	  clustering	  was	  done	  with	  an	  overlap	  
threshold	   between	  40%	  and	  50%	   initially	   and	   increased	   to	   95%	   for	   two	   clusters	   since	  
more	  than	  half	  of	  the	  fragments	  appeared	  in	  these	  two	  clusters.	  A	  tanimoto	  coefficient	  is	  
used	  as	  the	  metric	  for	  similarity	  purpose.	  The	  tanimoto	  coefficient	  τ=NAB	  /NA	  +NB	  –NAB	  
where	  NA	  is	  number	  of	  features	  (ON	  bits)	  in	  A,	  NB	  is	  the	  number	  of	  features	  (ON	  bits)	  in	  B,	  
and	  NAB	  is	  the	  number	  of	  features	  (ON	  bits)	  common	  to	  both	  A	  and	  B	  for	  two	  molecules	  A	  
and	  B	  [126].	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2.2.4.	  Selection	  of	  Cluster	  Representatives	  
The	  representatives	  from	  each	  cluster	  are	  selected	  by	  similarity	  searches	  using	  Sci-­‐finder	  
and	  Zinc	  databases.	  The	  similarity	  threshold	  is	  maintained	  at	  95%	  for	  most	  of	  the	  cluster	  
representatives.	  Further	  75%	  similarity	  threshold	  is	   implemented	  for	  representatives	  of	  
clusters,	   which	   did	   not	   reach	   95%	   similarity.	   Visual	   inspection	   to	   preserve	   the	   key	  
functional	  groups	  is	  also	  ensured	  during	  the	  similarity	  search.	  	  The	  list	  of	  the	  fragments	  is	  
sent	   to	   Sigma-­‐Aldrich	   for	   suggested	   compounds.	   The	   fragments	   obtained	   from	   the	  
similarity	  search	  are	  purchased	  from	  commercial	  sources.	  
	  
2.2.5.	  Quality	  Control	  (QC)	  and	  Plating	  
	  NMR	  spectroscopy	   is	  used	   for	   assessing	   the	  quality	  of	   the	  purchased	   compounds.	   Four	  
NMR	   spectra	   were	   acquired	   for	   each	   compound	   at	   a	   concentration	   of	   200μM	   in	   700	  
μliters	   90%	  H2O,	   10%	   D2O.	   The	   buffer	   contained	   10	  mM	  NaCl,	   10	  mM	  Na-­‐Phosphate,	  
pH=6,	  0.1	  mM	  EDTA.	   	  Quality	   control	   is	   run	  on	  a	  500	  Mhz	   spectrometer	  with	  an	   Innova	  
console	   and	   an	   HCN	   probe	   and	   a	   50-­‐position	   sample	   changer.	   	   The	   four	   QC	   spectra	  
included	  1d	  spectra	  with	  Watergate	  (64,	  256	  or	  320	  scans,	  12	  pm	  sweep	  width,	  32	  K	  data	  
points),	   and	   excitation	   sculpting	   (64	   scans,	   12	   ppm	   sweep	   width,	   32	   K	   data	   points),	  
respectively	   for	   solvent	   suppression,	   along	   with	   the	   WaterLogsy	   (512	   scans,	   12	   ppm	  
sweep	  width,	  32	  K	  data	  points,	  1	  ms	  mixing	  period)	  and	  CPMG	  (or	  T2	  filter)	  (64	  scans,	  12	  
ppm	  sweep	  width,	  32	  K	  data	  points,	  400	  ms	  mixing	  period).	  Excitation	  sculpting	  was	  used	  
for	   solvent	   suppression	   for	   the	   WaterLogsy	   and	   T2	   filter	   experiments	   (the	   details	   for	  
Watergate,	  WaterLOGSY	  and	  T2	   filter	   experiments	   are	  mentioned	   in	   chapter	  3).	   The	  1d	  
excitation	   sculpting	   experiment	   used	   identical	   parameters,	   including	   the	   same	   pulse	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program	  as	  the	  T2	  filter	  experiment,	  but	  with	  the	  T2	  filter	  period	  set	  to	  zero.	  Spectra	  were	  
converted	  to	  a	  format	  that	  was	  readable	  in	  TopSpin	  2.0	  (Bruker)	  and	  processed.	  Analysis	  
was	  aided	  by	   the	  use	  of	  AMIX	  software	   (Bruker).	  The	  compounds	  with	   spectra	   that	  did	  
not	  fit	  the	  expected	  spectral	  pattern	  are	  eliminated	  along	  with	  the	  compounds	  that	  gave	  
binding	  signal	  in	  the	  absence	  of	  RNA.	  The	  fragments	  that	  passed	  the	  QC	  are	  compared	  to	  
the	  representatives	  of	  the	  clusters	  to	  ensure	  all	  the	  clusters	  are	  represented.	  	  
	  
2.2.6.	  Screening	  of	  Fragments	  for	  Binding	  to	  the	  Bacterial	  Ribosomal	  A	  site	  RNA	  
The	  fragments	  that	  passed	  the	  QC	  are	  used	  for	  screening	  against	  the	  bacterial	  ribosomal	  
A-­‐Site	  RNA.	  	  One-­‐hundred-­‐two	  compounds	  were	  screened	  in	  29	  mixtures	  of	  3-­‐4	  per	  tube,	  
containing	   the	   same	   buffer	   as	   the	  QC	   spectra	   but	  with	   10μM	  A-­‐site	   RNA.	   A	   competitor	  
with	  known	  binding	  to	  the	  A-­‐site	  RNA,	  Gentamycin,	  was	  added	  to	  a	  concentration	  of	  30μM,	  
and	  experiments	  were	  repeated	  with	  identical	  parameters	  for	  each	  mixture.	  Spectra	  from	  
a	  hit	  compound	  are	   identified	  from	  the	  following	  characteristics:	  a	  positive	  signal	   in	  the	  
WaterLOGSY	  spectrum	  (320	  scans,	  1.2	  ms	  mixing	  period)	  and	  a	  reduction	  in	  signal	  in	  the	  
T2	  filter	   experiment	   (128	   scans,	   300	  ms	  T2	   filter	   period)	   relative	   to	   the	  1	  d	   experiment	  
with	   excitation	   sculpting.	   We	   expected	   that	   hits	   that	   bind	   specifically	   to	   the	  
aminoglycoside	  binding	  site	  show	  a	  reduction	   in	  positive	  signal	   in	   the	  WaterLOGSY	  and	  
some	  recovery	  of	  signal	  in	  the	  T2	  filter	  experiment	  when	  Gentamycin	  is	  added.	  However,	  
Gentamycin	  is	  a	  relatively	  weak	  affinity	  ligand	  compared	  to	  competitor	  ligands	  commonly	  
utilized	   in	   fragment	  screening	  against	  kinases.	  Ligands	  that	  showed	  small	  or	  ambiguous	  
indications	  of	  competition	  with	  Gentamycin	  were	  further	  tested	  as	  described	  below.	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2.2.7.	  Confirmation	  of	  the	  Fragment	  Hits	  
Hit	  candidates	  identified	  from	  the	  library	  screen	  are	  tested	  directly	  for	  binding	  to	  the	  A-­‐
site	  RNA.	  The	  buffer	   conditions	   are	  10	  mM	  NaCl,	   10	  mM	  Na	  phosphate	  pH	  6.7,	   0.1	  mM	  
EDTA	  in	  700	  μL	  of	  90%	  H2O,	  10%	  D2O.	  The	  concentration	  of	  the	  compounds	  is	  between	  
200-­‐300	   μM.	   WaterLOGSY,	   T2	   filter,	   and	   1D	   Watergate	   and	   excitation	   sculpting	  
experiments	  are	  acquired	  on	  a	  700	  Mhz	  Varian	  NMR	  spectrometer	  with	  an	  HCN	  cold	  probe.	  
A	   long	   acquisition	   (number	   of	   transients)	   1024)	   1D	  Watergate	   spectrum	   with	   a	   large	  
sweep	  width	  (24	  ppm)	  is	  performed	  to	  obtain	  a	  spectrum	  of	  the	  RNA	  Imino	  resonances.	  
	  
2.3.	  Results	  
2.3.1.	  RNA	  Binding	  Ligand	  Database	  
We	  obtained	  an	  RNA	  binding	  ligand	  database	  of	  120	  ligands.	  Each	  ligand	  has	  a	  reported	  
Kd	  value	  of	  less	  than	  or	  equal	  to	  50μM	  with	  RNA.	  	  A	  few	  ligands	  are	  included	  for	  which	  the	  
reported	  Kd	  is	  not	  available,	  if	  a	  PDB	  coordinate	  set	  existed	  showing	  the	  ligand	  bound	  to	  
an	   RNA.	   We	   incorporated	   compounds	   from	   a	   variety	   of	   sources,	   including	   antibiotics,	  
riboswitch	   effectors,	   and	  products	   of	   in	   vitro	  drug	  design	   studies.	  We	   intended	   to	   limit	  
redundancy	   in	   the	   database	   while	   including	   as	   much	   of	   proven	   RNA-­‐binding	   chemical	  
space	  as	  possible.	  Compounds	  that	  belonged	  to	  similar	  chemical	  classes	  were	  included	  if	  
they	  incorporated	  distinct	  chemical	  moieties	  that	  were	  not	  present	  elsewhere	  in	  the	  list.	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2.3.2.	  Fragment	  Database	  
The	  fragment	  database	  is	  enriched	  with	  small	  molecule	  fragments	  that	  are	  obtained	  after	  
the	  fragmenting	  and	  choosing	  of	  the	  representative	  fragments	  from	  the	  fragment	  clusters	  
as	  mentioned	  in	  the	  methods	  section.	  We	  obtained	  a	  total	  of	  260	  fragments.	  Many	  of	  these	  
fragments	  are	  similar	  in	  structure.	  The	  clustering	  reduced	  the	  fragment	  redundancy.	  The	  
clustering	  based	  on	  the	   fingerprints	  utilizes	  166	  MACCS	  keys	  that	  are	  a	  set	  of	  questions	  
about	  a	  chemical	  structure.	  	  Some	  of	  the	  questions	  are1)	  Are	  there	  fewer	  than	  3	  oxygens?	  
2)	  Is	  there	  a	  S-­‐S	  bond?	  3)	  Is	  there	  a	  ring	  of	  size	  4?	  4)	  Is	  at	  least	  one	  F,	  Cl,	  Br,	  or	  I	  present?	  
The	  result	   is	  a	   list	  of	  binary	  values	  –	  either	   true	  (1)	  or	   false	  (0).	  This	   list	   for	  a	  chemical	  
structure	  is	  called	  the	  MACCS	  key	  fingerprint	  for	  that	  structure.	  The	  descriptive	  clustering	  
is	  based	  on	  the	  physico-­‐chemical	  properties	  of	  a	  molecule.	  An	  example	  is	  shown	  in	  Figure	  
2.1	  with	  the	  molecule	  on	  the	  left	  and	  the	  descriptors	  on	  the	  right.	  	  
The	  clustering	  based	  on	  fingerprint	  and	  descriptive	  properties	  resulted	  in	  55	  descriptive	  
clusters	  and	  53	  finger	  print	  clusters.	  The	  cluster	  number	  3	  and	  cluster	  number	  74	  of	  the	  
fingerprint	   clusters	   had	   to	   be	   re-­‐clustered	   because	   more	   than	   half	   of	   the	   fragments	  
showed	  in	  these	  two	  clusters.	  The	  details	  of	  the	  clustering	  are	  mentioned	  in	  table	  2.2.	  The	  
rationale	  for	  re-­‐clustering	  the	  fingerprint	  cluster	  3	  and	  74	  is	  that	  it	  could	  be	  representing	  
the	   chemical	   space	   that	   has	   propensity	   to	   RNA	   and	   further	   clustering	   could	   result	   in	  
clusters	  that	  densely	  represent	  the	  RNA	  binding	  chemical	  space.	  	  We	  searched	  for	  at	  least	  
one	   purchasable	   compound	   that	   could	   represent	   each	   cluster,	   and	   some	   subclusters,	  
which	   had	   been	   identified	   through	   the	   above	   process	   (methods).	   A	   more	   exhaustive	  
catalogue	   of	   clusters	   and	   purchased	   fragments	   for	   the	   library	   is	   available	   in	   the	  
supplementary	  information	  of	  [124].	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Figure	  2.1:	  Example	  of	  (a)	  descriptive	  properties	  for	  a	  molecule	  in	  (b).	  	  
	  




ties and RNA-binding and whether such properties may conflict
with those required for drug design. We used MOE to calculate
the distribution of values for a set of conformation-independent
physicochemical descriptors for the RNA-binding ligand set.
For comparison, we analyzed a similar sized data set derived
from the Ashgate Drug Index (CamSoft). These compounds are
in commercial use as therapeutic drugs. In addition, we ran a
similar analysis on two publicly available “diversity” (from the
National Cancer Institute (NCI) and the University of Pittsburgh
Center for Chemical Methodologies and Library Development
(UPMCSD)) sets commonly used for virtual screening/in silico
docking exercises. We also calculated descriptor values for two
ligand sets obtained by searching the protein databank (PDB)
for small molecules identified as binding to kinases and
proteases. Both these classes of proteins include well established
drug targets. Finally, we formulated a ligand set of manageable
size that could be taken to represent ligands binding to any
protein in a “generic” sense (see methods section).
Comparative analysis of these ligand sets is shown in Figure
1 and, in more detail, in the Supporting Information. For all 35
physicochemical descriptors computed, the average value for
the RNA-binding set was within a standard deviation of that
for each of the other five ligand sets. In a few cases, discussed
in more detail in the Supporting Information, there were small
differences in the distribution of values for the four databases.
Average values for most 2D descriptors correlate with the
molecular weight. Average molecular weight is largest for RNA
and protease binding ligands (near 500), whereas average
molecular weight is slightly over 300 for the Ashgate and NCI
sets. Average values for total surface charge, fractional positive
charge, and the topological polar surface area (TPSA)39 are
higher for the kinase binding ligands than expected on the basis
of molecular weight.
We had set our threshold for RNA binding activity at a
relatively weak level (Kd < 50 µM) in order to ensure a thorough
exploration of RNA-binding chemical space for our fragment
library design below. In order to probe the possibility that by
doing so we may be somehow diluting the distinctiveness of
our RNA-binding ligands, we repeated the analysis with a subset
of 67 ligands with reported Kd of less than 3 µM (Table 1).
Again, the average value for each descriptor was within a
standard deviation of the average for the comparison ligand sets.
The average molecular weight is slightly higher for the set of
submicromolar RNA ligands than it is for the complete RNA
ligand set, as are the average values for the correlated 2D
descriptors. This effect, together with a small increase in TPSA,
suggests that the large, polar, and chemically complex ligands
pick up affinity through a larger surface area of interaction.
Choice of Fragment Library Ligands. Our analysis con-
vinced us that development of RNA binding ligands is not
intrinsically incompatible with drug development, but it gave
us no obvious “rules” for choosing compounds with propensity
to bind RNA. This result does not preclude the likelihood that
a finite set of chemical moieties constitute a “privileged”30 RNA
binding set. The special properties of these functionalities may
be too subtle or complex to detect using standard descriptors.
We proceeded with a strategy (Figure 2) to build our library
as directly as possible from fragments of compounds with
proven RNA-binding propensity. Data base ligand structures
were “cleaved” in silico (see Experimental Details). Alto-
gether approximately 250 fragments were identified. Many
of these fragments are chemically similar. Therefore, we
clustered the fragments, first, based upon chemical descriptors
and, second, based upon molecular fingerprints using MOE
(Figure 3). Altogether this process produced 55 descriptive
clusters and 53 fingerprint clusters. We wished to represent
each cluster in our library, but we noted that a disproportion-
ate fraction of the original fragments were represented in
two fingerprint clusters (Table 1, Figure 3, Table S3). We
Figure 1. Average values and standard deviations for physicochemical
descriptors for nine ligand sets. For each ligand set, two bars are shown:
the mean value is shown on the left and standard deviation on the right.
RNA: 125 ligands reported to bind RNA with Kd < 50 µM. NCI: 1944
NCI diversity set compounds. Pittcon: 327 UPMCSD virtual screening
set. Ashgate: 211 Ashgate Drug Index compounds. RNA_sub: 67
compound subset of RNA ligands with reported Kd < 3 µM. Fragments:
109 compounds that underwent QC for RNA-directed fragment library.
Kinase: 162 kinase-binding ligands identified from PDB. Protease: 282
protease-binding ligands identified from PDB. Protein: 628 protein
binding ligands identified from PDB. The following plots are shown
(from left to right): (a) molecular weight, (b) Chi0v (zero order atomic
valence connectivity index)53, (c) topological polar surface area39, (d)
hydrogen bond acceptors as defined by Lipinski54, (e) simulated log of
the partition coefficient in a water/octanol mixture, (f) positively charged
fraction of the summed partial charge.
Table 1. Clustering Statistics
parameter value
no. of descriptive clusters 55
no. of fingerprint clusters 53
subclusters of fingerprint cluster 3 71
sublusters of fingerprint cluster 74 19
total RNA-binding ligand fragments 260
total clusters + subclusters 198
compounds purchased 114
fragments passing QC 100
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Figure2.2:	   (a)	   Distribution	   of	   number	   of	   fragments	   per	   cluster	   derived	   from	  
fragmenting	  RNA-­‐binding	  ligand	  structures	  	  	  in	  silico	  	  	  and	  clustering	  the	  resulting	  
fragments	  according	  to	  physico-­‐chemical	  descriptors.	  (b)	  Distribution	  of	  number	  of	  
fragments	  per	  cluster	  derived	  from	  fragmenting	  RNA-­‐	  binding	  ligand	  structures	  	  	  in	  
silico	  	  	  and	  clustering	  the	  resulting	  fragments	  according	  to	  chemical	  fingerprints.	  	  
	  
2.3.3.	  Physico-­‐Chemical	  Analysis	  of	  the	  Fragments	  	  	  In	  silico	  	  	  and	  Quality	  	  	  
	  Control	  
	  
The	   cheminformatics	   tools	   are	   used	   to	   analyze	   the	   physico-­‐chemical	   properties	   of	   the	  
fragment	  molecules.	  The	  fragments	  have	  “leadlike”	  properties.	  
As	   compared	   to	   drugs,	   they	   tend	   to	   have	   lower	  MW,	   lower	   hydrophobicity	   and	   higher	  
solubility	   and	   bind	  weakly	   to	   the	   target.	   The	   fragments	   have	   a	   ClogP	   (solubility	   index)	  
value	  of	  less	  than	  3	  and	  molecular	  weight	  within	  75-­‐250.	  This	  fragment	  based	  approach	  
allowed	  us	  to	  explore	  the	  chemical	  space	  represented	  by	  the	  bulkier	  ligands.	  The	  quality	  
control	  as	  mentioned	  in	  the	  methods	  section	  resulted	  in	  102	  fragments	  that	  are	  plated	  as	  
described	  in	  methods.	  
2.3.4.	  Screening	  of	  the	  Fragment	  Library	  with	  the	  Ribosomal	  A-­‐site	  RNA	  
We	  used	  a	  27	  nucleotide	  ribosomal	  A-­‐site	  RNA	  with	  an	  internal	  loop	  from	  E.coli	  16srRNA	  
(Figure2.3)	   as	   the	   target	   RNA	   since	   it	   is	   previously	   shown	   to	   bind	   to	   aminoglycoside	  
judged that these clusters may represent a region of chemical
space with particularly favorable RNA-binding propensity.
We therefore further clustered these ligand subsets with the
aim of achieving a “denser” representation of the corre-
sponding chemical space regions.
We searched for at least one purchasable compound that could
represent each cluster, and some subclusters, which had been
identified through the above process. Figure 4 shows an exampl
of a descriptive cluster together with the original ligand
fragments composing the cluster and the purchasable fragment(s)
chosen t represent the cluster. A more exhaustive catalogue
of clusters and purchased fragments for the library is included
in the Supporting Information (Table S3).
Altogether, 102 compounds were initially selected, purchased,
survived quality control, and were plated as described in
Experimental Details.
Cheminformatics Analysis and Quality Control of the
RNA-Di ect d Fragment Library. We subjected the com-
pounds that we had chosen for the RNA directed fragment
library to the same descri tor anal sis that was described
Figure 2. (a) Schematic illustration of the need for selecting RNA-directed compounds for screening for binding to RNA. While we can assume
that there is some overlap between the regions of “chemical space” with the propensity to bind to RNA or to proteins, it is likely that the probabilities
for binding to the two classes of target will differ in any given region. Generic and commercial screening libraries, designed to cover the overlap
between protein-binding and “druglike” chemical spaces, yield low hit rates for RNA targets. Note simplifications: for example, regions of RNA-
binding space (and other subregions) are not necessarily contiguous. (b) Schematic of overall strategy for selection of an RNA-directed fragment
library and for screening the library against RNA. Fragment library compounds are derived from the database of RNA-binding ligands. NMR is
used to screen the library for compounds that bind with weak affinity to the RNA target. The complexes of these compounds with the RNA go into
structural studies and provide a starting point for structure-based design of more potent ligands.
Figure 3. (a) Distribution of number of fragments per cluster derived from fragmenting RNA-binding ligand structures in silico and clustering the
resulting fragments according to physicochemical descriptors. (b) Distribution of number of fragments per cluster derived from fragmenting RNA-
binding ligand structures in silico and clustering the resulting fragments according to chemical fingerprints. Over half of the fragments were clustered
together in either cluster 3 or 71. These two clusters were further subclustered (see text).
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antibiotics	  (refer	  to	  chapter	  1	  for	  A-­‐site	  RNA	  details).	  	  The	  construct	  shown	  in	  the	  Figure	  
2.3	  is	  similar	  to	  the	  A-­‐site	  construct	  previously	  used	  for	  NMR	  studies	  [127].	  	  We	  chose	  this	  
target	  for	  our	  first	  fragment	  library	  screen	  because	  the	  same	  ribosomal	  site	  was	  the	  target	  
for	  several	  of	  the	  known	  RNA-­‐	  binding	  ligands	  that	  provided	  the	  source	  of	  our	  fragment	  
structures.	  	  
	  
Figure	   2.3a:	   The	   secondary	   structure	   of	   the	   A-­‐site	   RNA	   used	   for	   screening	   the	  
fragment	   library.	   The	   G1491	   residue	   is	   the	   residue	   shown	   to	   interact	   with	  
Aminoglycosides	  (chapter1).	  	  
	  
The	   102	   fragments	   are	   screened	   for	   A-­‐site	   binding	   in	   29	   mixtures	   of	   three	   to	   four	  
compounds,	   each	   at	   200μM	   concentration,	   through	   the	   acquisition	   of	   four	   1D	   NMR	  
experiments	  on	  each	  mixture.	  Each	  sample	  contained	  10	  μM	  RNA.	  The	  methods	  section	  
has	   the	   details	   of	   the	   buffer	   components	   and	   the	   NMR	   experiments.	   The	   screening	  
experiments	   work	   on	   the	   principle	   of	   detecting	   ligand	   signals,	   through	   the	   transfer	   of	  
magnetization	   properties	   from	  bound	   to	   free	   signal	   via	   chemical	   exchange.	   Figure	   2.3b	  
shows	   an	   example	   of	   the	   screening	   results	   for	   one	   mixture.	   Five	   hit	   compounds	   are	  
obtained	   from	   the	   initial	   screen.	   The	   hit	   fragments	   are	   shown	   in	   table	   2.4.	   The	   initial	  
screen	   is	   followed	   by	   a	   “competition	   screen”	   with	   the	   known	   A-­‐site	   binding	   ligand,	  
Gentamycin,	  present.	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Figure	  2.3b:	  Screening	  data	  for	  a	  sample:	  The	  sample	  contained	  a	  mixture	  including	  
compounds	  2	  and	  4	  (table	  2.4)	  and	  two	  nonbinding	  compounds,	   together	  with	  27	  
nucleotide	   A-­‐site	   RNA.	   From	   top	   to	   bottom:	   WaterLOGSY,	   without	   and	   with	  
Gentamycin	  competitor,	  1D	  spectra	  with	  excitation	  sculpting	  (T2	  filter	  period	  of	  0	  s)	  
and	  with	  (0.3	  s)	  T2	  filter,	  without	  Gentamycin,	  and	  repeat	  of	  the	  excitation	  sculpting	  
1D	  with	   and	  without	   T2-­‐filter	  with	   Gentamycin	   present.	   Competition	   of	   4	   for	   the	  
Gentamycin	  site	   is	  evident	   from	  the	  recovery	  of	  signal	   in	  the	  T2	   filter	  experiment,	  
although	  little	  competition	  is	  observed	  in	  the	  WaterLOGSY.	  Binding	  of	  compound	  2	  
is	   indicated	  by	   signals	  near	  6.9	  and	  7.3-­‐8.1	  pm	   in	   the	  WaterLOGSY.	  A	  nonbinding	  
compound,	  a	  furan,	  gives	  negative	  signals	  between	  6.5	  and	  6.9	  ppm.	  
	  
The	  competition	  experiment	  indicates	  if	  any	  compounds,	  bind	  specifically	  to	  the	  known	  A-­‐
site	   “active-­‐site”	   (Figure	  2.3b).	  Some	  of	   the	  hit	   compounds	  showed	  reduced	  evidence	  of	  
binding	  as	  shown	  in	   table	  2.3.	   	  However	  some	  hits,	  such	  as	  2-­‐aminoqunoline	  (2),	  which	  
has	  been	  reported	  as	  a	  component	  of	  an	  A-­‐site	  active	  site	  binder,	  did	  not	  show	  reduced	  
evidence	   of	   binding	   upon	   addition	   of	   competitor.	   This	   result	   may	   indicate	   that	   the	  
competitor	   ligand	   does	   not	   bind	   tightly	   enough	   to	   fully	   displace	   the	   fragment	   hit.	  
Alternatively,	  the	  fragment	  may	  be	  capable	  of	  binding	  in	  the	  same	  region,	  or	  other	  parts	  of	  
the	  RNA,	  simultaneously	  with	  the	  competitor.	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Table	   2.3:	   The	   fragment	   hits	   from	   initial	   screen	   and	   the	   results	   from	   the	  




The	  five	  hit	  compounds	  are	  verified	  through	  follow-­‐up	  experiments	  performed	  at	  higher	  
sensitivity	   on	   a	   700	  Mhz	   spectrometer	  with	   a	   cold	  probe	   and	   a	   long	   acquisition	   time	   in	  
order	  to	  detect	  Imino	  signals	  from	  the	  RNA.	  The	  latter	  are	  diagnostic	  of	  RNA	  base	  pairing.	  
Chemical	  shift	  change	  and/or	  line	  broadening	  in	  this	  region	  indicate	  ligand	  contact	  with	  
the	   RNA.	   Figure	   2.4	   shows	   the	   follow-­‐up	   screening	   experiment	   for	   compound	  4	   A-­‐site	  
RNA.	  
product context and to present them to RNA targets in a more
“l adlike” form. One important qualification to this statement
is that at this stage our library is not restricted to compounds
that fit classical criteria for leadlikeness. For example, sugar
moieties that are not generally considered as good lead
candidates are included because of t ir proven role in RNA
recognition. Our fragments are more leadlike than the original
ligand sets.
Test Screen of the RNA-Directed Fragment Library. We
chose the A-site RNA as our first target to enhance the chanc s
of obtaining hits from “control” fragments. For example,
2-deoxystreptamine41 1 and 235 had already been reported in
the literature as A-site binding ligands. The latter was discovered
from a generic fragment library screen and incorporated into a
stronger affinity derivative, which was then included in our
original database. Thus, as we anticipated, we have recapitulated
interactions discovered in the literature. On the other hand, we
also obtained and confirmed A-site RNA binding by 4 and
lysinamide 5. Though the A-site RNA has been subject to
intense ligand binding studies and drug design efforts, including
a screen against 10 000 compounds in the above-cited study,35
we could not find a report of binding by these two common
compounds. That the strategy depicted in Figure 2, with the
RNA-directed fragment library, was able to identify novel
ligands for such a well-characterized RNA bodes well for the
prospects of identifying novel chemical starting points for other
RNA targets.
Screening the RNA Fragment Library against Other
RNA Targets. During the course of this study, we learned
lessons regarding the process of screening fragments for weak
binding to RNA using NMR. Some binding fragments do not
produce positive signals in the water-LOGSY (see Figure 5).
In these cases, the original screen gave an ambiguous result.
Only in the follow-up screen, in which the spectrum of the
excess ligand mixed with RNA is compared to that without
RNA, does the binding become clear. In that case, the compound
Figure 5. (a) Screening data. The sample contained a mixture
including compounds 2 and 4 and two nonbinding compounds,
together with 27 nucleotide A-site RNA. From top to bottom: water-
LOGSY, without and with gentamycin competitor, 1D spectra with
excitation sculpting (T2-filter period of 0 s) and with (0.3 s) T2 filter,
without gentamycin, and repeat of the excitation sculpting 1D with
and without T2-filter with gentamycin present. Competition of 4 for
the gentamycin site is evident from the recovery of signal in the
T2-filter experiment, although little competition is observed in the
water-LOGSY. Binding of compound 2 is indicated by signals near
6.9 and 7.3-8.1 pm in the water-LOGSY. A nonbinding compound,
a furan, gives negative signals between 6.5 and 6.9 ppm. (b) Follow-
up experiment confirming binding of 4 to A-site RNA. Water-
LOGSY, T2-filter, and 1D data are shown with (blue) and without
(black) RNA. (c) RNA imino resonances from samples containing
10:1 excess of the respective compounds. Compounds 1, 4, and 5
all interact with the RNA, as indicated by shifts in imino resonances,
notably in the signal for the G1491 residue (near 12 ppm), indicating
that all bind near the active site. The spectrum in the second panel
from the top, shows no change from the “free RNA” control,
indicating that diethyl nicotinamide does not bind A-site RNA.
Table 2. A-Site Fragment Hits
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Figure	  2.4:	  Follow	  up	  WaterLOGSY	  and	  T2	  filter	  experiments	  for	  the	  compound	  4.	  	  
WaterLOGSY,	  T2	  filter,	  are	  shown	  with	  (blue)	  and	  without	  (black)	  RNA.	  
	  
	  Figure	  2.5	  shows	  the	  follow	  up	  screen	  with	  10:1	  excess	  of	  ligand	  concentration.	  It	  is	  seen	  
from	  the	  RNA	  Imino	  resonances	  that	  Compounds	  1,	  4,	  and	  5	  all	  interact	  with	  the	  RNA,	  as	  
indicated	  by	  shifts	  in	  Imino	  resonances,	  notably	  in	  the	  signal	  for	  the	  G1491	  residue	  (near	  
12	  ppm),	   indicating	   that	  all	  bind	  near	   the	  active	  site.	  The	  spectrum	   in	   the	  second	  panel	  
from	   the	   top,	   shows	   no	   change	   from	   the	   “free	   RNA”	   control,	   indicating	   that	   diethyl	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2.4.	  Conclusion	  
We	   have	   learned	   lessons	   in	   conducting	   RNA	   targeted	   screens	   some	   of	   which	   are	   as	  
follows.	   The	   NMR	   techniques	   we	   used	   in	   this	   screen	   against	   the	   A-­‐site	   RNA	   are	   more	  
sensitive	   towards	   weak	   binding	   interactions	   and	   also	   require	   less	   material	   (RNA)	   as	  
compared	  to	  other	  methods	  which	  use	  (just	  1d	  RNA-­‐detected	  experiments	  [128])	  more	  
	  
	  
Figure	   2.5:	   RNA	   Imino	   resonances	   from	   samples	   containing	   10:1	   excess	   of	   the	  	  
compounds	  4,1,5,3	  (bottom	  to	  top).	  The	  top	  most	  panel	  is	  “RNA	  only”.	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RNA.	   Other	   research	   groups	   have	   used	   the	   “Saturation	   Transfer	   Difference”	   NMR	  
experiment	  to	  RNA	  binding	  ligands	  [129].	  However,	  our	  group	  and	  others	  	  [122]	  found	  	  
that	  the	  STD	  is	  not	  as	  sensitive	  as	  the	  WaterLOGSY	  and	  the	  T2	  filter	  experiments	  for	  RNA	  
[122].	  	  
Our	   screening	   method	   with	   a	   rational	   approach	   towards	   identifying	   ligands	   with	   RNA	  
bindability	  and	  also	  amenable	  for	  derivatization	  is	  designed	  to	  rescue	  the	  aforementioned	  
RNA	   binding	   functionalities	   in	   RNA	   targeted	   screens	   [124].Though	   screening	   with	  
“generic”	   fragment	   	   libraries	   against	   RNA	   has	   resulted	   in	   the	   discovery	   of	   some	   novel	  
ligands	  previously	  [128],	  it	  is	  likely	  to	  miss	  such	  functional	  moieties	  responsible	  for	  RNA	  
binding	  through	  these	  screens	  because	  generic	   fragment	   libraries	   include	  only	  drug	   like	  
molecules	  according	  to	  conventional	  criteria.	  Molecules	  such	  as	  those	  with	  sugar	  moieties	  
are	   not	   considered	   good	   leads	   though	   their	   ability	   to	   bind	   to	   RNA	   is	   established,	   for	  
example.	   At	   this	   time,	   clearly	   definable	   criteria	   that	   can	   be	   applied	   across	   the	   range	   of	  
RNA	  targets	  for	  enhancing	  the	  possibility	  of	  RNA	  binding	  are	  not	  uncovered.	  We	  chose	  the	  
fragments	  to	  mimic	  chemical	  functionalities	  already	  proven	  to	  bind	  to	  RNA	  in	  the	  context	  
of	  obtaining	  drug	  like	  hits	  for	  understanding	  the	  properties	  of	  ligands	  that	  bind	  to	  RNA	  in	  
our	  context.	  	  
This	   study	   represents	   a	   first	   step	   toward	   the	   development	   of	   an	   RNA-­‐directed	  
cheminformatics.	   We	   manually	   analyzed	   the	   physico-­‐chemical	   properties	   of	   the	  
fragments	  to	  obtain	  ligands	  that	  can	  be	  specifically	  used	  for	  RNA	  screening	  with	  specific	  
advantages	  over	  screening	  RNA	  with	  original	  or	   large	   ligands	   like	  Aminoglycosides.	  The	  
fragments	  have	  smaller	  polar	  surface	  area	  (because	  of	  which	  non	  specific	  interactions	  can	  
be	   reduced),	   are	   amenable	   for	   further	   “growing”	   to	   develop	   specificity	   and	   affinity	   for	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specific	  RNA	  targets.	  They	  are	  not	  targeted	  against	  a	  specific	  target	  structure	  in	  our	  case	  
(addressing	   the	   problem	   with	   using	   SBDD).	   The	   fragments	   that	   are	   multiple	   hits	   (for	  
different	  targets)	  can	  be	  used	  for	  	  	  in	  silico	  	  	  screening	  against	  flexible	  RNA	  targets	  by	  the	  
probing	   of	   target	   flexibility	   through	  multiple	   conformations	   observed	  with	  multiple	   hit	  
fragments,	  fragments	  will	  complement	  	  	  in	  silico	  	  	  screening	  methods	  recently	  designed	  to	  
incorporate	  RNA	  induced	  fit	  [129,	  130].	  However,	  further	  iterations	  of	  the	  screening	  and	  
addition	   of	   new	   fragments	   to	   the	   library	  will	   lead	   to	   the	   development	   of	   drug	   leadlike	  
libraries	   with	   our	   proposed	   fragment	   based	   approach.	   As	   we	   hoped	   that	   such	   a	  
development	   would	   be	   realized,	   a	   fragment-­‐based	   strategy	   has	   since	   been	   used	   in	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CHAPTER	   3:	   DETERMINING	   THE	   STRUCTURAL	   ELEMENTS	   REQUIRED	  
FOR	   LIGAND	   DISCRIMINATION	   BETWEEN	   ON	   AND	   OFF	   STATE	   SAM-­‐I	  
RIBOSWITCH	  CONFORMATIONS	  	  
	  
3.1.	  	  	  	  Introduction	  
The	  ongoing	  discovery	  of	  riboswitches	  in	  the	  last	  one	  and	  a	  half	  decades,	  has	  added	  a	  new	  
dimension	   to	   our	   understanding	   of	   the	   role	   of	   RNA	   as	   a	   gene	   regulatory	   element.	  
Riboswitches	  are	  folded	  RNA	  elements	  that	  sense	  and	  bind	  to	  certain	  cellular	  metabolites	  
and	  regulate	  the	  expression	  of	  genes	  related	  to	  the	  metabolites[132,	  133].	  Riboswitches	  
are	  found	  near	  the	  5’	  untranslated	  region	  of	  mRNA	  in	  gram	  positive	  bacteria,	  a	  few	  plants	  
and	   in	   certain	   fungi	   [134].	   Riboswitch	   gene	   control	  mechanisms	   include	  modulation	   of	  
rho-­‐independent	   transcription	   terminator	   formation,	   sequestering	   of	   ribosome	   binding	  
sites,	   formation	  of	  ribozymes	  and	  control	  of	  alternative	  splicing	   [74,	  135].	  Riboswitches	  
appear	   capable	   of	   manipulating	   the	   expression	   of	   genes	   related	   to	   metabolite	  
biosynthesis	  without	  direct	  interaction	  with	  proteins.	  Moreover,	  riboswitches	  have	  been	  
suggested	  as	  potential	  drug	  targets	  ([37,	  81,	  101,	  102,	  131,	  136-­‐138]),	  and	  for	  a	  number	  
of	   potential	   engineering	   applications[139-­‐141],	   highlighting	   the	   importance	   of	  
understanding	   mechanisms	   for	   specificity	   and	   recognition	   of	   riboswitches	   by	   small	  
molecule	  ligands[139,	  142].	  
The	   S	   box	   system,	   also	   called	   the	   SAM-­‐I	   riboswitch	  was	   identified	   by	   careful	   sequence	  
data	   analysis	   in	   B.subtilis	   (Moszer	   et	   al.,	   1995;	   Kunst	   et	   al.,	   1997)	   [143].	   The	   SAM-­‐I	  
riboswitch	  controls	  the	  expression	  of	  genes	  involved	  in	  sulfur	  metabolism,	  synthesis	  and	  
transport	   of	   sulfur-­‐containing	   amino	   acids	   using	   S-­‐adenosyl	   methionine	   (SAM)	   as	   the	  
effector	  molecule[70,	   106,	   144-­‐146].	   The	   SAM-­‐I	   riboswitch	   is	   one	  of	   five	   classes	  within	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the	   S-­‐box	   family.	   	   Each	   class	   has	   its	   own	   sequence	   conservation	   and	   gene	   control	  
mechanism[147].	   In	   the	   SAM-­‐I	   riboswitch,	   binding	   of	   SAM	   to	   the	   riboswitch	   causes	  
structural	  rearrangement	  of	  the	  RNA	  leading	  to	  transcription	  modulation[148,	  149].	  	  The	  
small	  molecule	  SAM	  is	  the	  cue	  for	  bacterial	  sulfur	  metabolism.	  The	  remarkable	  ability	  of	  
such	  a	  small	  molecule	  to	  alter	  the	  global	  structure	  of	  the	  macromolecule	  (RNA)	  motivates	  
the	   search	   for	   an	   in-­‐depth	   understanding	   of	   the	   regulatory	   mechanism.	   	   Such	   an	  
understanding	   in	  turn	  will	  provide	   insights	   into	  the	  principles	  of	  metabolite	  recognition	  
and	  discrimination	  by	  RNA.	  	  
The	   SAM-­‐1	   riboswitch	   is	   comprised	   of	   two	   functional	   domains	   (Figure	   3.1).	   The	   first	  
domain	   called	   the	   aptamer	   binds	   to	   SAM	   at	   raised	   cellular	   SAM	   concentration.	   Under	  
these	  conditions,	  the	  second	  domain,	  called	  the	  expression	  platform,	  undergoes	  structural	  
rearrangement	  to	  allow	  the	  formation	  of	  a	  stable	  transcription	  terminator	  stem-­‐loop.	  At	  
low	  cellular	  SAM	  levels,	  the	  interplay	  between	  the	  two	  domains	  is	  altered	  to	  stabilize	  the	  
antiterminator	  (AT).	  These	  structural	  alterations	   in	   the	  expression	  platform	  allow	  read-­‐
through	   transcription[150,	   151].	   The	   crystal	   structures	   of	   the	   SAM-­‐I	   riboswitch	   in	  
T.tencongensis	  upstream	  from	  the	  metF-­‐H2	  gene	  and	  B.subtilis	  upstream	  from	  the	  yitJ	  gene	  
revealed	  that	  SAM	  binds	  to	  a	  pocket	  formed	  by	  four	  coaxially	  stacked	  helices	  (P1,	  P2,	  P3,	  
P4)	   joined	   by	   junctions	   J1/2,	   J2/3	   and	   J3/4	   (Figure	   1)	   [108].	   Mutational	   analysis	   and	  
biophysical	   studies	   show	   that	   a	   kink-­‐turn	   mediated	   pseudoknot	   formation	   assists	   the	  
global	  folding	  of	  the	  riboswitch	  cooperatively	  with	  magnesium	  present	  [152,	  153].	  	  
Since	   the	   riboswitch	   is	   believed	   to	   undergo	   conformational	   changes	   from	   transcription	  
‘On’	  state	  to	  ‘Off’	  state	  in	  the	  presence	  of	  SAM,	  the	  question	  arises:	  how	  can	  a	  limited	  set	  
of	   contacts	   by	   a	   small	   molecule	   ligand	   cause	   a	   large-­‐scale	   rearrangement	   of	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secondary	  structure	  folding	  in	  the	  target	  macromolecule?	  The	  dynamic	  nature	  of	  the	  
expression	   platform	   poses	   a	   major	   challenge	   in	   understanding	   the	   gene	   control	  
mechanism.	  	  In	  the	  absence	  of	  SAM,	  the	  P1	  helix	  is	  dynamic	  even	  in	  the	  isolated	  aptamer	  
[151].	  
We	   investigate	   the	   structural	   features	   of	   the	   T.tencongensis	   metF,	   B.subtilis	   yitJ	   SAM-­‐I	  
riboswitches	   that	  are	   responsible	   for	   the	  discrimination	  of	   the	   ligand	  by	   the	   riboswitch	  
and	   also	   the	   discrimination	   of	   the	   On	   and	   Off	   states	   of	   the	   riboswitch	   by	   the	   ligand.	  
T.tencongensis	  metF,	  SAM-­‐I	  riboswitch	  (Figure	  3.1)	  B.subtilis	  yitJ	  SAM-­‐I	  riboswitch	  (Figure	  
3.2)	  are	  shown.	  As	   is	  clear	   from	  these	  Figures,	   the	  base	  pairing	  patterns	   in	   the	  P1	  helix	  




Figure	   3.1:	   The	   secondary	   structure	   of	   the	  T.tencongensis	  metF	   SAM-­‐I	   riboswitch.	  
The	  residues	  in	  green	  are	  conserved.	  The	  similarity	  in	  base	  pairing	  between	  the	  P1	  
helix	  and	  the	  AT	  is	  shown	  in	  the	  boxed	  region.	  (Adapted	  from	  	  [58]).	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This	  observation,	   led	  us	  to	  the	  design	  of	  RNA	  constructs	  to	  1)	  mimic	  the	  On	  state	  of	  the	  
T.tencongensis	  SAM-­‐1	  riboswitch	  (On	  constructs)	  (Figure	  3.3),	  2)	  mimic	  aspects	  of	  an	  Off	  
state	   tertiary	  structure,	  within	  the	  context	  of	  a	  putative	  On	  state	  secondary	  structure	   in	  
the	   B.subtilis	   yitJ	   SAM-­‐I	   riboswitch	   (Hybrid	   constructs).	   Our	   preliminary	   SAM	   binding	  
results	   with	   the	   On	   constructs	   and	   the	   hybrid	   constructs	   indicate	   that	   the	   hybrid	  
constructs	  (Figure	  3.4)	  of	  the	  B.subtilis	  yitJ	  SAM-­‐I	  riboswitch	  bind	  the	  SAM	  with	  moderate	  
affinity.	   We	   examine	   the	   basis	   for	   discrimination	   by	   SAM	   between	   On	   and	   Off	   state	  
riboswitch	   RNAs,	   in	   terms	   of	   secondary	   and	   tertiary	   structure	   using	   the	   B.subtilis	   yitJ	  
SAM-­‐I	  riboswitch	  as	  a	  model	  system.	  	  
	  
	  
Figure	  3.2:	  The	  Secondary	  structure	  and	  sequence	  of	  B.subtilis	  yitJ	  SAM-­‐I	  riboswitch.	  
The	  residues	  of	  the	  junction	  regions	  J1/2,J3/4	  and	  J1/4	  are	  colored	  in	  red,	  pink	  and	  
blue	   respectively.	   The	   aptamer,	   AT	   and	   T	   are	   decision-­‐making	   regions	   that	  
represent	   the	   aptamer,	   antiterminator	   and	   the	   terminator	   sequences.	   The	   P1-­‐P4	  
are	  helices	  of	  the	  SAM-­‐I	  riboswitch.	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While	   ligand	  affinity	   is	  much	   reduced	  compared	   to	   that	   for	   the	  aptamer,	  binding	   to	   the	  
hybrid	  constructs	  shows	  a	  similar	  pattern	  of	  sensitivity	  to	  mutations	  and	  ionic	  conditions	  
as	   reported	   for	   the	   former.	   Thus,	   the	   mutant	   binding	   data	   are	   consistent	   with	   the	  
conclusion	   that	   the	   hybrid	   RNAs	   mimic	   aspects	   of	   aptamer	   tertiary	   structure,	   which	  
mediate	  SAM	  binding.	  Consistent	  with	  previous	  indications	  that	  a	  minimal	  length	  P1	  helix	  
is	  necessary	   for	  SAM	  binding,	  continuous	  stacking	  between	  P1	  and	  AT	  helical	  regions	   is	  
required	   for	   SAM	   binding	   to	   hybrids.	   We	   discuss	   the	   implications	   for	   models	   of	  




Figure	  3.3:	  T.tencongensis	  On	   constructs	  GGU_P1	   (left,	   the	   residues	   in	   red	  are	   the	  
altered	  residues	  to	  mimic	  the	  P1	  helix),	  GGAG_AT_U4	  (right).	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Figure	  3.4:	  B.	  subtilis	  yitJ	  SAM-­‐I	  riboswitch	  AT	  and	  AAT	  hybrid	  constructs	  used	  for	  
SAM	  binding	  studies.	  Helices	  P2,	  P3,	  P4	  and	   the	   junctions	  regions	   J1/2,	   J3/4,	   J1/4	  
are	  represented	  with	  sticks	  as	  they	  remain	  consistent	  in	  all	  the	  hybrid	  constructs.	  	  
	  
3.2.	  	  	  	  Methods	  and	  Materials	  
3.2.1.	  	  	  Materials	  
Synthetic	   DNA	   oligos	   for	   generating	   DNA	   templates	   by	   PCR	   were	   purchased	   from	  
Integrated	   DNA	   technologies	   (IDT),	   Inc	   (USA).	   Equilibrium	   dialysis	   (Dispo	   equilibrium	  
dialyzer	  5000	  MWCO)	  chambers	  were	  purchased	  from	  Harvard	  apparatus,	  Massachusetts,	  
USA.	   	  The	  S-­‐adenosyl–L-­‐methionine-­‐methyl-­‐	   3H,	   32P	   labeled	  ATP	   for	  5’RNA	  end	   labeling	  
are	   purchased	   from	   Perkin	   Elmer,	   California,	   USA.	   The	   NTPs	   for	   in	   vitro	   transcription	  
were	  purchased	  from	  Sigma	  Aldrich.	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3.2.2.	  	  	  Methods	  
3.2.2.1.	  DNA	  Template	  Synthesis	  
The	  synthetic	  oligo	  nucleotides	  purchased	  form	  IDT	  were	  purified	  by	  denaturing	  PAGE	  on	  
12%	   acrylamide	   gel,	   electro-­‐eluted	   and	   recovered	   by	   ethanol	   precipitation.	   Oligo	  
nucleotide	  concentration	  was	  determined	  using	  U.V	  absorbance	  at	  260nM.	  	  
	  
3.2.2.1.1.	   Cassette	   Polymerase	   Chain	   Reaction	   for	  B.subtilis	   yitJ	  SAM-­‐I	   Riboswitch	  
with	  Hammerhead	  Ribozyme	  
	  
The	   long	   templates	   for	   transcription	   reactions	  were	   synthesized	   by	   creating	   a	   cassette	  
with	  2	  rounds	  of	  PCR	  reactions.	  First	  round	  of	  PCR	  reactions	  were	  done	  with	  over-­‐lapping	  
oligo	  nucleotides	  [154].	  Details	  of	  the	  sequences	  used	  for	  each	  round	  and	  the	  design	  for	  
the	  hammerhead	  ribozyme	  cleavage	  are	  included	  in	  table	  3.1.	  
The	  T7	  promoter	  and	  hammerhead	  ribozyme	  coding	  sequences	  are	   incorporated	   in	   the	  
second	  round	  of	  PCR.	  A	  schematic	  for	  the	  cassette	  PCR	  is	  shown	  in	  the	  Figure	  3.5.	  Similar	  
DNA	   templates	   for	   all	   the	   hammerhead	   ribozyme	   integrated	   hybrid	   constructs	   are	  
generated	  for	  SAM	  binding	  experiments	  using	  cassette	  PCR	  strategy.	  	  
PCR	   reactions	   are	   done	   in	   100μL	   with	   2mM	  MgCl2,	   10PM	   DNA	   template	   strands,	   1μM	  
primers,	  200μM	  dNTPs	  and	  taq	  polymerase.	  The	  PCR	  cycle	  includes	  a	  940C	  denaturation	  
step,	  58-­‐620C	  annealing	  step	  (based	  on	  the	  primer	  melting	  temperatures),	  720C	  extension	  
step.	  31	  cycles	   for	   first	   round	  PCR	  were	  done.	  DNA	   from	  the	   first	   round	  PCR	   is	  used	  as	  
template	  for	  the	  second	  round	  PCR	  along	  with	  the	  appropriate	  primers	  (modified	  primers	  
are	   used	   to	   generate	   the	   template	   strand	   with	   5’	   modified	   nucleotides	   to	   ensure	  
homogenous	  3’	  ends	  of	  RNA)	  and	  the	  hammerhead	  ribozyme	  coding	  bottom	  strand	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Figure	  3.5:	   	   Schematic	   representation	  of	   cassette	  PCR	   strategy.	  The	   first	   round	  of	  
PCR	   cycles	   generates	   the	   riboswitch	   coding	   sequence	   represented	   in	   black	   color.	  
The	   second	   round	   of	   PCR	   cycles	   generates	   riboswitch	   (black),	   hammerhead	  
ribozyme	  (cyan)	  and	  T7	  promoter	  coding	  regions	  (green).	  To	  produce	  templates	  for	  
RNA	   transcription,	   the	   following	   DNA	   oligonucelotide	   sequences	   (Overlapping	  
templates)	  were	  added	  to	  a	  PCR	  reaction	  for	  the	  first	  stage	  of	  the	  cassette	  strategy.	  	  
	  
	  The	  second	  round	  PCR	  was	  done	   in	  similar	  conditions	  as	   the	   first	  round.	  The	  amplified	  
DNA	  on	  a	  2%	  agarose	  gel	  is	  shown	  in	  Figure	  3.6.	  	  
Table	  3.1:	  List	  of	  yitJ	  SAM-­‐I	  riboswitch	  hybrid	  constructs	  and	  their	  primers	  used	  to	  
generate	  the	  templates.	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5’	  GGT	  TCT	  TAT	  CAA	  GAG	  AAG	  CAG	  AGG	  GAC	  TGG	  CCC	  GAC	  GAA	  GCT	  TCA	  GCA	  ACC	  GGT	  
GTA	  ATG	  GCG	  ATC	  AGC	  CAT	  GAC	  CAA	  GGT	  GCT	  AAA	  TCC	  AGC	  AAG	  CTC	  GAA	  3’	  
	  
5’	  AAA	  GTC	  CTC	  TTA	  AGA	  AGA	  AGA	  CTT	  TGT	  CAG	  TGA	  TTT	  TGT	  CTC	  TTC	  TTA	  TCT	  TCC	  
AAG	  CTG	  TTC	  GAG	  CTT	  GCT	  GGA	  TTT	  AGC	  ACC	  TTG	  GTC	  ATG	  GCT	  GAT	  CGC	  CAT3’	  
	  
3.2.2.1.2.	  Cloning	   for	  Generating	  DNA	  Templates	   for	   the	   In	  vitro	  Transcriptions	  of	  
the	  T.tencongensis	  SAM-­‐I	  Riboswitch	  Constructs	  
	  
The	   T.tencongensis	   aptamer	   and	   the	   “ON	   conformers”	   are	   synthesized	   by	   in	   vitro	  
transcriptions	  run	  on	  DNA	  templates	  generated	  by	  plasmid	  PCR	  reactions.	  	  
	  
	  
Figure	  3.6:	  A	  2%	  ethidium	  bromide	   stained	  agarose	   gel	  with	  50	  base	  pair	   ladder	  
(lane	  1),	  the	  yitjP1_AT	  lanes	  (2,3)	  are	  the	  DNA	  products	  from	  the	  first	  round	  of	  PCR,	  
the	  yitjP1_AT_RIBOZYME	  lanes	  (4,5,6,7)	  are	  the	  DNA	  from	  second	  round	  of	  PCR.	  	  
	  
The	  DNA	   insert	   coding	   for	   the	   riboswitch	   construct	   is	   ligated	   into	   a	   restricted	   plasmid	  
with	   a	   HDV	   ribozyme	   coding	   sequence	   and	   T7	   promoter	   coding	   sequence.	   The	   PCR	   to	  
generate	   the	   insert	  was	  done	   according	   to	  methods	  mentioned	   in	   section	  3.2.2.1.1.	  The	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plasmid	  is	  linearized	  according	  to	  the	  EcoR1	  and	  NcoI	  restriction	  enzyme	  (New	  England	  
Biolabs)	  requirements	  (table	  3.2).	  




The	  ligation	  reaction	  with	  the	  gel	  purified	  restricted	  insert	  and	  the	  plasmid	  was	  done	  at	  
was	  done	  using	  T4	  DNA	  ligase	  (Promega)	  at	  160C	  for	  12	  hours	  (table	  3.3).	  	  	  
	  
Table	  3.3:	  Ligation	  Reactions	  for	  Restricted	  Plasmid	  and	  Insert.	  
	  
	  
Transformation	  of	   the	  plasmid	   is	  by	   incubating	  50μl	  of	   competent	  cells	  with	   	  2-­‐10ng	  of	  
the	   plasmid	   DNA	   for	   30	   minutes	   with	   	   gentle	   mixing	   followed	   by	   	   heat	   shock	   for	   45	  
seconds	  at	  420C.	  The	  reaction	  is	  placed	  on	  ice	  for	  10	  minutes.	  The	  transformed	  cells	  are	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grown	  on	  LB	  agar	  plates	  with	  Amplicillin.	  The	  clones	  have	  been	  confirmed	  by	  colony	  PCR	  
reactions	  and	  by	  sequencing.	  	  
The	   templates	   for	   the	   in	   vitro	   transcription	   of	   the	   T.tencongensis	   SAM-­‐I	   riboswitch	  
constructs	  are	  obtained	  by	  colony	  PCR	  reactions	  with	  appropriate	  HDV	  and	  T7	  primers.	  
The	  primers	  are	  T7	  promoter	   (5’,	  GCGCGCGAATTCTAATACGACTCACTATAG,	  3’)	   and	   the	  
HDV	  ribozyme	  in	  the	  vector	  (5’,	  GAGGTCCCATTCATTCGCCATGCCGAAGCATGTTG,	  3’).	  
	  
3.2.2.2.	  	  	  In	  vitro	  Transcriptions	  
The	   in	   vitro	   transcriptions	   for	   the	   hammerhead	   ribozyme	   integrated	  B.subtilis	  and	   the	  
HDV	  ribozyme	  integrated	  T.tencongensis	  riboswitch	  constructs	  are	  done	  in	  40	  mM	  MgCl2,	  
8.0	  mM	  NTPs	  from	  Sigma	  Aldrich,	  80	  mg/mL	  8000	  MW	  PEG,	  and	  100μL	  PCR	  template	  in	  
250	   μL	   reactions.	   The	   hammerhead	   ribozyme	   cleavage	   is	   attained	   after	   4	   hours	   of	  
transcription	   at	   370C	  without	   any	   excess	  magnesium.	  HDV	   ribozyme	   cleavage	   required	  
20mM	   excess	   of	   magnesium	   at	   600C	   for	   20	   minutes.	   	   The	   RNA	   is	   purified	   on	   a	   12%	  
acrylamide	   denaturing	   gel	   containing	   7M	   Urea.	   The	   appropriate	   gel	   slices	   with	   the	  
riboswitch	  are	  electroeluted,	  ethanol	  precipitated	  overnight	  and	  dialyzed	  in	  high	  salt	  and	  
low	   salt	   buffers	   followed	   by	   desalting	   in	   PD10	   columns.	   The	   RNA	   is	   concentrated	   by	  
lyophilizing	   or	   using	   3000	  MWCO	   Amicon	   filters.	   The	   RNA	  was	   refolded	   by	   heating	   to	  
95°C	   and	   snap	   cooled	   on	   ice	   and	   supplemented	  with	   2mM	  MgCl2	   and	   used	   for	   binding	  
experiments.	  Each	  RNA	  was	  run	  on	  ethidium	  bromide	  stained	  12%	  acrylamide	  analytical	  
gel	  for	  size,	  concentration	  and	  integrity	  verification.	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3.3.2.3.	  	  	  Equilibrium	  Dialysis	  
Single	  point	  SAM	  binding	  assays	  are	  done	  with	  100nM	  SAM	  and	  3μM	  RNA	  according	   to	  
established	  protocols	  [106,	  155].	  100nM	  SAM	  (10.0CI/mmol,	  12000	  counts	  per	  minute)	  in	  
a	  total	  volume	  of	  30uL	  in	  equilibrium	  dialysis	  buffer	  (500mM	  KCl,	  50mM	  Tris	  HCL	  pH	  7.5,	  
20mM	  MgCl2)	  was	   added	   to	   chamber	   A	   of	   Dispo	   equilibrium	   dialyzer.	   	   The	   RNA	   to	   be	  
tested	  for	  binding	  is	  heated	  to	  950C	  for	  5	  minutes	  and	  snap	  cooled	  on	  ice	  for	  10	  minutes	  
before	   the	   binding	   experiment.	   3µM	  RNA	   to	   be	   tested	   for	   binding	   in	   a	   total	   volume	   of	  
30µL	   in	   equilibrium	   dialysis	   buffer	   is	   added	   to	   chamber	   B	   and	   equilibrated	   at	   room	  
temperature	   for	   12	   hours	  with	   shaking.	   Aliquots	   from	   each	   chamber	   are	   collected	   and	  
counted	  separately	  in	  the	  scintillation	  counter.	  The	  ratio	  of	  number	  of	  counts	  in	  chamber	  
B	  to	  chamber	  A	  is	  used	  as	  a	  measure	  of	  SAM	  binding.	  Averaging	  of	  at	  least	  three	  replicates	  
with	  standard	  deviation	  is	  used	  as	  the	  B/A	  ratio	  for	  each	  RNA.	  
	  
3.2.2.4.	  	  	  	  SAM	  Titration	  (Scatchard	  Analysis)	  
	  
Affinity	  of	  SAM	  to	  B.subtilis	  aptamer	  is	  calculated	  from	  the	  data	  obtained	  from	  scatchard	  
analysis	   using	   equilibrium	   dialysis	   to	   quantitate	   SAM	   binding	   as	   a	   function	   of	  
concentration.	  	  200nm	  B.subtilis	  yitJ	  aptamer/hybrid	  RNA	  was	  added	  to	  chamber	  B	  of	  the	  
Dispo	   equilibrium	   dialyzer	   and	   various	   concentrations	   of	   tritiated	   SAM	   (10.0CI/mmol,	  
12000	  counts	  per	  minute)	  ranging	  from	  10nM	  to	  3	  μM	  is	  added	  in	  chamber	  A	  along	  with	  
equilibrium	  dialysis	  buffer	  (500mM	  KCl,	  50mM	  Tris	  HCL	  pH	  7.5,	  20mM	  MgCl2).	  30uL	  was	  
the	   total	   volume	   in	   each	   chamber.	   Degradation	   of	   SAM	   was	   taken	   into	   account	   by	  
eliminating	  10%	  of	  the	  counts	  in	  each	  chamber.	  Affinity	  of	  SAM	  to	  the	  aptamer/hybrid	  is	  
calculated	  from	  the	  scatchard	  plot,	  plotted	  using	  SAM	  bound	  (Lb),	  free	  SAM	  (Lf),	  total	  SAM	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(Lt)	  were	  all	  calculated	  from	  the	  number	  counts	  in	  chamber	  A	  and	  chamber	  B	  [106,	  155].	  
The	  outlier	  points	  obtained	  using	  dialysis	  chambers	  due	  to	  leaks	  in	  the	  membrane	  and	  air	  
bubbles	  are	  eliminated.	  
	  
Figure	  3.7:	  Secondary	  structure	  of	  the	  hammerhead	  ribozyme	  integrated	  B.subtilis	  
SAM-­‐I	   riboswitch	   hybrid	   construct.	   The	   arrow	   indicates	   the	   point	   of	   ribozyme	  
cleavage.	  	  
	  
3.2.2.5.	  	  	  	  Inline	  Probing	  Assay	  
Inline	   probing	   reactions	   with	   the	   3P1_10AT,	   3P1_9AT	   and	   3P1_10AT_5’GCC	   hybrid	  
constructs.	  The	  RNA	  required	  was	  generated	  as	  mentioned	  in	  the	  in	  vitro	  transcriptions	  
above.	   The	   dephosphorylation	   and	   5’end	   32P	   labelling,	   inline	   probing	   reactions	   in	   the	  
presence	   of	   100µM	   SAM	   are	   done	   according	   to	   the	  methods	  mentioned	   in	   [106].	   RNA	  
dephosphorylation	   reactions	   are	   done	   with	   10pM	   RNA	   in	   the	   20µL	   reactions	   with	  
1unit/µL	  Shrimp	  alkaline	  phosphatase	  enzyme	  and	  10x	  reaction	  buffer	  and	  incubated	  at	  
370	   C	   for	   30	   minutes.	   The	   dephosphorylated	   RNA	   is	   purified	   by	   phenol	   chloroform	  
extraction,	  ethanol	  precipitation.	  5’	  end	  labeling	  of	  the	  dephosphorylated	  RNA	  is	  done	  in	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the	  presence	  of	  4µL	  of	  5x	  phosphorylation	  buffer,	  1uL	  of	  10µM	  dephosphorylated	  RNA,	  
6µl	   of	   (γ-­‐32P)	   ATP	   (adenosine	   triphosphate)	   (6000mCi/mmole),	   2.5µL	   of	   10U/µL	   T4	  
polynucleotide	  kinase	   in	   a	   total	   volume	  of	  10µL	  and	   incubated	  at	  370	  C	   for	  30	  minutes.	  
The	   labeled	   RNA	   is	   purified	   by	   ethanol	   precipitation.	  The	   inline	   probing	   reactions	   are	  
done	   by	   incubating	   1µL	   labeled	   RNA	   in	   5µL	   of	   inline	   reaction	   buffer	   and	   100µM	  
metabolite	   at	   room	   temperature	   for	   40	   hours.	   	   Denaturing	   10%	   PAGE	   and	   its	   analysis	  
using	   molecular	   dynamics	   phosphor	   imager	   was	   done	   to	   analyze	   the	   RNA	   cleavage	  
patterns.	  	  
	  
3.2.2.6.	  BPP	  Calculation	  
The	   base	   pair	   probability	   was	   calculated	   at	   37	   °C	   using	   the	   RNAfold	   program	   in	   the	  
Vienna	  RNA	  package.	  The	  probabilities	  of	  base	  pairs	  in	  the	  proposed	  AAT	  and	  AT	  models	  
are	   plotted	   according	   to	   the	   position	   as	   annotated	   in	   the	   Figure	   2b.	   Two	   versions	   of	  
sequences	   are	   used	   in	   the	   calculation.	   The	   one	   without	   terminator	   (T)	   includes	   the	  
sequence	  to	  form	  either	  AAT	  or	  AT	  without	  the	  3’	  strand	  of	  the	  terminator.	  The	  other	  one	  
is	  the	  full-­‐length	  sequence	  of	  the	  riboswitch,	  in	  which	  the	  terminator	  can	  completely	  form.	  
	  
3.2.2.7.	  Nuclear	  Magnetic	  Resonance	  (NMR)	  Spectroscopy	  Experiments	  
1d,	  WaterLOGSY	   and	   T2	   filter	   experiments	   are	   used	   to	   detect	   SAM	   and	   small	  molecule	  
binding	   with	   the	   different	   RNA	   constructs.	   The	   binding	   experiments	   work	   on	   the	  
principles	   involved	   in	   the	   transfer	   of	   magnetization	   properties	   from	   the	   ligand	   to	  
RNA[124].	  The	  NMR	  samples	  were	  made	  with	  200-­‐250	  μM	  ligand,	  10-­‐20μM	  RNA	  in	  a	  total	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of	  500μL	  with	  10mM	  sodium	  phosphate,	  10mM	  sodium	  chloride	  and,	  0.2mM	  EDTA	  with	  




3.3.1.	  SAM	  Binding	  with	  the	  T.tencongensis	  SAM-­‐I	  Riboswitch	  Aptamer	  and	  On	  
Conformers	  as	  Seen	  from	  1d	  Proton	  NMR	  
	  
The	  T.tencongensis	  metF	   riboswitch	  aptamer	   (henceforth	   referred	   to	  as	   “T.	   tencongensis	  
aptamer”)	   SAM	   binding	   is	   monitored	   using	   NMR	   1d	   experiments.	   The	   ligand	   peaks	  
experience	  changes	  in	  the	  chemical	  environment	  upon	  interacting	  with	  the	  RNA	  in	  ligand	  
detected	  NMR	   spectroscopy.	   Such	   changes	   are	   readily	   observed	   in	  WaterLOGSY	   and	  T2	  
Filter	  experiments.	  The	  WaterLOGSY	  experiment	  is	  a	  highly	  sensitive	  NMR	  technique	  that	  
has	   applications	   in	   detecting	   small	   molecule	   interactions	   with	   macromolecules.	   The	  
WaterLOGSY	   is	  based	  on	   the	   transfer	  of	   the	  magnetization	   to	   the	  small	  molecule	   (SAM)	  
from	   the	  macromolecule	   (RNA)	   through	  water	  molecules	   [156].	  The	   transfer	   that	   takes	  
place	   is	   from	  water	  bound	   to	   the	  macromolecule	   and	   the	   ligand.	   If	   the	   ligand	   is	  bound,	  
then	   when	   it	   exchanges	   protons	   with	   water	   that	   leads	   to	   NOEs	   with	   water,	   and	   these	  
show	  up	  with	  a	  positive	  sign	  because	  the	  ligand	  is	  bound	  to	  the	  RNA	  and	  tumbling	  slowly.	  	  
The	  bound	  water	  molecules	  present	  at	  the	  interface	  of	  ligand-­‐RNA	  interaction	  contribute	  
to	  the	  high	  sensitivity	  of	  the	  WaterLOGSY	  experiment.	  The	  T2	  filter	  experiment	  works	  by	  
monitoring	  the	  T2	  relaxation	  time	  of	  the	  small	  molecule	  (SAM)	  [157].	  The	  small	  molecule	  
“tumbles”	   faster	   than	   a	   large	  molecule	   (RNA)	   but	   slowly	  when	   associated	  with	   a	   large	  
molecule.	  The	   intensity	  of	   the	   ligand	  peak	  decreases	  when	   it	   interacts	  with	   the	  RNA	  as	  
compared	  to	  the	  peak	  intensity	  of	  the	  free	  ligand.	  	  In	  this	  case,	  the	  intensity	  of	  the	  ligand	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peak	  in	  a	  conventional	  one-­‐dimensional	  experiment	  may	  also	  decrease	  and	  the	  peak	  may	  
broaden	   due	   to	   exchange	   between	   free	   and	   bound	   forms.	   In	   RNA	   detected	   NMR	  
spectroscopy,	   the	  RNA	  peaks	   show	  change	   in	   the	  position	  or	   intensity	  or	   type	  of	  peaks	  
when	  the	  RNA	  interacts	  with	  a	  small	  molecule	  ligand.	  1D	  proton	  Watergate	  experiments	  
are	  used	  to	  suppress	  the	  large	  water	  signal	  for	  RNA	  detected	  NMR.	  We	  use	  these	  methods	  
to	  detect	  the	  SAM	  binding	  to	  the	  T.tencongensis	  SAM-­‐I	  riboswitch	  constructs.	  	  
	  
3.3.2	   The	   Aptamer	   Binds	   to	   SAM	   as	   Seen	   from	   1d	   Proton	   NMR	   and	   Equilibrium	  
Dialysis	  
	  
	   	  
Figure	   3.9:	   WaterLOGSY	   experiment	   for	   SAM	   in	   the	   presence	   and	   absence	   of	  
T.tencongensis	  SAM-­‐I	   riboswitch	   aptamer	   (10	  μM	  aat).	   	   The	   spectrum	   is	   split	   into	  
two	   regions	   for	   scaling.	   The	   peaks	   in	   blue	   are	   the	   ligand	   peaks	   that	   increase	   in	  
intensity	  upon	  binding	  to	  the	  RNA.	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The	  aptamer	  construct	  of	   the	  T.tencongensis	   SAM-­‐I	   riboswitch	  shows	  binding	   to	  SAM	   in	  
the	  WaterLOGSY	  experiment	  as	  shown	  in	  Figure	  3.9.	  
	  Equilibrium	   dialysis	   experiments	   are	   done	   to	   validate	   the	   SAM	   binding	   to	   the	  
T.tencongensis	  SAM-­‐I	  riboswitch	  aptamer.	  The	  TPP	  thiC	  riboswitch	  was	  used	  as	  a	  negative	  
control.	  As	  expected,	  the	  SAM-­‐I	  aptamer	  showed	  high	  affinity	  binding	  with	  a	  b/a	  ratio	  of	  
~8	   (Well	   within	   the	   range	   reported	   in	   literature	   using	   equilibrium	   dialysis).	   The	   TPP	  
aptamer	  did	  not	  show	  any	  binding.	  	  
	  
	  
Figure	   3.10:	   Equilibrium	   dialysis	   data	   for	   T.tencongensis	   aptamer,	   TPP	   aptamer.	  
The	   SAM	   in	   the	   SAM	   only	   and	   the	   TPP	   aptamer	   dialysis	   apparatus	   equilibrates	  
equally	  between	  the	  two	  chambers	  shown	  by	  a	  b/a	  ratio	  of	  ~1.	  	  
	  
3.3.3.	   The	   SAM	   Binding	   to	   T.tencongensis	   SAM-­‐I	   Riboswitch	   ON	   Constructs	   as	  
Observed	  by	  NMR	  and	  Equilibrium	  Dialysis	  
	  
The	  T.tencongensis	  On	  construct	   GGAA_AT_U4	   (Figure	   3.3)	   shows	   SAM	   binding	   in	   NMR	  
experiments.	   The	   WaterLOGSY	   and	   the	   T2	   filter	   experiments	   are	   optimized	   with	  
temperatures	  from	  10-­‐450C	  (data	  not	  shown)	  and	  concentrations	  of	  RNA	  from	  10-­‐25μM	  
and	  20mM	  magnesium.	  	  	  
The	  On	  construct	  GGAG_AT_U4	  shows	  clear	  binding	   in	  both	  the	  WaterLOGSY	  and	  the	  T2	  














	   65	  
not	   show	   significant	   binding	   implying	   that	   the	   NMR	   techniques	   picked	   up	   some	   weak	  
interactions	   between	   the	   ligand	   and	   the	   SAM-­‐I	   riboswitch	   constructs.	   The	  WaterLOGSY	  
technique,	   which	   is	   highly	   sensitive	   to	   weak	   binding	   interactions,	   did	   not	   show	   any	  
binding	  to	  the	  TPP	  thiC	  aptamer.	  	  
The	  SAM	  binding	  data	  from	  the	  T.tencongensis	  aptamer	  and	  the	  On	  conformers	  indicates	  
that	  the	  SAM	  makes	  some	  interactions	  with	  the	  On	  conformers	  that	  can	  be	  detected	  using	  
NMR	  but	  not	  with	  equilibrium	  dialysis.	  
	  
Figure	  3.13:	  T2	  filter	  SAM	  binding	  experiment	  with	  the	  GGAG_AT_U4	  construct	  in	  the	  
presence	   of	  magnesium	   at	   25	   0C.	  We	   used	   the	   small	  molecule	   dCTP	   as	   a	   positive	  
control.	  The	  peaks	  highlighted	  in	  grey	  are	  from	  SAM	  and	  the	  peaks	  in	  black	  box	  are	  
from	  dCTP.	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Figure	  3.14	  WaterLOGSY	  experiment	  for	  GGAG_AT_U4	  construct	  at	  250C.	  The	  peaks	  
in	  the	  shaded	  region	  represent	  the	  SAM	  peaks.	  In	  the	  absence	  of	  Mg,	  the	  SAM	  peaks	  
near	  8.1ppm	  show	  an	  increase	  in	  the	  intensity.	  With	  the	  addition	  of	  magnesium,	  the	  
peaks	  at	  2.0ppm	  show	  an	  increase	  in	  the	  intensity.	  The	  peaks	  in	  shaded	  region	  are	  




Figure	  3.15:	  Equilibrium	  dialysis	  data	  for	  the	  T.tencongensis	  On	  constructs.	  	  
	  
Equilibrium	  dialysis	  is	  a	  powerful	  technique	  in	  quantifying	  the	  small	  molecule	  binding	  to	  
macromolecules.	  It	  can	  be	  used	  to	  detect	  weak	  binding	  but	  is	  not	  sensitive	  towards	  long	  
range	   or	   short-­‐	   lived	   interactions	   between	   the	   small	  molecule	   and	   the	  macromolecule.	  
This	  preliminary	  data	  is	  useful	  for	  us	  to	  design	  more	  SAM-­‐I	  riboswitch	  constructs	  that	  are	  
useful	   in	  probing	  the	  structural	  elements	  of	   the	  riboswitch	  necessary	   for	  SAM	  detection	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riboswitch	   that	   is	   similar	   to	   the	   T.tencongensis	   SAM-­‐I	   riboswitch	   in	   sequence	   and	  
secondary	  structure	  (Figures	  3.1,3.2)	  
	  
3.3.4.	  B.	  subtilis	  yitJ	  SAM-­‐I	  Riboswitch	  SAM	  Binding	  
	  
3.3.4.1.	  BPP	  Calculations	  and	  RNA	  Secondary	  Structure	  Folding	  Data	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
In	  a	  transcriptional	  riboswitch,	  the	  expression	  platform	  determines	  whether	  transcription	  
is	   terminated.	   A	   competition	   between	   the	   formation	   of	   a	   terminator	   or	   antiterminator	  
(AT)	   hairpin	   decides	   the	   outcome.	   For	   the	   SAM-­‐I	   riboswitch,	   the	   formation	   of	   the	   AT	  
involves	  a	  competition	  with	  the	  P1	  helix	  within	  the	  aptamer.	  Since	  the	  riboswitch	  region	  
encompassing	   the	   competition	   between	   these	   two	   helices	   is	   transcribed	   before	   the	  
terminator	   hairpin	   is,	   the	   AT/P1	   competition	   is	   likely	   to	   bias	   the	   final	   outcome	   of	  
riboswitch-­‐regulated	  transcription.	  	  
Until	  now,	  most	  experimental	  studies	  of	  the	  dynamics	  of	  riboswitch	  expression	  platforms	  
have	  utilized	  a	  two-­‐state	  model	  for	  RNA	  secondary	  structure.	  The	  chemical	  and	  enzymatic	  
probes	   used,	   however,	   do	   not	   provide	   quantitative	   measures	   of	   riboswitch	   conformer	  
populations.	   Predicted	   secondary	   structures,	   base	   pairing	   probability	   predictions	   at	  
minimal	   free	   energy	   and	   comparative	   sequence	   analysis	   can	   provide	   a	   basis	   for	  
interpreting	  riboswitch-­‐folding	  data.	  While	  predictions	  of	  a	  single	  lowest	  energy	  structure	  
(the	  so-­‐called	  “MFE”)	  are	  often	  used	  for	  this	  purpose,	  the	  secondary	  structure	  of	  any	  given	  
RNA	   in	   solution	   is	  determined	  by	   the	  distribution	  of	   the	  RNA’s	   secondary	   structures	   at	  
thermodynamic	  equilibrium	  [158,	  159].	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Here	  we	  used	  nucleic	   acid	  base	  pairing	  probability	   calculations,	   based	  upon	   a	  partition	  
function,	  to	  simulate	  the	  competition	  between	  the	  P1	  and	  the	  AT	  of	  the	  B.	  subtilis	  yitJ	  SAM-­‐
I	  riboswitch.	  	  Extensive	  qualitative	  data	  regarding	  the	  folding	  of	  this	  riboswitch	  has	  been	  
reported.	   The	   base	   pairing	   probability	   simulations	   (Figure	   3.16)	   predict	   that	   for	   a	  
transcript	  length	  at	  which	  the	  AT	  helix	  has	  been	  fully	  transcribed	  both	  the	  P1	  (green)	  and	  
AT	   (red)	   helices	   are	   populated.	   The	   sum	   of	   the	   probability	   of	   forming	   base	   pairs	   at	  
positions	  4,5,6,7	  represented	  by	  (black)	  is	  almost	  equivalent	  to	  1.	  Moreover,	  the	  predicted	  
BPP	   for	   P1	   helix	   formation	   declines	   and	   that	   for	   AT	   helix	   formation	   increases	   for	   each	  
position	  moving	  down	  the	  sequence	  as	  presented	   in	  Figure	  2a.	  This	  result	  predicts	   that	  
the	   RNA	   has	   a	   propensity	   to	   form	   thermodynamic	   intermediates	   that	   can	   allow	   the	  
formation	  of	  base	  pairs	  in	  the	  P1	  and	  also	  the	  AT	  helix	  simultaneously.	  	  
	  
	  
Figure	  3.16:	  Base	  pairing	  probability	  calculation	  for	  B.subtilis	  yitJ	  SAM-­‐I	  riboswitch	  
(selected	  sequence	  shown	   in	   the	  right).	  Positions	  of	   the	  base	  pairs	  are	  numbered	  
from	  1	  to	  12.	  	  	  
	  
This	  prediction	  raises	  the	  question	  as	  to	  whether	  SAM	  would	  bind	  to	  these	  “intermediate”	  
conformers.	  Addressing	  this	  question	  can	  help	  delineate	  the	  determinants	  of	  SAM	  binding	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specificity	  for	  the	  aptamer	  structure,	  since	  discrimination	  between	  folds	  should	  be	  crucial	  
for	  the	  riboswitch	  mechanism.	  
	  
3.3.4.2.	   A	   SAM-­‐I	   Riboswitch	  Hybrid	   Binds	   to	   SAM	  with	   Affinity	   in	   the	  Micromolar	  
Range	  
	  
The	  sulfur	  anionic	  moiety	  of	  the	  SAM	  interacts	  electrostatically	  with	  the	  minor	  groove	  of	  
the	  first	  two	  base	  pairs	  of	  the	  P1	  helix	  [108].	  	  We	  constructed	  a	  model	  RNA	  molecule	  that	  
is	   constrained	   to	   form	  a	  hybrid	  structure	  containing	   the	   first	   three	  base	  pairs	  of	   the	  P1	  
helix,	  and	  ten	  base	  pairs	  of	  an	  AT	  helix	  (3P1_10AT).	  This	  construct	  resembles	  structures	  
predicted	  as	  minor	  conformers	  by	   the	  calculations	   in	  Figure	  3.16.	  Residues	   in	   the	  T	  are	  
truncated	  to	  constrain	  the	  formation	  of	  the	  AT	  (Figure	  3.4).	  	  
The	  dissociation	  constant	  for	  the	  SAM-­‐I	  riboswitch	  aptamer	  and	  the	  hybrid	  (3P1_10AT)	  of	  
SAM	  were	   determined	   using	   scatchard	   analysis	   from	   equilibrium	  dialysis	   (Figure	   3.18)	  
[149].	   The	   dissociation	   constant	   for	   the	   aptamer	  measured	   in	   this	   way	   is	   32	   nM.	   This	  
value	   is	   within	   the	   range	   of	   what	   has	   been	   previously	   reported	   (table	   3.3).	   Scatchard	  
Analysis	  yielded	  Kd	  for	  SAM	  binding	   to	   the	  hybrid	  3p1_10AT	  of	  ~790nM.	   	  As	  a	  negative	  
control,	  SAM	  binding	  was	  tested	  by	  equilibrium	  dialysis	   for	  ribosomal	  A-­‐site	  RNA	  and	  a	  
putative	   Mycobacterium	   tuberculosis	   thiC	   riboswitch	   aptamer	   RNA	   control	   (data	   not	  
shown).	  No	  potential	  SAM	  binding	  is	  detected	  with	  the	  A-­‐site	  RNA	  or	  the	  thiC	  riboswitch.	  
The	   Kd	   	   	   estimates	   for	   the	   aptamer	   and	   3P1_10AT	   calculated	   using	   the	   single	   point	  
equilibrium	  dialysis	  data	  obtained	  with	  3µM	  RNA	  and	  100nM	  SAM	  agree	  with	  the	  value	  
captured	  by	  scatchard	  analysis	  to	  +/-­‐15%.	  For	  subsequent	  measurements	  on	  other	  RNA	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constructs	  we	  used	  single	  point	  measurements	  at	  ranges	  of	  RNA	  and	  SAM	  concentrations	  
that	  yielded	  the	  highest	  sensitivity	  data.	  	  
	  
Table	  3.3:	  Reported	  Kd	  values	  for	  different	  SAM-­‐I	  riboswitch	  constructs	  determined	  
using	  different	  methods.	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Figure	  3.17:Scatchard	  analysis	  for	  a)	  B.	  subtilis	  yitJ	  SAM-­‐I	  riboswitch	  aptamer.	  The	  
sequence	  used	  for	  this	  analysis	  is	  in	  Figure	  3.2	  that	  includes	  residues	  1	  to	  119.	  b)	  B.	  
subtilis	  yitJ	  SAM-­‐I	  riboswitch	  3P1_10AT	  hybrid	  shown	  in	  Figure	  3.	  The	  variable	  r	  is	  
the	  ratio	  of	  bound	  ligand	  to	  total	  RNA	  concentration.	  The	  variable	  LF	  represents	  free	  
ligand	  [106].	  
	  
3.3.4.3.	   Sensitivity	   of	   SAM	   Binding	   to	   Ions	   and	   Mutations	   for	   Hybrid	   Constructs	  
Parallels	  That	  for	  the	  Aptamer	  
	  
Metal	  ions	  play	  an	  important	  role	  in	  secondary	  structure	  folding	  of	  RNA	  [166].	  	  [167].	  In	  
particular,	  Mg	  has	  been	   shown	   to	  be	   required	   for	  optimal	  binding	  of	   SAM	   to	   the	   SAM-­‐I	  
riboswitch	   and	   for	   aptamer	   induced	   folding	   [152].	   X-­‐ray	   structures	   of	   the	   SAM	   bound	  
SAM-­‐I	   riboswitch,	   and	  MD	   simulations	  derived	   from	   the	  X-­‐ray	   coordinates,	   indicate	   the	  
critical	   role	   played	   by	   Mg	   ions	   in	   facilitating	   ligand	   interactions	   with	   P1,	   P3	   and	   J1/2	  
region	  [108,	  152,	  164,	  168,	  169].	  We	  reasoned	  that	  if	  tertiary	  folding	  and	  the	  mode	  of	  SAM	  
binding	  in	  the	  3P1_10AT	  mimics	  that	  of	  the	  full-­‐length	  aptamer,	  then	  magnesium	  ions	  will	  
be	  required	  to	  obtain	  optimal	  SAM	  binding	  to	  3P1_10AT.	  Measurements	  in	  the	  presence	  
and	  absence	  of	  magnesium	  (Figure	  3.18a)	  clearly	  indicate	  the	  necessity	  of	  magnesium	  for	  
optimal	   SAM	  binding.	  The	  B/A	   ratio	  decreased	  by	  more	   than	   two	   fold	   (as	   compared	   to	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binding	   with	   the	   snap	   cooled	   RNA	   in	   presence	   of	   magnesium)	   when	   1)	   Freshly	  
synthesized	  RNA	  is	  not	  snap	  cooled.	  In	  this	  case	  barely	  any	  binding	  was	  detected	  (Figure	  
3.18a),	   2)	   Freshly	   synthesized	   RNA	   snap	   cooled	   in	   the	   absence	   of	   magnesium	   bound	  
weakly	   in	   a	   detectable	   range	   of	   B/A	   ratio	   above	   1.5,	   3)	   RNA	   samples	   that	   were	   pre-­‐
hybridized	  with	  Mg	  and	  stored	  at	   -­‐200C	  were	   found	  to	   lose	  SAM-­‐binding	  activity	  during	  
storage,	  but	  SAM	  binding	  was	  restored	  by	  repeating	  the	  heat/snap	  cooling	  process	  (data	  
not	  shown).	  
	  
Figure	  3.18	  a)	  Ratio	  of	  Number	  of	  counts	  in	  chamber	  b	  to	  chamber	  a	  in	  equilibrium	  
dialysis	   for	  B.	   subtilis	  yitJ	  SAM-­‐I	   riboswitch	   aptamer	   and	   3p1_10AT	   hybrid	   in	   the	  
presence	   and	   absence	   of	   magnesium	   dependent	   folding.	   b)	   B.	   subtilis	   yitJ	   SAM-­‐I	  
riboswitch	   3P1_10AT	   pseudoknot	   mutants.	   c)	   Equilibrium	   dialysis	   data	   for	  
Aptamer	   (AAT)	   (blue),	   Pseudoknot	   mutant	   (pink),	   pseudoknot	   compensatory	  
mutant	   (green),	   3P1_10AT	   (purple)	   and	   3P1_10AT_G11	   mutant	   (cyan).	  
Equilibration	   of	   SAM	   in	   the	   two	   chambers	   is	   shown	  with	   SAM	  only	   (orange).	   The	  
error	  bars	  represent	  the	  standard	  deviation	  for	  three	  replicates	  for	  experiment.	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  It	  was	   reported	   that	  mutation	  of	   the	   two	  guanine	   residues	   in	   the	   apical	   loop	  of	   the	  P2	  
helix	  in	  the	  aptamer	  (boxed	  nucleotides	  in	  the	  Figure	  3.18b)	  decreased	  the	  SAM	  binding,	  
while	  compensatory	  mutation	  induced	  by	  mutating	  the	  J3/4	  region	  restored	  the	  affinity	  to	  
SAM	  [161,	  170].	  This	  pattern	  reflects	  the	  formation	  of	  a	  kink-­‐turn-­‐stabilized	  pseudoknot	  
interaction	  between	  the	  P2	  loop	  and	  J3/4	  [152].	  We	  introduced	  the	  same	  mutations	  in	  the	  
SAM-­‐I	   riboswitch	   hybrid	   3P1_10AT	   pseudoknot	   region	   (3P1_10AT_P2	   mutant).	   In	   the	  
equilibrium	  dialysis	  assay,	  the	  3P1_10AT_P2	  mutant	  decreased	  the	  ratio	  of	  counts	  in	  the	  
chamber	  containing	  to	  RNA	  to	  that	  containing	  SAM	  only	  to	  less	  than	  half	  (Figure	  3.18c)	  as	  
compared	   to	   3P1_10AT.	   Compensatory	   mutation	   in	   the	   J3/4	   designed	   to	   restore	  
pseudoknot	  base	  pairing,	  restores	  the	  affinity	  to	  SAM.	  These	  trends	  match	  those	  reported	  
in	  SAM	  binding	  studies	  to	  the	  wild	  type	  yitJ	  SAM-­‐I	  riboswitch	  aptamer	  [161,	  170].	  	  
The	  G11	  residue	  of	  the	  aptamer	  in	  junction	  J1/2	  with	  G11.C44–G58	  triple	  makes	  contact	  
with	   the	  methionine	  moiety	  of	   SAM	   through	  hydrogen	  bonds.	  The	   carboxylate	  group	  of	  
SAM	   is	   recognized	   by	   the	   G11	   via	   the	   N1	   and	   N2	   Watson-­‐Crick	   face	   [108,	   168].	   We	  
hypothesized	  that	  mutating	  the	  G11	  residue	  will	  decrease	  SAM	  binding	  to	  the	  3P1_10AT	  
hybrid,	  as	  reported	  within	  the	  context	  of	  the	  aptamer	  alone	  [171].	  As	  expected	  mutating	  
the	   G11	   residue	   decreased	   the	   SAM	   binding	   drastically	   in	   the	   3P1_10AT	   construct	   to	  
undetectable	  levels	  (Figure	  3.18c).	  	  	  
	  
3.3.4.4.	  SAM	  Binding	  Requires	  Stabilization	  of	  the	  P1	  Helix	  by	  Coaxial	  Stacking	  with	  
an	  AT	  Helix	  in	  Hybrid	  Constructs	  
	  
The	  P1	  helix	  minor	  groove	  forms	  one	  side	  of	  the	  binding	  pocket	  for	  SAM	  as	  shown	  in	  the	  
SAM-­‐I	   riboswitch	  crystal	   structures	   [108,	  168].	   	  The	   sulfur	  anionic	  moiety	  of	   the	   ligand	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interacts	   electrostatically	   with	   the	   minor	   groove	   of	   the	   first	   two	   base	   pairs	   of	   the	   P1	  
helix[108,	  168].	  Mutations	  of	   these	  P1	  helix	   residues	   [106,	  172],	   	  disruption	  of	  P1	  helix	  
base	  pairs,	  or	  shortening	  of	   the	  P1	  helix	   [172]	  dramatically	  reduces	  SAM	  binding	   to	   the	  
aptamer.	  To	  test	  the	  role	  of	  the	  AT	  in	  SAM	  binding	  in	  the	  hybrid,	  we	  tested	  SAM	  binding	  
with	  ‘3P1_only’	  with	  RNA	  concentration	  of	  8µM	  and	  ligand	  concentration	  100nM,	  (Figure	  
5a).	  The	  3P1_only	  construct	  that	  lacks	  the	  complete	  AT	  and	  consists	  of	  only	  3	  base	  pairs	  in	  
the	   P1	   helix	   yielded	   a	   B/A	   ratio	   of	  ~1.2	   in	   the	   equilibrium	  dialysis	   assay,	   indicative	   of	  
minimal	  SAM	  binding.	  This	  minimal	  SAM	  binding	  observed	  with	  3P1	  only	   indicates	   that	  
the	  AT	  segment	  contributes	  to	  SAM	  binding	  in	  the	  hybrid	  construct.	  We	  reasoned	  that	  the	  
AT	  helix	  might	  be	  forming	  a	  coaxial	  stack	  with	  three	  P1	  base	  pairs,	  thus	  stabilizing	  the	  P1	  
helix	  formation	  that	  is	  necessary	  for	  SAM	  binding	  [106,	  107,	  172].	  To	  test	  this	  possibility,	  
we	   deleted	   a	   residue	   in	   the	   3’	   end	   of	   the	   AT	   helix	   (3P1_9AT),	   thus	   preventing	   the	  
possibility	  of	  optimal	  coaxial	  stacking.	  As	  expected	  the	  3P1_9AT	  construct	  shows	  minimal	  
binding	  with	  SAM	  with	  a	  B/A	   ratio	  of	  1.16	   (Figure	  3.19).	  We	  utilized	   in-­‐line	  probing	   to	  
obtain	   a	   more	   direct	   indication	   of	   P1	   helix	   formation	   in	   the	   3P1_9AT,	   3P1_10AT	   and	  
3P1_10AT_5’GCC	  constructs	  (Figure	  3.2a,	  3.2b).	  The	  3P1_10AT_5’GCC	  construct	  is	  shown	  
in	  Figure	  3.21a.	   It	   is	  designed	  to	  create	   instability	   in	   the	  3P1_10AT	  hybrid	   in	   the	  P1-­‐AT	  
stacking	  region.	  Unlike	  chemical	  modification	  methods,	  which	  rely	  on	  primer	  extension	  to	  
detect	  chemical	  reactivity,	  this	  technique	  enabled	  us	  to	  work	  with	  the	  hybrid	  constructs	  
with	   fixed	   3’	   ends.	   As	   expected,	   the	   addition	   of	   SAM	   leads	   to	   changes	   in	   the	   pattern	   of	  
cleavage	  for	  3P1_10AT	  (Figure	  3.21b).	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Figure	  3.19:	  The	  ratio	  of	  number	  counts	  in	  chamber	  b	  to	  chamber	  a	  in	  equilibrium	  
dialysis	  assay	  for	  B.	  subtilis	  yitJ	  aptamer,	  and	  other	  hybrid	  constructs.	  SAM	  binding	  
observed	  for	  the	  3P1_10AT	  hybrid	  is	  reduced	  dramatically	  when	  the	  possibility	  for	  
optimal	   coaxial	   stacking	  with	   the	  AT	  helix	   is	  disrupted.	  The	  error	  bars	   represent	  
standard	  deviation	  for	  atleast	  three	  replicates	  of	  each	  experiment.	  	  	  
	  
These	   include	   protection	   of	   J3/4	   residues	   involved	   in	   pseudoknot	   formation	   and	  
enhanced	   cleavage	   of	   a	   G	   residue	   closing	   the	   P4	   helix.	   The	   conserved	   three-­‐nucleotide	  
motif,	  GAU,	  which	  participates	   in	   the	  putative	  3P1	  helix,	   is	  protected	   in	   the	  presence	  of	  
SAM,	  while	   enhanced	   cleavage	   is	   observed	   in	   the	   adjoining	   J3/4.	   This	   pattern	   parallels	  
that	  reported	  for	  SAM	  binding	  to	  aptamer	  or	  full	  length	  yitJ	  riboswitch	  constructs[106].	  A	  
similar	  but	  more	  modest	  pattern	  of	  SAM-­‐induced	  changes	   in	  cleavage	   levels	   is	  observed	  
for	   3P1_9AT,	   consistent	   with	   a	   lower	   level	   of	   SAM	   binding	   as	   compared	   to	  
3P1_10AT_5’GCC	  and	  3P1_10AT.	  
	  
3.3.4.5.	   SAM	  Binding	   to	   the	  Hybrids	   Increases	  Marginally	   as	   the	   Length	   of	   the	   P1	  
Helix	  Increases	  
	  
Previous	   reports	   show	   that	   a	   stable	   P1	   helix	   is	   crucial	   for	   the	   binding	   of	   SAM	   to	  
aptamer[151,	  173],	  while	  our	  measurements	  indicate	  that	  stacking	  on	  an	  AT	  helix	  can	  to	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how	  SAM	  binding	  would	  be	  affected	  by	   the	  relative	   lengths	  of	  P1	  and	  AT	  helices	  within	  
the	   competition	   region	   shown	   in	  Figure	  3.2.	  The	  P2_AT	  construct,	  which	   contains	  a	   full	  
length	  AT	  helix	  but	  no	  P1	  helix	  or	  J1/2,	  showed	  minimal	  binding	  with	  a	  B/A	  ratio	  of	  ~1.	  
	  
	  
Figure	  3.21:	  10%	  denaturing	  acrylamide	  gel	  showing	  the	  cleavage	  pattern	  in	  inline	  
probing	  experiment	  for	  3P1_9AT	  (A)	  and	  3P1_10AT	  (B),	  3P1_10AT_5’GCC.	  The	  lanes	  
in	  the	  two	  gels	  from	  1-­‐5	  represent	  No	  reaction,	  Partial	  alkaline	  digested	  RNA,	  RNase	  
T1	  digested	  RNA,	  cleaved	  RNA	  in	  inline	  probing	  buffer	  without	  SAM,	  cleaved	  RNA	  in	  
inline	  probing	  buffer	  with	  100	  μM	  SAM.	  The	  arrows	  in	  red	  and	  blue	  indicate	  regions	  
with	  enhanced	  and	  reduced	  cleavage.	  	  
	  
The	  binding	  of	  SAM	  to	  the	  different	  hybrids	  represented	  by	  B/A	  ratio	  is	  within	  2.5-­‐4.5	  in	  
the	   equilibrium	   dialysis	   assay	   (Figure	   3.22a)	   at	   RNA	   concentration	   of	   3µM	   and	   SAM	  
concentration	   of	   100nM.	   Even	   2P1_11AT,	   with	   a	   P1	   helix	   as	   short	   as	   two	   base	   pairs,	  
shows	  readily	  detectable	  binding	  to	  SAM.	  The	  2P1_11AT	  construct	  nonetheless	  binds	   to	  
SAM	  with	  weakest	  affinity	  amongst	  all	  the	  hybrid	  constructs.	  As	  the	  number	  of	  base	  pairs	  
in	  the	  P1	  helix	  is	  increased	  there	  is	  a	  small	  increase	  in	  SAM	  binding.	  The	  differences	  in	  Kd	  
are	   very	   close	   to	   standard	   deviation	   for	  multiple	   single	   point	  measurements,	   however.	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Nonetheless	  the	  consistency	  of	  the	  trend	  of	  increasing	  affinity	  is	  consistent	  with	  a	  modest	  




Figure	   3.22:	   a)	   Ratio	   of	   number	   of	   counts	   for	   chamber	   b	   to	   chamber	   a	   in	  
equilibrium	   dialysis	   for	   B.	   subtilis	   yitJ	   SAM-­‐I	   riboswitch	   hybrid	   constructs	  
(constructs	   constrained	   to	   form	  hybrids	  without	   any	   competing	   nucleotides)	   and	  
the	   P2_AT	   construct	   in	   which	   the	   J1/2	   region	   and	   the	   5’	   of	   the	   P1	   helix	   are	  
truncated.	  b)	  Ratio	  of	  number	  of	  counts	  for	  chamber	  B	  to	  chamber	  A	  in	  equilibrium	  
dialysis	   for	   B.	   subtilis	   yitJ	   SAM-­‐I	   riboswitch	   hybrid	   constructs	   with	   competing	  
nucleotides	   (6P1_10AT,	   8P1_11AT)	   and	   non	   base	   pairing	   nucleotides	  
(3p_10at_5’GCC,	   4P1_9AT5’GAC).	   C)	   Secondary	   structure	   of	   4P1_9AT_5’GAC	   and	  
3P1_10AT_5’GCC	  constructs.	  	  
	  
3.3.4.6.	  SAM	  Binding	  to	  the	  Hybrids	  Is	  Very	  Sensitive	  to	  Structural	  Defects	  Near	  the	  
Binding	  Site	  
	  
The	   predictions	   in	   Figure	   3.16	   suggest	   that	   under	   some	   conditions	   the	   riboswitch	  may	  
form	   conformations	   that	   include	   the	   formation	   of	   hybrids	   containing	   partial	   P1	   and	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partial	  AT	  helices.	  We	  were	  therefore	  led	  to	  speculate	  as	  to	  whether	  the	  hybrid	  constructs	  
shown	   in	   Figure	   3.4b	   could	   be	   appropriate	   model	   systems	   for	   SAM	   binding	   to	   such	  
intermediate	  conformations.	  Presumably	   the	  context	  of	  a	  riboswitch	  containing	  those	  5’	  
residues	  that	  have	  been	  truncated	  in	  our	  constructs	  would	  present	  a	  different	  binding	  site	  
geometry.	   Addition	   of	   non	   base	   pairing	   nucleotides	   on	   the	   5’	   end	   of	   the	   P1	   helix	  
represented	  by	  the	  3P1_10AT_5’GCC	  construct	  decreased	  the	  SAM	  binding	  dramatically	  to	  
a	  B/A	   ratio	   of	   1.4	   (Figure	   3.22b)	   as	   opposed	   to	   a	   B/A	   ratio	   of	   4.4	  with	   3P1_10AT.	   The	  
inhibitory	   effect	   of	   adding	   non-­‐pairing	   5’	   nucleotides	   is	   much	   less,	   however,	   for	   the	  
4P1_9AT_5’GAC	  construct	  Figure	  3.22b).	  This	  value	  is	  half	  the	  value	  of	  SAM	  binding	  with	  
4P1_9AT	  (Figure	  3.22a).	  	  
Competing	   nucleotides	   included	   from	   the	   3’	   end	   of	   the	   AT	   helix	   represented	   by	  
6P1_10_AT	   and	   8P1_11AT	   constructs	   do	   not	   hinder	   SAM	   binding	   with	   a	   B/A	   ratio	   of	  
~4.01	  and	  4.3	  respectively	   (Figure	  3.22b).	  Thus,	  addition	  of	  5’	  nucleotides	   inhibits	  SAM	  
binding	  if	  the	  5’	  overhang	  has	  two	  characteristics:	  1)	  non-­‐complementarity	  to	  residues	  on	  
the	  opposing	  strand,	  and	  2)	   the	  non-­‐complementary	  residues	  are	  near	   the	  SAM	  binding	  
site.	  
3.3.4.7.	   A	   Three-­‐dimensional	   Model	   for	   SAM	   Binding	   to	   Hybrid	   ON/OFF	   SAM-­‐I	  
Riboswitch	  Conformation	  
	  	  
Given	   that	   our	   equilibrium	   dialysis	   measurements	   suggested	   continuous	   stacking	  
between	   P1	   and	   AT	   helix	   segments,	   we	   constructed	   a	   three-­‐dimensional	   model	   of	  
3P1_10AT.	  	  
As	  shown	  in	  Figure	  3.24a,	  MC-­‐sym	  can	  exhaustively	  sample	  the	  possible	  integration	  of	  the	  
AT	   helix	   into	   the	   X-­‐ray	   derived	   coordinates	   for	   the	   aptamer	   core	   without	   introducing	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steric	   clashes.	   Then	   we	   used	   vdW	   interaction	   energy	   to	   monitor	   the	   co-­‐axial	   stacking	  
between	   the	   partial	   P1	   helix	   and	   the	   incomplete	   AT	   helix.	   The	   stacking	   for	   two	   sets	   of	  
nucleobases—U107-­‐A108	   and	   A1-­‐U132	   are	   monitored.	   The	   2D	   histogram	   of	   the	   vdW	  
energies	   is	   displayed	   in	   Figure	   3.24b.	   The	   results	   show	   that	   MC-­‐sym	   predicts	   some	  
models	   with	   the	   co-­‐axial	   stacking	   feature	   as	   demonstrated	   by	   the	   area	   with	   favorable	  
vdW	  energies	  in	  both	  sets	  of	  nucleobases.	  One	  structural	  model	  with	  the	  co-­‐axial	  helical	  
stacking	  is	  shown	  in	  Figure	  3.24c.	  The	  hybrid	  model	  (Figure	  3.4)	  indicates	  that	  the	  partial	  
AT	   helix	   can	   form	   a	   continuous	   stack	  with	   the	   partial	   P1	   helix	  with	   little	   indication	   of	  
steric	  clash	  with	  other	  segments	  of	  the	  aptamer	  structure,	  as	  predicted	  based	  upon	  the	  X-­‐
ray	  coordinates.	  	  
	  
3.3.5.	  	  Discussion	  
3.3.5.1.	  The	  Basis	  for	  Discrimination	  Between	  Riboswitch	  Conformations	  by	  SAM	  Is	  
More	  Complex	  than	  Suggested	  by	  Secondary	  Structure	  Diagrams	  
	  
SAM	   riboswitches	   are	   an	   instructive	   example	   of	   nature	   using	   secondary	   and	   tertiary	  
structure	   folding	   for	   specific	   molecular/metabolite	   recognition.	   	   Our	   work	   is	   aimed	   at	  
understanding	  how	  RNA	  folding	  is	  integrated	  with	  metabolite	  binding	  to	  make	  a	  genetic	  
decision.	   Functionally,	   the	   aptamer	   is	   considered	   to	   be	   the	   biosensing	   domain	   of	   the	  
riboswitch,	   utilizing	   3D	   structural	   motifs	   [108,	   168,	   174-­‐177].	   Five	   classes	   of	   SAM	  
riboswitch	  aptamers	  recognize	  SAM	  specifically-­‐each	  using	  distinct	  binding	  pockets	  and	  
structural	   motifs	   [178].	   The	   expression	   platform	   undergoes	   large	   secondary	   structure	  
changes	  to	  execute	  the	  gene	  expression	  controlling	  decision.	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Figure	   3.24:	   (a)	   Superposition	   of	   models	   generated	   from	   MC-­‐sym	   sampling	   for	  
hybrid	  construct	  3P1-­‐10AT.	  The	  region	  shown	  in	  blue	  is	  from	  the	  crystal	  structure	  
of	  the	  yitJ	  SAM-­‐I	  riboswitch	  (PDB:3NPB)	  [168].	  The	  part	  in	  red	  is	  the	  AT	  helix	  from	  
MC-­‐sym	  modeling.	   (b)	  2D	  histogram	  of	   the	  vdW	   interaction	  energies	  between	   the	  
nucleobase	  of	  U107	  and	  that	  of	  A108	  and	  between	  the	  nucleobase	  of	  A1	  and	  that	  of	  
U132.	  A	  more	  negative	  value	  of	  vdW	  energy	  here	  indicates	  better	  stacking	  between	  
the	   nucleobases.	   (c)	   An	   example	   of	  models	   sampling	   the	   co-­‐axial	   helical	   stacking	  
between	  the	  partial	  P1	  and	  the	  AT	  helix	  with	  SAM	  docked	  into	  the	  binding	  pocket	  
based	   on	   the	   binding	   mode	   observed	   in	   the	   aptamer	   crystal	   structure.	   SAM	   is	  
shown	   in	  vdW	  representation	  with	  carbon	  colored	   in	  yellow.	  The	  partial	  P1,	   J4/1	  
and	   P4	   helix	   are	   shown	   in	   blue,	   J1/2	   in	   orange,	   J3/4	   in	  magenta	   and	   P2	  &	   P3	   in	  
green.	  The	  modeled	  AT	  helix	  is	  shown	  in	  red.	  
	  
In	  the	  case	  of	  the	  SAM-­‐I	  riboswitch	  the	  aptamer	  domain	  has	  been	  well	  characterized	  [144,	  
175,	   178].	   It	   has	   been	   more	   challenging	   to	   devise	   strategies	   to	   study	   the	   expression	  
platform	  because	  of	   its	  high	  sequence	  variability	  [143].	   	  Secondary	  structure	  models	  for	  
most	   riboswitch	  On	   states	   differ	   dramatically	   from	   two-­‐dimensional	   representations	   of	  
the	  Off	  state	  [106,	  151,	  178,	  179].	  For	  the	  SAM-­‐I	  (and	  many	  other)	  riboswitches	  however,	  
the	  switching	  mechanism	  requires	  that	  the	  base	  compositions	  of	  the	  P1	  and	  AT	  helices	  be	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similar.	  In	  that	  case,	  one	  cannot	  dismiss	  the	  possibility	  of	  an	  On	  state	  secondary	  structure	  
that	  mimics	  some	  aspects	  of	   the	  Off	   state	   in	   its	   tertiary	   folding,	  with	   the	  AT	  helix	  being	  
positioned	   in	   a	   manner	   to	   replace	   the	   P1	   helix.	   Moreover,	   RNA	   structure,	   like	   protein	  
structure,	   is	   more	   accurately	   described	   in	   solution	   as	   a	   Boltzmann	   distribution	   of	  
conformer	  populations,	  rather	  than	  a	  single	  structure	  [180,	  181].	  This	  may	  be	  especially	  
true	   of	   unliganded	   riboswitches,	   which	   are	   the	   product	   of	   evolutionary	   selection	   for	  
conformational	   dynamics.	   Therefore	   riboswitches	   are	   likely	   to	   sample	   conformers	  with	  
“hybrid”	   On	   and	   Off	   state	   character,	   with	   the	   interchange	   between	   them	   facilitated	   if	  
tertiary	  folds	  are	  similar.	  	  
These	   considerations	   led	   us	   to	   test	   the	   SAM	   binding	   properties	   of	   a	   set	   of	   SAM-­‐I	  
riboswitch	   constructs	   constrained	   to	   form	   likely	   conformational	   intermediates.	  
Truncating	   and	  mutating	   riboswitches	   and	  other	   folded	  RNAs	  has	  been	  a	   very	   effective	  
means	  of	  constraining	  conformational	  dynamics	  to	  facilitate	  biophysical	  studies	  [178,	  182,	  
183].	   This	   strategy	   enabled	   us	   to	   detect	   a	   reduced	   level	   of	   binding	   to	   conformational	  
substrates	  that	  will	  be	  transiently	  present	  in	  partly	  or	  fully	  transcribed	  SAM-­‐I	  riboswitch	  
domains	  in	  solution.	  	  
	  
3.3.5.2.	   SAM	   Recognizes	   Similar	   Tertiary	   Characteristics	   in	   Hybrid	   and	   Aptamer	  
SAM-­‐I	  Riboswitch	  RNA	  Segments	  
	  
	  We	  observed	  SAM	  binding	  to	  all	  RNA	  constructs	  that	  contained	  a	  partial	  P1	  helix,	  as	  long	  
as	   a	   potential	   AT	   helix	   extending	   to	   the	   P1	   helix	   boundary	  was	   present	   (Figures	   3.19-­‐
3.22).	  The	  kink-­‐turn	  mediated	  pseudoknot	   interaction	  acts	  as	  an	  auxiliary	   for	  the	  global	  
folding	   in	   the	   native	   SAM	   aptamer	   structure	   leading	   to	   a	   tight	   compaction	   upon	   SAM	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binding	   [152,	   172].	   According	   to	   our	   measurements	   for	   3P1_AT_P2	   mutant	   and	   its	  
compensatory	   construct	   (Figure	   3.22),	   similar	   dependence	   on	   the	   pseudoknot	   for	   SAM	  
binding	   is	   seen	   in	   the	   hybrids.	   The	   magnesium	   effect	   on	   the	   aptamer	   is	   previously	  
observed	  from	  FRET	  studies,	  gel	  shift	  assays,	  and	  chemical	  probing	  [151,	  152,	  172].	  	  The	  
magnesium	   dependence	   observed	   in	   the	   hybrids	   (Figure	   3.19)	   is	   similar	   to	   the	  
magnesium	   dependence	   observed	   in	   the	   isolated	   aptamer	   construct.	   The	   magnesium	  
based	  SAM	  binding	  data	  and	  the	  pseudoknot	  mutational	  analysis	   in	  the	  hybrids	  indicate	  
that	  the	  junction	  regions	  and	  the	  helices	  in	  the	  aptamer	  region	  of	  the	  hybrids	  retain	  the	  
global	  folding	  and	  SAM	  binding	  mode	  observed	  in	  the	  isolated	  aptamer	  constructs.	  	  	  	  
We	   have	   constructed	   a	   model	   of	   3P1_AT,	   which	   shows	   that	   an	   AT	   helix	   can	   be	  
accommodated	  within	  a	  global	  architecture	  resembling	   the	  aptamer	   fold	  observed	   in	  X-­‐
ray	  structures	  (Figure	  3.24).	  The	  model	  has	  been	  constructed	  using	  the	  X-­‐ray	  coordinates	  
for	  all	  elements	  outside	  of	  the	  AT	  helix.	   	  MD	  simulations	   indicate	  that	  this	  configuration	  
with	   SAM	   bound	   is	   relatively	   stable,	   but	   that	   the	   P1	   helix	   base	   pairs	   dissociate	   in	   the	  
absence	  of	  SAM	  (Huang	  et	  al,	  manuscript	  in	  preparation).	  	  
	  
3.3.5.3.	   Minimal	   P1	   Helices	   Required	   for	   SAM	   Recognition	   can	   be	   Stabilized	   in	  
Hybrids	  by	  Coaxially-­‐stacked	  AT	  Helices	  
	  	  
Our	  hybrid	  constructs	  of	  the	  B.subtilis	  yitJ	  SAM-­‐I	  riboswitch	  include	  the	  AT	  helix	  which	  is	  
part	  of	   the	  expression	  platform.	  The	  SAM	  binding	  data	  with	   the	  hybrids	  presented	  here	  
suggests	  that	  aptamer	  is	  not	  the	  only	  domain	  that	  can	  affect	  SAM	  binding	  and	  recognition.	  
Our	  data	  suggests	  that	  the	  nucleotides	  in	  the	  AT	  helix	  can,	  up	  to	  a	  point,	  substitute	  for	  P1	  
helix	   base	   pairs	   in	   SAM	   recognition.	   Recent	   studies	  with	   the	   SAM-­‐I	   riboswitch	   showed	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that	  aptamers	  having	  3	  or	  4	  or	  even	  6	  base	  pairs	  in	  the	  P1	  helix	  in	  aptamer	  constructs	  do	  
not	   terminate	   transcription	   as	   a	   result	   of	   addition	   of	   10μM	   SAM	   [172].	   This	   is	   in	  
agreement	  with	   our	   SAM	  binding	  data	  with	   the	  3P1	  only	   construct	   (Figure	  3.19),	   since	  
transcription	  termination	  is	  associated	  with	  SAM-­‐induced	  P1	  helix	  formation.	  The	  hybrid	  
constructs	  2P1_11AT,	  3P1_10AT,	  4P1_9AT,	  5P1_8AT	  and	  6P1_7AT	  all	  bind	  to	  SAM,	  though	  
with	   reduced	   affinity	   compared	   to	   the	   aptamer	   (Figures	   3.18-­‐3.22).	   Thus	   the	   AT	   can	  
contribute	   to	   SAM	   recognition	   along	   with	   the	   remaining	   crucial	   components	   of	   the	  
aptamer.	  	  In	  particular,	  in	  addition	  to	  helices	  P2-­‐P4	  and	  the	  pseudoknot	  interaction,	  a	  P1	  
helix	  nucleation	  site	  and	  constrained	  J1/2	  are	  required,	  since	  binding	  is	  not	  detectable	  for	  
P2_AT	   (Figure	  3.19).	   It	   is	  worth	  noting	   that	   the	   first	   two	  base	  pairs	  of	   the	  P1	  helix	  and	  
residues	  in	  J1/2	  are	  involved	  in	  critical	  contacts	  with	  SAM	  according	  to	  X-­‐ray	  data	  [107,	  
108,	  168,	  178]	  and	  MD	  simulations	  [184].	  
The	  SAM	  binding	  results	  with	  the	  3P1	  only,	  3P1_9AT	  (Figure	  3.19)	  suggest	  that	  the	  3P1	  is	  
stabilized	  by	  the	  AT	  helix	  through	  putative	  stacking	  interaction	  between	  the	  two	  helices	  
(also	  seen	   from	  the	  MD	  simulations).	  Thus,	   in	   the	  absence	  of	  a	  continuously	  stacked	  AT	  
helix,	   the	   shortened	  P1	  helices	  do	  not	   form	  and	  no	  SAM	  binding	  pocket	   is	  present.	  Our	  
data	  with	  the	  3P1_10AT5’GCC	  (Figure	  3.22)	  show	  that	  the	  5’GCC3’	  sequence	  on	  the	  5’	  end	  
of	   the	   P1	   helix	   in	   the	   3P1_10AT	   hybrid	   construct	   inhibits	   SAM	   binding.	   This	  
destabilization	   may	   be	   due	   to	   disruption	   of	   the	   P1/AT	   coaxial	   stack,	   leading	   to	   a	  
dissociation	   of	   the	   three	   P1	   helix	   base	   pairs.	   Alternatively,	   it	   may	   arise	   from	   steric	  
interference	  between	  the	  5’	  overhanging	  nucleotides	  and	  the	  ligand	  or	  its	  binding	  pocket.	  
When	   1	   base	   pairing	   nucleotide	   is	   added	   on	   the	   P1	   helix	   represented	   by	   the	  
4P1_9AT5’GAC,	   SAM	  binding	   is	   inhibited	   relative	   to	  4P1_9AT	   (Figure	  3.22),	   but	   far	   less	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inhibition	   is	   observed	   than	   when	   a	   similar	   substitution	   of	   unpaired	   5’	   nucleotides	   is	  
added	  to	  the	  3P1_10AT	  to	  make	  3P1_10AT5’GCC.	  As	  the	  length	  of	  the	  P1	  helix	  increases,	  
the	  stability	  of	   the	  P1	  helix	   increases,	  but	  steric	  clash	  with	   the	  binding	  site	  may	  also	  be	  
reduced.	  	  
These	  results	  also	  hint	  at	  a	  dynamic	  mechanism	  in	  which,	  upon	  the	  formation	  of	  each	  base	  
pair	   in	  the	  P1	  helix,	   the	  equilibrium	  is	   forced	  towards	  the	  Off	  state.	  We	  can	  hypothesize	  
that	   this	  mechanism	  may	  be	  present	   in	   the	   constructs	   6P1_10AT	  and	  8P1_11AT,	  which	  
contain	  the	  potential	  for	  competing	  P1	  and	  AT	  helices.	  While	  we	  cannot	  say	  which,	  if	  any,	  
conformers	  predominate	  in	  these	  two	  constructs	  in	  the	  absence	  of	  ligand,	  we	  suggest	  that	  
SAM	  binding	  will	  push	  the	  equilibrium	  towards	  those	  states	  that	  contain	  longer	  P1	  helices.	  
This	   mechanism	   is	   bolstered	   by	   the	   increasing	   SAM	   binding	   trend,	   however	   weak,	  
observed	   with	   the	   increasing	   length	   of	   the	   P1	   helix	   in	   the	   hybrids.	   The	   apparent	  
interference	  of	  5’	  overhangs	  near	  the	  SAM	  binding	  pocket	  with	  SAM	  binding	  will	  push	  the	  
equilibrium	  even	  more	  strongly	   in	   the	  direction	  of	  an	  extended	  P1.	  Our	  MD	  simulations	  
with	  6P1_10AT	  indicate	  a	  “branch	  migration”	  event	  in	  the	  presence	  of	  SAM	  (Huang	  et	  al,	  
manuscript	   in	   preparation).	   	   	   Further	   research	   needs	   to	   be	   done	   in	   the	   AT	   region	   in	  
conjunction	   with	   the	   P1	   helix	   to	   pin	   down	   the	   mechanistic	   aspects	   of	   the	   P1	   and	   AT	  
stacking	  and	  branch	  migration.	  	  
	  
3.3.5.4.	  The	  Role	  of	  Conformational	  Dynamics	  and	  Conformational	  Selection	  in	  SAM	  
Binding	  
	  
Earlier	   studies	   indicated	   that	   an	   ensemble	   of	   conformational	   states	   exists	   in	   the	  
unliganded	  SAM-­‐I	  riboswitch	  aptamer	  [151,	  173].	  	  SAM	  selectively	  prefers	  some	  of	  these	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intermediate	   conformations	   for	   binding.	   The	   extension	   of	   the	   riboswitch	   transcript	   to	  
include	   3’	   nucleotides	  with	   the	   potential	   to	   compete	  with	   P1	   helix	   base	   pairing	   should	  
increase	   the	   conformational	   heterogeneity	   of	   the	   conformer	   population.	   In	   solution,	  
2P1_11AT,	  3P1_10AT,	  4P1_9AT,	  5P1_8AT,	  6P1_7AT	  and	  8P1_5AT	  represent	  SAM-­‐selected	  
conformational	  species,	  along	  with	  the	  aptamer.	  The	  hybrids	  3P1	  ONLY,	  P2-­‐AT,	  3P1_9AT	  
represent	  conformational	  species	  of	  the	  SAM-­‐I	  riboswitch	  that	  are	  not	  preferred	  by	  SAM	  
for	  binding.	  With	  stronger	  affinity	  for	  the	  aptamer	  (forming	  the	  full	  P1	  helix)	  than	  for	  the	  
hybrids,	  SAM	  would	  rapidly	  shift	  the	  equilibrium	  towards	  the	  Off	  state.	  We	  do	  not	  have	  an	  
explanation	  as	  to	  why	  the	  constructs	  8P1_5AT	  and	  8P1_11AT,	  which	  contain	  the	  potential	  
to	  form	  full	  P1	  helices,	  bind	  SAM	  with	  weaker	  affinity	  than	  the	  truncated	  aptamer	  (Figure	  
6).	  Nonetheless,	   the	   implication	  of	   the	   latter	   finding	   is	   that	  SAM	  binding	   can	  eventually	  
destabilize	   full	  AT	  helix	   formation,	   thus	   facilitating	   the	  downstream	   formation	  of	  a	   rho-­‐
independent	  terminator	  hairpin.	  Our	  rational	  design	  of	  the	  hybrids	  reveals	  the	  elements	  
of	   the	   SAM-­‐I	   riboswitch	   that	   confer	   the	   ability	   to	   recognize	   and	   bind	   SAM	   beyond	   the	  
aptamer	  domain.	  
	  
3.3.5.5.	  Pathways	   for	   the	  SAM-­‐induced	  Riboswitch	  Conformational	  Folding	  During	  
Transcription	  
	  
	  It	  has	  been	  shown	   that	   some	  riboswitches	  operate	  on	  a	  kinetic	  and/or	   thermodynamic	  
control	  mechanism	  [185,	  186].	  The	  SAM-­‐I	  riboswitch	  is	  a	  transcriptional	  riboswitch.	  The	  
timescale	  at	  which	  the	  decision	  is	  to	  be	  made	  between	  the	  formation	  of	  either	  conformer	  
is	   in	   seconds	   considering	   the	   processivity	   of	   prokaryotic	   RNAP	   [67].	   Whether	   this	  
timescale	   is	   sufficient	   for	   the	   growing	   transcript	   to	   fold	   under	   conditions	   of	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thermodynamic	  equilibrium	  depends	  on	  rates	  for	  folding	  and	  ligand	  binding.	   It	  will	  also	  
be	   affected	   by	   the	   presence	   of	   proteins	   and	   other	   components	   of	   the	   transcription	  
complex.	   It	   has	   been	   suggested	   that,	   in	   the	   presence	   of	   SAM,	   the	   decision	   to	   form	   the	  
aptamer	  conformation,	  and	  therefore	  to	  terminate	  transcription,	  is	  fixed	  by	  SAM	  binding	  
before	   the	   AT	   helix	   is	   transcribed	   [178,	   179].	   Our	   findings	   are	   consistent	   with	   this	  
hypothesis.	   If	   SAM	   is	  bound	   to	   the	  partial	   riboswitch	   transcript	   containing	   the	  aptamer	  
conformation	  with	  full	  P1	  helix,	  the	  20-­‐100	  fold	  preference	  of	  the	  ligand	  for	  the	  aptamer	  
over	  AT-­‐helix	  containing	  conformers	  will	  prevent	  AT	  helix	  formation.	  
At	   the	   same	   time,	   our	   results	   also	   suggest	   the	   possibility	   of	   a	   second	   path	   for	   SAM-­‐
induced	   conformational	   switching.	   Folding	   of	   the	   On	   conformer,	   which	   consists	   of	  
proximally-­‐formed	  helical	  base	  pairs,	  may	  be	  more	  rapid	  than	  the	  formation	  of	  distal	  base	  
pairs	   required	   for	   the	   P1	   helix	   [184,	   187].	   This	   may	   be	   especially	   true	   if	   the	   latter	   is	  
slowed	   by	   transient	   pairing	   of	   purine	   residues	   from	   the	   junction	   regions	   with	   5’	  
pyrimidine	  residues	  from	  the	  P1	  helix	  (Huang	  et	  al,	  manuscript	  in	  preparation).	  Moreover,	  
literature	  reports	  suggest	  that	  before	  SAM	  binding	  P1	  helix	  formation	  will	  be	  somewhat	  
dynamic	  [172,	  173].	  If	  AT	  helix	  formation	  can	  stabilize	  the	  nucleation	  of	  a	  nascent	  P1	  helix,	  
then	   our	   results	   show	   that	   SAM	   could	   bind	   to	   the	   resulting	   hybrid	   conformation.	  
Furthermore,	   SAM	  binding	   should	   result	   in	   rapid	   conversion	   to	   a	   fully	   formed	  P1	  helix	  
and	  freeing	  of	  potential	  AT-­‐forming	  residues	  to	  participate	  in	  terminator	  formation.	  	  One	  
attractive	   aspect	   of	   this	   model	   is	   that	   it	   predicts	   that	   termination	   will	   require	   μM	  
concentrations	  of	  SAM	  to	  stabilize	  the	  transition	  state.	  In	  vitro	  transcription	  assays	  with	  
the	   yitJ	  SAM-­‐I	   riboswitch	   do	   indicate	   that	   much	   higher	   levels	   of	   SAM	   are	   required	   for	  
	   87	  
transcription	   termination	   than	   would	   be	   predicted	   based	   upon	   in	   vitro	   equilibrium	  
measurements	  of	  SAM	  binding	  affinity	  [179].	  
Distinguishing	   between	   these	   two	   pathways	   requires	   consideration	   of	   the	   complex	  
interplay	  between	  SAM	  binding,	  RNA	  folding,	  transcriptional	  pausing,	  and	  the	  role	  of	  the	  
transcription	  complex	  itself.	  	  	  
	  
3.4.	  Conclusions	  
The	   SAM	   binding	   studies	   with	   the	   “alternative”	   structures	   mentioned	   in	   this	   paper	  
indicate	   three	   major	   aspects	   of	   the	   SAM-­‐I	   riboswitch	   folding	   responsible	   for	   ligand	  
discrimination	   between	   the	   two	   functional	   conformers	   of	   the	   riboswitch	   1)	   Stable	   P1	  
helix	  is	  necessary	  for	  the	  SAM	  binding	  and	  recognition,	  2)	  the	  AT	  helix	  can	  play	  a	  role	  in	  
the	   transition	   from	   the	  On	   state	   to	   the	  Off	   state	   of	   the	   riboswitch	   by	   stabilizing	   the	  P1	  
helix	  with	  stacking	  interactions.	  As	  the	  length	  of	  the	  P1	  helix	  increases,	  the	  stability	  of	  the	  
P1	  helix	  increases,	  and	  the	  affinity	  for	  SAM	  increases.	  3)	  That	  SAM-­‐binding	  affinity	  for	  the	  
hybrid	   conformers	   is	   weaker	   by	   1-­‐2	   orders	   of	   magnitude	   compared	   to	   that	   for	   the	  
aptamer	  implies	  that	  SAM	  binding	  to	  hybrids	  would	  rapidly	  convert	  them	  to	  the	  Off	  state.	  
Our	   study	   indicates	   that	   SAM	   can	   bind	   to	   a	   SAM-­‐I	   riboswitch	   segment	   which	   is	  
constrained	   to	   form	   a	   full	   length	   antiterminator	   (2P1_11AT),	   and	   also	   to	   hybrid	  
constructs	  which,	  within	   the	  context	  of	  a	   full-­‐length	  riboswitch,	  would	  block	   terminator	  
formation.	  This	  result	  may	  appear	  counterintuitive.	  Nonetheless,	  the	  mechanism	  for	  SAM-­‐
I	   riboswitch	   function	   is	   readily	   compatible	   with	   our	   findings.	   On	   the	   other	   hand,	   our	  
results	   show	   the	   minimal	   secondary	   structure	   requirements	   to	   form	   a	   SAM-­‐binding	  
competent	   tertiary	   fold,	   for	   SAM-­‐I	   riboswitches.	  Other	   riboswitches,	   such	   as	   the	  purine	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[188]	   and	   lysine	   [90]	   riboswitches,	   as	   well	   as	   simpler	   systems	   such	   as	   the	   quenosine	  
[189]	  and	  SAMIII-­‐SMK	  [190]	  riboswitch,	  also	  contain	  helix-­‐competing	  motifs.	   It	  remains	  
to	  be	  seen	  what	  role	  may	  be	  played	  by	  conformational	  intermediates,	  which	  combine	  Off	  
state	  tertiary	  structure	  characteristics	  with	  On	  state	  secondary	  structure	  elements	  in	  the	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CHAPTER	  4:	  SUMMARY	  AND	  FUTURE	  DIRECTIONS	  
	  
This	  work	  focuses	  on	  understanding	  the	  role	  of	  a	  small	  molecule	  in	  RNA	  folding	  and	  the	  
basis	  for	  RNA-­‐small	  molecule	  recognition	  (T.tencongensis	  metF	  SAM-­‐I	  riboswitch	  and	  the	  
B.subtilis	  yitJ	  SAM-­‐I	  riboswitch	  and	  the	  RNA	  directed	  small	  molecule	   library).	  The	  SAM-­‐I	  
riboswitch	   is	  known	  to	  be	   involved	   in	  controlling	  the	  genes	  responsible	   for	  virulence	   in	  
certain	   pathogenic	   bacteria	   (See	   chapter	   1).	   The	   two	   SAM-­‐I	   riboswitches	  mentioned	   in	  
this	   work	   recognize	   a	   ligand	   (SAM)	   with	   high	   specificity	   coupled	   with	   conformational	  
changes	   in	   the	  RNA	   to	  modulate	  gene	  expression.	  Though	  competing	  P1	  and	  AT	  helices	  
were	   identified	   earlier,	   structural	   research	   on	   the	   SAM-­‐I	   riboswitch	   done	   prior	   to	   this	  
have	  not	  addressed	  the	  role	  of	  the	  AT	  helix	  in	  the	  gene	  regulation	  mechanism.	  Our	  work	  
with	  the	  SAM-­‐I	  riboswitch	  extends	  the	  structural	  studies	  into	  the	  AT	  helix	  and	  reveals	  the	  
elements	  necessary	  for	  SAM	  to	  distinguish	  between	  the	  On	  and	  Off	  states	  of	  the	  B.	  Subtilis	  
yitJ	  SAM-­‐I	  riboswitch.	  Our	  work	  is	  motivated	  towards	  the	  hypothesis	  that	  SAM	  could	  bind	  
weakly	  to	  the	  hybrids	  or	  On	  constructs	  derived	  from	  the	  identification	  of	  the	  base	  pairing	  
pattern	  similarity	  between	  the	  AT	  and	  P1	  helices	  in	  both	  the	  riboswitches	  
We	   used	   ligand	   binding	   detection	   techniques	   like	   NMR,	   equilibrium	   dialysis	   and	   inline	  
probing.	  NMR	  is	  very	  sensitive	   to	   the	  detection	  of	  weak	  binding	  and	  an	  effective	   tool	   to	  
probe	   the	   dynamics	   of	   a	  macromolecule	   and	   its	   interactions	  with	   small	  molecules	   and	  
vice	   versa.	   In	   our	   case,	   the	   SAM-­‐I	   riboswitch	   being	   a	   large	   molecule	   for	   NMR,	   with	  
overlapping	  peaks,	  we	  had	  difficulties	   in	   optimizing	  RNA-­‐detected	   SAM	  binding	   studies	  
useful	  for	  structure	  analysis.	  However	  we	  have	  been	  successful	  in	  detecting	  SAM	  binding	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using	   NMR	   with	   ligand	   detected	   experiments.	   We	   used	   NMR	   to	   show	   that	   the	   SAM-­‐I	  
riboswitch	  aptamer	  and	  an	  On	  construct	  induces	  changes	  in	  ligand	  peaks.	  	  
Equilibrium	  dialysis	   is	  highly	  sensitive	   to	   ligand	  binding	  and	  can	  be	  effectively	  used	   for	  
quantification	  of	  the	  binding	  affinity.	  We	  used	  equilibrium	  dialysis	  to	  detect	  and	  quantify	  
SAM	  binding	   for	   the	   SAM-­‐I	   riboswitch	   constructs.	   In	   the	  hybrids,	  we	   could	   see	   a	  minor	  
increase	  in	  the	  binding	  to	  SAM	  as	  the	  length	  of	  the	  P1	  helix	   is	   increased.	  Previously,	  the	  
apparent	  Kd	  with	  SAM	  was	  determined	  to	  be	  within	  a	  range	  of	  4nM-­‐30nM	  for	  the	  aptamer	  
only	   (with	   8	   base	   pairs	   in	   the	   P1	   helix,	   without	   antiterminator	   residues)	   and	   the	   full	  
length	  SAM-­‐I	  riboswitch	  with	  the	  residues	  involved	  in	  the	  formation	  of	  the	  terminator	  as	  
well,	  in	  which	  the	  AT	  is	  not	  expected	  to	  form	  in	  the	  SAM	  bound	  configuration.	  In	  our	  study	  
with	  the	  hybrids,	  we	  observed	  an	  apparent	  Kd	  of	  ~500nM	  (8p1_5AT).	  We	  could	  not	  see	  
“full”	   binding	   in	   the	   8P1_5AT	   as	   seen	   in	   the	   aptamer	   or	   in	   the	   full-­‐length	   riboswitch.	  
Geometric/steric	   interference	   caused	   by	   the	   AT	   helix	   could	   be	   restricting	   the	   P1	   helix	  
from	  binding	  to	  SAM	  optimally.	  Another	  explanation	  for	  the	  decreased	  SAM	  binding	  in	  the	  
8P1_5AT	  could	  be	  that	  the	  bulge	  in	  the	  AT	  helix	  causes	  slippage	  in	  AT	  helix	  base	  pairing	  
and	  causing	  instability	  at	  the	  P1/AT	  interface	  in	  the	  8P1_5AT	  construct	  (Figure	  4.1).	  	  	  This	  
leads	  to	  the	  hypothesis	  that	  the	  AT	  is	  necessary	  to	  stabilize	  the	  partially	  formed	  P1	  helix	  
(as	   seen	   from	   the	   data	   presented)	   yet	   could	   be	   involved	   in	   controlling	   the	   terminator	  
formation	  based	  on	  the	  physiological	  SAM	  concentration.	  One	  experiment	  we	  propose	  is	  
to	  test	  with	  8P1_4AT.	  If	  the	  SAM	  binding	  increases,	  by	  decreasing	  the	  number	  of	  AT	  base	  
pairs,	  the	  “strand	  switching”	  mechanism	  in	  which	  the	  AT	  helix	  “unzips”	  allowing	  SAM	  to	  
completely	  bind	  to	  the	  aptamer	  and	  make	  the	  residues	  of	  the	  AT	  available	  for	  terminator	  
formation	   can	   be	   plausible	   for	   this	   riboswitch.	   Ultimately	   a	   crystal	   structure	   of	   the	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8P1_5AT	  will	  give	  the	  insights	  into	  the	  role	  of	  the	  AT	  helix	  and	  the	  single	  base	  (U)	  bulge.	  	  
In	  order	  to	  crystallize	  the	  8P1_5AT,	  the	  AT	  helix	  loop	  has	  to	  be	  modified	  into	  a	  tetraloop.	  
Hence	   another	   8P1_5AT	   with	   a	   tetraloop	   has	   to	   be	   tested	   for	   SAM	   binding	   to	   obtain	  
similar	  SAM	  binding	  level	  as	  with	  the	  original	  8P1_5AT	  hybrid.	  
	  
	  
Figure	   4.1:	   A	   secondary	   structure	   representation	   for	   8P1_5AT	   and	   the	   probable	  
slippage	  caused	  by	  the	  u	  bulge	  in	  the	  AT	  shown	  at	  the	  opposite	  end	  of	  the	  arrow.	  	  
	  
The	  SAM	  binding	  data	  from	  our	  mutations	  in	  the	  J1/2,	  P2	  helix	  in	  the	  hybrids	  show	  that	  
the	   global	   folding	   of	   the	   riboswitch	   by	   the	  Kink-­‐turn-­‐assisted	   Pseudoknot	  with	   tertiary	  
interactions	  is	  similar	  to	  that	  of	  the	  aptamer.	  The	  A109	  and	  U86	  in	  the	  J4/1	  and	  the	  J3/4,	  
respectively,	   form	   a	   base	   pair	   in	   the	   aptamer	   as	   seen	   from	   the	   crystal	   structure	   [108].	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hybrids	  or	  alternatively	  a	  high-­‐resolution	  crystal	   structure	  of	  any	  hybrid	  will	  give	  more	  
insights	   into	   the	   global	   folding	   of	   the	   riboswitch	   in	   the	   hybrid	   configuration	   and	   also	  
reveal	  the	  interhelical	  stacking	  interactions	  	   	  between	  the	  P1	  helix	  and	  the	  AT	  helix.	  The	  
crystal	   structure	   will	   show	   the	   effect	   of	   a	   stable	   complete	   P1	   helix	   and	   P1/AT	   hybrid	  
helices	  in	  the	  long-­‐range	  interactions	  mentioned	  above	  along	  with	  more	  insights	  into	  the	  
folding	  of	  the	  RNA	  to	  attain	  high	  affinity	  for	  SAM	  binding.	  
The	   inline	   probing	   shows	   the	   distinction	   between	   the	   SAM	   binding	   observed	   in	   the	  
3P1_10AT	  and	  the	  3p1_10AT_5’GCC	  and	  3P1_9AT	  constructs.	  	  
	  
	  
Figure	  4.1:	  A	  model	  for	  SAM-­‐I	  riboswitch	  folding	  in	  the	  presence	  of	  SAM.	  	  The	  blue	  
line	  and	  the	  dashed	  blue	  line	  indicate	  tertiary	  interactions.	  The	  shaded	  region	  
indicates	  putative	  P1	  helix	  nucleation	  region.	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Our	   results	   that	   the	   SAM-­‐I	   riboswitch	   hybrids	   bind	   to	   SAM	   open	   a	   new	   venue	   for	  
riboswitch	  drug	  targeting.	  More	  structural	  information	  on	  the	  SAM	  bound	  hybrids	  will	  be	  
useful	   in	   developing	   high	   affinity	   ligands	   to	   the	   hybrids.	   The	   ligand	   bound	   hybrid	   can	  
stabilize	  the	  riboswitch	  in	  the	  hybrid	  configuration	  and	  not	  allow	  the	  formation	  of	  the	  P1	  
helix	  and	  remain	  in	  a	  permanent	  On	  state	  or	  in	  the	  hybrid	  state	  with	  weak	  expression	  of	  
the	   genes.	   Rationally	   it	  will	   be	  more	   difficult	   to	   design	   ligands	   to	   the	   aptamer	   itself	   to	  
shutdown	   the	   gene	   expression	   since	   the	   aptamer	   has	   evolved	  with	   high	   specificity	   for	  
SAM.	  The	  hybrids	  could	   form	  “alternate”	  binding	  pocket	   that	  can	  accommodate	  a	   ligand	  
other	   than	   SAM.	   All	   the	   aforementioned	   experiments	   can	   be	   tested	   in	   vitro	   [88],	   and	  
functional	  screens	  can	  be	  used	  to	  test	  the	  role	  of	  hybrids	  in	  vivo	  if	   ligand	  binding	  to	  the	  
hybrids	  are	  identified.	  	  	  
The	   RNA	   directed	   library	   is	   constructed	   specifically	   to	   assemble	   ligands	   with	   RNA	  
bindability	  and	  understand	   the	  modes	  of	  novel	  RNA-­‐ligand	  binding	  properties	   from	   the	  
obtained	  hits.	  Though	  we	  obtained	  2	  new	  hits	  from	  our	  library	  against,	  the	  16s	  ribosomal	  
RNA	  that	  is	  previously	  shown	  to	  bind	  to	  some	  aminoglycoside	  antibiotics,	  more	  detailed	  
structure	  of	  the	  bound	  ligand	  is	  required	  for	  understanding	  the	  desired	  properties	  of	  RNA.	  
Also	   the	   larger	   RNA	   targets	   like	   the	   riboswitch	   have	   to	   be	   screened.	   Large	   RNAs	   are	  
folded	   through	   long-­‐range	   tertiary	   interactions	   for	   function	   and	   can	   potentially	   form	  
binding	  pockets	  for	  ligands.	  We	  tried	  to	  optimize	  the	  screening	  parameters	  for	  screening	  
the	  yitJ	  SAM-­‐I	  riboswitch	  using	  NMR	  and	  equilibrium	  dialysis.	  	  Since	  it	  is	  shown	  that	  the	  S-­‐
adenosyl	   homocysteine	   binds	   to	   the	   SAM-­‐I	   riboswitch	   with	   400nM	   apparent	   Kd,	  and	  S-­‐
adenosyl	   cysteine	   with	   ~30	   micromolar	   apparent	   Kd,	   that	   fall	   in	   the	   weak	   binding	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category	  (as	  expected	  for	  the	  fragment’s	  affinity	  from	  the	  library	  screen)	  these	  ligands	  can	  
be	  used	  for	  optimizing	  the	  NMR	  directed	  binding	  experiments.	  
In	   summary,	   we	   have	   used	   various	  methods	   (equilibrium	   dialysis,	   RNA	   detected	   NMR,	  
ligand	   detected	   NMR,	   inline	   probing,	   mutational	   analysis)	   to	   understand	   the	   role	   of	   a	  
small	  molecule	  in	  RNA	  binding	  and	  folding.	  Our	  findings	  can	  be	  applicable	  and	  useful	  for	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